philip agop philip, m.d., ph.d., f.r.c.p., f.a.b.c...

53
Page 1 of 53 PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C. CURRENT POSITION Professor of Oncology, Pharmacology and Medicine Kathryn Cramer Endowed Chair in Cancer Research Vice President of Medical Affairs Department of Oncology Karmanos Cancer Institute Wayne State University School of Medicine Office Address #1 Office Address #2 Karmanos Cancer Institute Karmanos Cancer Center at 4100 John R Street Farmington Hills (Weisberg) Mail Code: HW04HO 31995 Northwestern Hwy. Detroit, MI 48201 USA Farmington Hills, MI 48334 Phone: 1-313-576-8728 Phone: 1-248-538-4701 Fax: 1-313-576-8767 E-mail: [email protected] Education Ph.D. in Clinical Pharmacology and Pharmacogenetics, University of London, 1982 - 1986 Guy’s Hospital Medical School, London, UK M.D., University of Baghdad, College of Medicine, Baghdad, Iraq 1971 - 1977 Baccalaureate, Baghdad College, American Jesuit Fathers, Baghdad, Iraq 1965 – 1971 Post-Graduate Training Fellowship in Leadership Course (18 months), Advisory Board Company, D.C. 2014 - 2015 Fellow in Medical Oncology, MD Anderson Cancer Center, Houston, Texas 1993 - 1995 Senior Registrar in Medical Oncology, University of Oxford and Imperial Cancer 1988 - 1993 Research Fund, Clinical Oncology Unit, Churchill Hospital, Oxford, United Kingdom Registrar in Medical Oncology, Christie Hospital and Holt Radium Institute, Manchester, 1988 - 1988 University of Manchester, United Kingdom Registrar in Medical Oncology, Charing Cross Hospital, University of London, London, 1986 - 1988 United Kingdom Clinical Research Fellow and Honorary Registrar, Department of Clinical Pharmacology 1982 - 1986 and Lymphoma Unit, Guy's Hospital Medical School, University of London, London, United Kingdom Resident Medical Officer, St. Raphael Hospital, Baghdad, Iraq 1981 - 1982 Lecturer in Clinical Pharmacology, Baghdad University Medical College, Baghdad, Iraq 1981 - 1982 Senior Resident in Internal Medicine, Medical City Teaching Hospital, University of 1980 - 1981 Baghdad, Iraq Resident in Internal Medicine, Al-Taji Hospital, Baghdad, Iraq 1978 - 1980

Upload: others

Post on 28-Jul-2020

30 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C ...igicc.org/wp-content/uploads/2019/05/Philip-Agop-Philip-CV.pdfPage 1 of 53 . PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C

Page 1 of 53

PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C.

CURRENT POSITION Professor of Oncology, Pharmacology and Medicine Kathryn Cramer Endowed Chair in Cancer Research Vice President of Medical Affairs Department of Oncology Karmanos Cancer Institute Wayne State University School of Medicine Office Address #1 Office Address #2 Karmanos Cancer Institute Karmanos Cancer Center at 4100 John R Street Farmington Hills (Weisberg) Mail Code: HW04HO 31995 Northwestern Hwy. Detroit, MI 48201 USA Farmington Hills, MI 48334 Phone: 1-313-576-8728 Phone: 1-248-538-4701 Fax: 1-313-576-8767 E-mail: [email protected] Education Ph.D. in Clinical Pharmacology and Pharmacogenetics, University of London, 1982 - 1986 Guy’s Hospital Medical School, London, UK M.D., University of Baghdad, College of Medicine, Baghdad, Iraq 1971 - 1977 Baccalaureate, Baghdad College, American Jesuit Fathers, Baghdad, Iraq 1965 – 1971 Post-Graduate Training Fellowship in Leadership Course (18 months), Advisory Board Company, D.C. 2014 - 2015 Fellow in Medical Oncology, MD Anderson Cancer Center, Houston, Texas 1993 - 1995 Senior Registrar in Medical Oncology, University of Oxford and Imperial Cancer 1988 - 1993 Research Fund, Clinical Oncology Unit, Churchill Hospital, Oxford, United Kingdom Registrar in Medical Oncology, Christie Hospital and Holt Radium Institute, Manchester, 1988 - 1988 University of Manchester, United Kingdom Registrar in Medical Oncology, Charing Cross Hospital, University of London, London, 1986 - 1988 United Kingdom Clinical Research Fellow and Honorary Registrar, Department of Clinical Pharmacology 1982 - 1986 and Lymphoma Unit, Guy's Hospital Medical School, University of London, London, United Kingdom Resident Medical Officer, St. Raphael Hospital, Baghdad, Iraq 1981 - 1982 Lecturer in Clinical Pharmacology, Baghdad University Medical College, Baghdad, Iraq 1981 - 1982 Senior Resident in Internal Medicine, Medical City Teaching Hospital, University of 1980 - 1981 Baghdad, Iraq Resident in Internal Medicine, Al-Taji Hospital, Baghdad, Iraq 1978 - 1980

Page 2: PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C ...igicc.org/wp-content/uploads/2019/05/Philip-Agop-Philip-CV.pdfPage 1 of 53 . PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C

Page 2 of 53

Intern in Internal Medicine and General Surgery, Medical City Teaching Hospital, 1977 - 1978 University of Baghdad, Baghdad, Iraq Faculty Appointments Professor in Pharmacology (secondary appointment) 2016 - present Endowed Dr. Kathryn Cramer Professor of Cancer Research 2015 - present Professor with Tenure, Department of Oncology with secondary appointment at Dept 2010 - present of Internal Medicine, School of Medicine, Wayne State University, Detroit, MI, USA Professor with Tenure, Department of Internal Medicine, Wayne State University, 2006 - present Detroit, MI Clinical Professor in Oncology, Karmanos Cancer Institute, NCI-designated 2003 - 2006 Comprehensive Cancer Center, Detroit, MI Professor (Clinician-Educator Track) in Internal Medicine, Wayne State University, 2003 - 2006 School of Medicine, Department of Internal Medicine, Division of Hematology/Oncology, Detroit, MI Associate Professor in Oncology, Karmanos Cancer Institute, NCI-designated 1998 - 2003 Comprehensive Cancer Center Detroit, MI Associate Professor (Clinician-Educator Track) in Medicine, Wayne State University, 1998 - 2003 School of Medicine, Department of Internal Medicine, Division of Hematology/Oncology, Detroit, MI Assistant Professor (Clinician-Educator Track), Karmanos Cancer Institute, NCI- 1995 - 1998 designated Comprehensive Cancer Center, Wayne State University, School of Medicine, Department of Internal Medicine, Division of Hematology/Oncology, Detroit, MI Hospital or Other Professional Appointments Vice President for Medical Affairs, Karmanos Cancer Hospital, Detroit 2012 - present President of Medical Staff, Karmanos Cancer Hospital, Detroit 2010 - 2012 Leader of Gastrointestinal and Neuroendocrine Oncology Multidisciplinary Team 2006 - present Attending Physician at Karmanos Cancer Hospital 2005 - present Attending Physician in Hematology/Oncology at the Detroit Medical Center (DMC), 1995 - present Detroit, MI. Privileges at Harper University Hospital, Detroit Receiving Hospital and Hutzel Hospital COMMITTEES Member, Department of Oncology Review Committee, 2018 Member, Metastatic Pancreatic Cancer Guideline Panel, ASCO 2018 Chair, Budget Advisory Committee, School of Medicine, WSU 2017 - Leader of hepatopancreaticobiliary track and member of planning committee of 2017 - present ASCO GI Member, Recruitment and retention subcommittee of the CLC, 2017 - Poster Judging Panel for the 2017 Medical Student Research Symposium Jan 12-13, 2017 Abstract selection Committee, Annual NANET meeting 2017 Member, Promotion & Tenure Committee, WSU 2011, 2015-2017 Ad hoc external member, Promotions Committee, Harvard Medical School 2016

Page 3: PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C ...igicc.org/wp-content/uploads/2019/05/Philip-Agop-Philip-CV.pdfPage 1 of 53 . PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C

Page 3 of 53

Member, Caris, Center of Excellence GI Tumor Group, 2016 - Member, Policy Committee, KCC 2016 - Member, Promotion & Tenure Committee, Dept of Oncology 2016 – present Member, Advisory Board, The Skyfoundation, Inc 2015 - present Member of Planning Committee, led the Medical Oncology Working Group, 2015, 2017 Annual Karmanos Meeting Chair, Data Safety Monitoring Committee, Aslan Pharma 2017 – Member, KCC Quality and Compliance Subcommittee, 2017 – Member, Weisberg Expansion Committee, 2017 - Member, Steering Committee, Phase III APACT Trial, 2015 - Member, Physician Lab Advisory Council 2015 Member, Data Safety Monitoring Committee, Lexicon #1606.301-303 2016 - Member, ad hoc, Dr Rosner PT Committee, Department of Dermatology and CMMG 2015 and 2016 Member, Organizing Committee, International GI Symposium, Turkey 2014 - present Member, Hearing Panel, WSU 2014 - 2020 Member, Professionalism Committee, WSU 2014 - 2020 Member, KCI/McLaren Integration Steering Committee 2014 -present Member, ASCO Metastatic Pancreas Cancer Guideline Committee 2014, 2018 Member, Editorial Board for “Together we’re better”, KCI/McLaren 2014 – present Grant reviewer, Molecular Therapeutics Program 2014 – present Member of GI/NET track, McLaren Medical Oncology Care Plans 2014 - present Member, Hospitalist Liaison Committee 2014 – present Member, Scientific Strategy Planning Retreat 5/5/2014 Member, International Pancreatic Cancer Forum 2014 - present Member, Medical Advisory Board, Pancreatic Action Network (PanCan) 2012 - present Chair, Clinic Improvement Initiative Working Group 2012 - present Chair, Utilization Review Committee, KCC 2012 - present Chair, HPIC, KCC 2012 - present Member, Steering Committee, Molecular Therapeutics Program, KCI 2012 - present Member, Executive Committee of the School of Medicine, Wayne State University 2011 – 2014 Department of Oncology P&T and Salary and Appointment Committee, Karmanos 2011 - present Cancer Institute Co-Leader of the GI Subcommittee of the California NO1 Consortium 2011 - 2014 President, KCI Medical Executive Committee 2011 - 2012 Member, KCC Board of Directors 2010 - present President Elect, Medical Staff Leadership Council, Karmanos Cancer Center 2008 - 2010 Chair, Protocol Review and Monitoring Committee 2003 - 2011 Member, IDEA (International Development and Education Award) through ASCO 2009 - 2014 Member, Executive Committee of the Faculty Senate, Wayne State University 2007 - 2010 Member, Chair of Pathology Search Committee, Dean’s Office, School of Medicine, 2007 - 2008 Wayne State University Member, Clinical Leadership Council, Karmanos Cancer Institute 2006 - present Member, Financial Conflict of Interest Committee, Wayne State University 2006 - 2010 Leader, Organizing Committee, State of Science Meeting on Pancreas Cancer 2006 - 2007 Sponsored by NCI (November 30th & December 1st, 2007) Member, ASCO Educational Committee, Non-Colorectal GI 2005 - 2008 School of Medicine Committee to review the Department of Surgery 2005 Member, MD/PhD admission committee, School of Medicine, Wayne State University 2005 Member, CTEP site visit to New York University, Cancer Center 2004 Member of the Scientific Leadership Council, Karmanos Cancer Institute 2003 - 2011 Leader of Pancreas Cancer Subcommittee and member of the Steering Committee for GI 2000 - present Cancer, Southwest Oncology Group (SWOG) Member of the Intergroup Task Force on Pancreatic Cancer 2000 - present Member, DMC Hematology/Oncology Pharmacy Therapeutics Subcommittee 1999 - 2002 Member, Fellows Education Committee, Oncology Fellowship Oncology Program, WSU 1999

Page 4: PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C ...igicc.org/wp-content/uploads/2019/05/Philip-Agop-Philip-CV.pdfPage 1 of 53 . PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C

Page 4 of 53

Wertz Clinical Care Center Operational Focus Group, Karmanos Cancer Institute 1998 Member, Drug Development Program, Karmanos Cancer Institute 1997 - 2005 Member, Wertz Business/Clinical Audit Committee, Karmanos Cancer Institute 1997 - 2000 Member in the Protocol Review Committee, Karmanos Cancer Institute 1996 - 2003 Member, Primary Cancer Prevention Task Force, Karmanos Cancer Institute 1995 - 2000 Human Applications Group, Institute of Chemical Toxicology, Wayne State University 1995 - 2000 SERVICE Patient Care Medical Oncology – Karmanos Cancer Hospital, Harper University Hospital, Detroit In-Patients Receiving Hospital, and Hutzel Hospital, Detroit, MI Medical Oncology - Karmanos Cancer Hospital, Harper University Hospital, Detroit Consults Receiving Hospital, and Hutzel Hospital, Detroit, MI GI Multidisciplinary Program – One clinic/week (Monday) Outpatients Farmington Karmanos Center Clinic - Two clinics/week (Tuesday/Wednesday) Major Professional Societies • European Society of Medical Oncology (ESMO) 2017 - • International Liver Cancer Association (ILCA) 2010 - present • North America Neuroendocrine Tumor Society (NANET) 2015 - • American Pancreatic Association (APA) 2000 - present • American Society of Clinical Pharmacology and Therapeutics (ASCPT) 1998 - 2004 • American College of Physicians (ACP) 1998 - 2000 • NSABP 1998 - 2000 • Society of Toxicology, Michigan Regional Chapter 1996 - 2004 • Southwest Oncology Group (SWOG) 1995 - present • American Society of Clinical Oncology (ASCO) 1995 - present • American Association for Cancer Research (AACR) 1995 - present • Pharmacology and Molecular Mechanisms Group (PAMM) of the European 1990 - present Organization for Research and Treatment of Cancer (EORTC) Board Certifications • ABIM re-certification in Medical Oncology 2015 - 2025 • ABIM certification in Medical Oncology 2005 – 2015 • ABIM certification in Internal Medicine 2004 - 2014 • Accreditation in the Subspecialty of Medical Oncology by the Joint Committee for 1991

Higher Medical Training of the United Kingdom and the Royal College of Physicians of the UK

• M.R.C.P. (Internal Medicine Diploma), Royal College of Physicians of the United 1985 Kingdom

• Fellowship of the Royal College of Physicians (FRCP) of the UK Licensures • Michigan State Medical License (active), #4301066240 Exp 01/2020 • Kansas State Medical License (inactive), #04-25728 • General Medical Counsel of the United Kingdom (UK Licensure, inactive), #3386011 Honors and Awards • Wayne State University Medical School Teaching Award 2015 • Outstanding Instructor in Oncology Award, Karmanos Cancer Institute, Oncology 2014

Fellowship Program

Page 5: PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C ...igicc.org/wp-content/uploads/2019/05/Philip-Agop-Philip-CV.pdfPage 1 of 53 . PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C

Page 5 of 53

• Best Doctors of America 2009 - present • HOUR Detroit Magazine Top Docs 2009, 2011, 2016,

2017 • Wayne State University Medical School Teaching Award 2004 • Outstanding Instructor in Oncology Award, Wayne State University, Oncology 2001

Fellowship Program • Wayne State University Medical School Teaching Award 1999 • Fellows Competition Award, M.D. Anderson Cancer Center 1994 • Scholarship from University of Baghdad - Clinical Pharmacology/Medical Oncology 1982 - 1986 • Fourth in Internal Medicine course, Medical School 1977 • Ninth graduate in class of 300 from Medical School 1977 • First in the Pharmacology and Therapeutics Course, Medical School 1974 • Fifth graduate in the Country for the National Baccalaureate Exam 1971 COMMUNITY OUTREACH Leader, Karmanos Team, PanCan Purple Stride, Cehney Park, 6/17/2017 Colon cancer day at KCC 3/21/2017 Speaker, PurpleLight, Pancreatic Action Network, Detroit 10/23/2016 Exploration Health Program regarding "Stomach Cancer" b roll 6/24/2016 Pancreatic Cancer Expert Interview, The Omnia-Prova Education Collaborative, Inc. 5/27/2016 Sky Foundation Pancreatic Cancer Luncheon/Presentation, The Townsend Hotel, 5/18/2016 Birmingham, MI PanCan Action Network Walk, Ford Field, Detroit, MI 5/14/2016 Speaker, PanCan, Leadership Breakfast, Red Wings Club, Detroit 3/24/2016 Pancreatic Cancer Speaking Event by KCI, Monroe Golf & Country Club, Monroe, MI 5/12/2015 Sky Foundation Pancreatic Cancer Luncheon/Presentation, The Townsend Hotel, 11/2/2014 Birmingham, MI Community-Based Oncology Clinical & Research Forum, Hospitality House, 10/29/2014 McLaren Health, Flint, MI McLaren Leadership Meeting, Soaring Eagle, Mt. Pleasant, MI 9/22/2014 Cruising for Cure Event, Bellaire, MI 7/20/2014 Neuroendocrine Tumor Patient Conference, Marriott Hotel Troy, Troy, MI 5/16/2014 Groups GI Steering Committee, Development Approval Strategy Meeting, Chicago, IL 1/30/2014 Commentary in HemOncToday on “MicroRNA Biomarkers in ……” by Shultz et al 2014 Co-Chairing the annual Purple Stride Pancreatic Action Network’s Event, Detroit Zoo, Royal Oak, MI 9/29/2013 Talk, Cruising for Cure Event, Bellaire, MI 7/19/2013 Chris4Life Colon Cancer Foundation’s First Annual Scope It Out 5K Run/Walk for Colon Cancer Awareness, Willow Metro Park, Belleville, MI 11/3/2012 Purple Light Lansing, PanCan Presentation 10/1/2012 Lecture and Discussion, “Issues in clinical research”, McLaren Flint Hospital 7/11/2012 PanCan Advocacy Day 2012 – participation included visit to the offices of Michigan congress and senate members 6/15/2012 Rick Thie and the Jane H. Thie Memorial Fund Presentation 11/30/2011 PurpleLight Detroit, PanCan Presentation 11/20/2011 St. Sarkis Apostolic Church Fellowship 9/18/2011 PanCan Educational Event Presentation, Karmanos Cancer Institute (Auditorium) 9/8/2011 Pancreas Research Presentation to KCI Donors 8/3/2011 PanCan Advocacy Day 2011 – participation included visit to the offices of Michigan congress and senate members 6/13/2011 WJR 760 AM radio interview on the Frank Beckmann Show regarding Breakthrough Blood Test 1/4/2011 WXYZ Channel 7 News interview with Carolyn Clifford regarding Breakthrough Blood Test

Page 6: PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C ...igicc.org/wp-content/uploads/2019/05/Philip-Agop-Philip-CV.pdfPage 1 of 53 . PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C

Page 6 of 53

1/3/2011 WDET’s The Craig Fahle Show interview regarding pancreatic cancer as a result of the news of Aretha Franklin’s diagnosis 12/16/2010 XWYZ Channel 7, 60 second segment with Cynthia Canty on why it is important to see a cancer specialist when there’s a cancer diagnosis 10/15/2010 Channel 7 News interview with Carolyn Clifford and patients Terry Fornwall & Patricia Kraus sharing their journey with cancer and beating odds with help of Karmanos 2/17/2010 Channel 7 News to discuss legendary Tigers announcer, Ernie Harwell’s inoperable tumor in his bile duct 9/2009 Channel 7 program on pancreas cancer and Ricky Sandoval, Detroit Lions Director of Security 2/2008 Channel 2 program with Lila Lazarus on pancreas cancer and Late Mayor Guido 5/2007 TV Channel 4 News live phone bank on colorectal cancer 2/2/2007 Fundraising for KCI at Panera Bread Dearborn – Michael Guido Pancreas Research Fund 01/2007 TV Channel 4 News, interview on the results of reduction of incidence of breast cancer 12/2006 Radio interview with WWJ on a recent article on Aspirin and risk of breast cancer 6/3/2005 Question and answer session with 5th grade students at the AGBU Alex Manougian School in Southfield, MI 6/2004 Lecture at the Gilda’s Club in Royal Oak to patients and relatives 3/9/2004 Radio show interview, "Senior Solutions" on colorectal cancer 3/3/2004 WPGR, Live radio program with Dr. Jimmy Womack on colorectal cancer 2/15/2004 Chaldean Radio live interview on colorectal cancer 10/2003 Presentation and media interviews, Colossal Colon Tour opening ceremony, Detroit 920/03 Lecture on Cancer Prevention, Association of Armenians from Istanbul 11/2002 Magazine interview with Metro Parent on new drugs and trials in breast cancer 11/30/2001 Radio WJR “diagnosis of breast cancer” 10/2001 TV Channel 2, “Oral Chemotherapy for Colorectal Cancer” 4/2001 WHMI/FM interview on new treatments for colo-rectal cancer 4/2001 Interview with “Daily Macomb” Newspaper on colorectal cancer screening 3/2001 “Flashpoint” Sunday Program, Channel 4 TV, interview on Colorectal Cancer Screening 3/2001 Comcast TV interview on Breast Cancer with Frankie Dorcell 3/2001 Pancreas Cancer Support Group Meeting at Karmanos Cancer Institute 2/2001 Pancreas Cancer Support Group Meeting at Karmanos Cancer Institute 10/2000 Channel 4 News, “New anticancer drug” 5/2000 Channel 4 News, “Questions from the Public” on Colorectal Cancer 3/2000 Pancreas Cancer Support Group Meeting at Karmanos Cancer Institute 2/2000 Live interview on WWJ 950 on the sale of anti-cancer drugs on the Internet 1/99 Channel 4 TV News, "Colo-rectal Cancer Week" 9/15/98 Channel 50, “Ethnicity and Outcome of Breast Cancer” 6/1/98 WOMC Radio Station, “New Drugs in Cancer” 5/13/98 Channel 4 TV News, “Questions from the Public” 5/6/98 Channel 4 TV News, “Angiostatin, Endostatin” 5/4/98 Channel 4 TV News, “Colo-Rectal Cancer” 11/97 Seminar, Breast Cancer in the New Millennium, “Clinical Pathways for Advanced Stage Breast Cancer 2/19/97 Secretary, Armenian Medical Association of Great Britain 1988 - 1992 JOURNAL EDITORIAL ACTIVITY Associate Editor: International Journal of Gastrointestinal Cancer Member of Editorial Board:

Page 7: PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C ...igicc.org/wp-content/uploads/2019/05/Philip-Agop-Philip-CV.pdfPage 1 of 53 . PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C

Page 7 of 53

Community Oncology, Translational Oncology, International Journal of Clinical and Experimental Medicine, American Journal of Translational Research, Journal of Cancer Research & Therapy, Member Editorial Advisory Board: Cancer Medicine Lancet Oncology International Advisory Board 2014-2017 Ad hoc reviewer for: Journal of Clinical Oncology, Scientific Reports, European Journal of Cancer, British Journal of Cancer, Pancreas, Drug Metabolism and Disposition, Cancer, Journal of Clinical Outcomes Management, Cancer Research, International Journal of Cancer, Clinical Cancer Research, Expert Opinion on Pharmacotherapy, Cancer Investigation, The Oncologist, Oncology, American Journal of Clinical Oncology, Cancer Chemotherapy and Pharmacology, Future Medicine, Gut, Hepatology, Nature Reviews in Clinical Oncology, Annals of Surgical Oncology, Mount Sinai Journal of Medicine, Molecular Cancer, Journal of Hepatology, The Journal of Investigative Medicine, The Pharmacogenomics Journal, JAMA Oncology, JAMA Surgery, JNCCN, JNCI, Clinical Colorectal Cancer, Oncotaregt, Mayo Clinic Proceedings, Journal of Community and Supportive Oncology, Drugs, Cancer immunology Research Editorial Consultant for: Physician’s Information and Education Resource (PIER) (2003-2006) TEACHING ACTIVITIES AT WAYNE STATE UNIVERSITY (1995-present) Graduate Students (Cancer Biology Program)

Lecturer, Department of Pharmacology and Psychiatry, October 2015 Lecturer, Cancer Mini Course, Department of Pharmacology, November 2015 Lecturer, GI Cancers, Mini-course in cancer chemotherapy, November 2017 Lecturer, CB7210 Fundamentals of Cancer Biology Course - “Clinical issues: detection, diagnosis and treatment” (4/26/11, 1/26/10, 1/27/09, 1/20/08, 1/20/07, 1/20/06, 1/20/05, 1/27/04, 1/16/03) Ph.D. Student rotation in clinic (7/08, 7/07, 6/06, 8/05, 7/05, 6/05, 7/03, 6/03, 7/01, 6/01, 8/99, 6/99, 8/97, 8/96) Cancer Biology Student Rotation: Brittany Haynes (6/13) Lecturer, Cancer Biology Program (CB725), Cancer Prevention and Control Course - “Role of Carcinogen-Metabolizing Enzymes in Cancer Susceptibility” (2/99, 2/98)

WSU Medical Students Hem/Onc Ambulatory Rotation, Ms. Preethi Sriranga, (1/2017 - )

HemOnc Ambulatory Rotation, Ms. Jannel Lee, 3/2016 Hem/Onc Ambulatory Rotation, Ali Raufi, MD, (4/10)

Hem/Onc Ambulatory Rotation, Jatinder Singh, MD, (3/10) Oncology Elective, Sevan Karadolian, (10/05) Hematology/Oncology Clinic Rotation (2/02, 1/02, 9/01, 4/99, 2/97) Physical diagnosis mid-term examiner (2/00) Internal Medicine Teaching Rounds (1/99, 6/98) OSCE Proctor for IIIY Medical Students (6/99, 6/98) USMLE Step II Course (8/98)

Page 8: PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C ...igicc.org/wp-content/uploads/2019/05/Philip-Agop-Philip-CV.pdfPage 1 of 53 . PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C

Page 8 of 53

Physical Diagnosis for sophomore medical students (2/97-4/97, 2/96-4/96) Pharmacology course for second year medical students (9/96)

WSU Internal Medicine Residency Training Program Medical Specialty Teaching Rounds, Karmanos Cancer Hospital, 6 weeks/year (2006-present) Medical Specialty Teaching Rounds, Harper Hospital (5/13 – 5/29, 2005)

Medical Specialty Teaching Rounds, Harper Hospital (12/14 – 12/29, 2004) Medical Specialty Teaching Rounds, Harper Hospital (12/14 – 12/29, 2003)

Medical Oncology Teaching Rounds - Harper Hospital - (1/02, 9/01, 10/00, 10/99, 10/96) Visiting Professor, Grace-Sinai Hospital (5/01, 12/00) Outpatient Oncology Teaching, two sessions per week, (1999 - present) Internal Medicine Board Review Course: "Gastrointestinal Malignancies" (10/99, 4/99) Internal Medicine Rounds at Harper Hospital (1/99) Morning Report (1/99)

Division of Hematology and Oncology, Core Oncology Lecture Series, Bi-monthly (1998-1995) Internal Medicine Rounds at Harper Hospital (6/98)

Morning Report at Harper Hospital (6/98) Morning Report at Harper Hospital (10/96) Internal Medicine Rounds at Detroit Receiving Hospital - (12/95)

Morning Report at Detroit Receiving Hospital (12/95)

WSU Hematology/Oncology Fellowship Training Program GI Multidisciplinary Clinic rotations 12 months/year – (present) Medical Specialty Teaching Rounds, Karmanos Cancer Hospital, 5 weeks/year (2006-present) Breast Clinic, 6 months/year (2002 - 1995) Fellow’s Core lecture Series (6/01, 1/01) Fellow’s Clinic, 1 month/year (January 1997, March 1996)

WSU Gastroenterology Fellowship Training Program Lecture, GI Grand Rounds, Neuroendocrine Tumors, 12/8/2017

WSU Oncology Outpatient Elective – Wertz Cancer Center: 4th year Medical Student, James Kochkodan (12/16) 4th year Medical Student, Jannel Lee-Allen (2/16) 4th year Medical Student, Shamaya Cregh (3/15) 4th year Medical Student, Ben Gervacio (12/10) 4th year Medical Student, Shivang Shaw (11/09)

WSU Breast Surgery Fellowship

Clinic Rotation (12/02) WSU Radiation Oncology Residency Training Program

Lectures (6/99, 6/98, 3/96) Hematology/Oncology Clinic Rotation (7/98, 3/97-9/97, 8/96)

WSU Physician Assistants’ Course Lectures (9/2017, 9/2016, 9/2015, 11/2014, 11/2013, 12/2012, 12/2011, 12/2010, 12/2009, 11/2008, 12/2007, 12/2006, 12/2005, 12/2004, 12/2003, 12/2002, 12/2001, 12/1999, 12/1998, 10/1997, 8/1996)

Nurse Practitioner Training

Clinic Rotations (1/03, 12/02, 2/00, 10/99, 2/99, 3/98, 10/97) International Observers

Page 9: PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C ...igicc.org/wp-content/uploads/2019/05/Philip-Agop-Philip-CV.pdfPage 1 of 53 . PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C

Page 9 of 53

Dr Ahmed Salah, King Fahad Specialist Hospital, Dammam, Saudi Arabia (May/June 2014) Dr Jacques Azzi, University of Balamand, Lebanon (9/11) Dr Abdullah Al-Khattibi, King Abdul Aziz Medical School, Jeddah, Saudi Arabia (2/11)

WSU/KCI CME ACTIVITIES GI Cancer Symposium - Course Director/Planning Committee Member (annual) 2003 – present GI Tumor Board - Director (weekly) 2003 – present ProMedica/KCI Symposium - Planning Committee Member 2008, 2009 Karmanos Cancer Institute’s Grand Rounds - Co-Director (weekly) 2003 - 2010 Supportive Care Symposium - Course Director 2003, 2004 Multidisciplinary Therapy of Breast Cancer - Course Director 2001, 2002, 2003 Pancreatic Research Conference - Activity Director (monthly) 2000 - 2008 GI Oncology Update - Course Director 2000 TEACHING ACTIVITIES AT OTHER UNIVERSITIES (1980-1995) University of Oxford, School of Medicine, Residency Training Program in Internal 1988 - 1993 Medicine; Fellowship Training Program in Medical Oncology University of London, Charing Cross Hospital, Residency Training Program in Internal 1986 - 1988 Medicine University of London, Guy’s Hospital Medical School, Clinical Pharmacology course 1982 - 1986 for medical students University of Baghdad, College of Medicine, Pharmacology courses for medical students 1980 - 1982 MENTORSHIP Anteneh Tefaye, MD, Junior Faculty 2016 – present Asfar Azmi, PhD, Junior faculty/basic science 2016 - present Mandana Kamgar, MD, HemOnc Fellow 2017 – present Mohamed Usman, MD, HemOnc Fellow 2016 - present Maria Diab, MD, WSU IM resident 2017 - present Kevin Zhang, 3rd year WSU medical student Nov 2015 - present Hemchandra Mahaseth, MD, KCI Junior Faculty 2012 – 2015 Mohammed Salem, MD, HemOnc Fellow 2011 – 2015 Minsig Choi, MD, KCI Junior Faculty 2010 – 2015 Medical Student/Research, Elon Knoll 2009 Internal Medicine Resident, Dr. Abdel Alqwasmi 2008 – 2015 International Oncologist (ASCO IDEA Program), Dr.Yan Li (China) 2008 Hem/Onc Fellow, Nazik Hamad (focused GI Oncology Training/3d year) 2007 Internal Medicine Resident, Dr S Zafar 2007 Internal Medicine second year resident, Dr M Mobayed (WSU Oncology Fellow in 2008) 2006 - 2012 International Oncologist (ASCO Program), Dr Mehmet Artac 2006 Internal Medicine second year resident, Dr. Vera Maranci (U of M Oncology Fellow) 2005 - 2007 Internal Medicine second year resident, Dr. C. Deol (currently WSU Oncology Faculty) 2005 - 2006 Internal Medicine Intern, Dr. Pallavi Jasti (currently Faculty VA Hospital) 2003 - 2004 Internal Medicine Residency Intern, Dr. Nirav 2002 Medical Oncology Fellowship Program, (Dr. Bassel El-Rayes, prior WSU GI Oncology 2000 - 2004 Faculty; currently GI Oncology Director at Emory University) Internal Medicine Resident (Elective in the laboratory), Dr. Kambeez Berenji 1999 Summer High-School Student (in lab) (Anuj Prasher) 1998 Summer Wayne State University College Student, (Mr. Mohamed Rehman) 1997 Medical Oncology Fellowship Program (Dr. Shirish Gadgeel, currently WSU Thoracic 1996 - 2000 Oncology Faculty) Laboratory Research, Visiting Scholar, (Dr. A. Akhtar) 1996 - 1997

Page 10: PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C ...igicc.org/wp-content/uploads/2019/05/Philip-Agop-Philip-CV.pdfPage 1 of 53 . PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C

Page 10 of 53

STUDY SECTION/GRANT REVIEW Pancreatic Cancer UK, grant review 2016, 2017 Pancreatic Action Network Grant Review, 2017 Pancreatic Action Network, Site selection Committee for Precision Medicine 2016 Quinquennial Review, work of the research group led by Professor Jeff Evans 2015, 2016 Cancer Research UK Scientific Review Committee, Pancreatic Action Network/AACR 2014, 2015 Pancreatic Cancer UK Innovation Fund Reviewer 2015 Review of Indiana University - Purdue University Indianapolis (IUPUI), Indiana 2015 SWOG and Hope Impact Award review 2015 NIH, Outstanding Scientific Achievement Awards March 2015 Grant reviewer, UK Pancreatic Cancer Fund 2012- present Reviewer, Selection Committee, Stand Up to Cancer, AACR/Farah Fawcett Foundation, HPV related cancers 2013-2014 NCI’s PO1 Review Panel, DC 10/2011 NIH PO1 Grant Review Committee Member, Rockville, MD 9/2011 NIH PO1 Grant Review Committee Member, Bethesda, MD 9/2010 UCSD Pancreatic SPORE EAB Member, San Diego, CA 7/2010 NIH PO1 Grant Review Committee Member, Bethesda, MD 5/2010 Swiss National Science Foundation Grant Reviewer 2010 Qatar National Research Fund 2009 - present

GRANT SUPPORT

1. Merck: 2016-064: A Phase III Study of Pembrolizumab (MK-3475) vs. Best Supportive Care as Second-Line Therapy in Subjects with Previously Systemically Treated Advanced Hepatocellular Carcinoma. PI 07/26/16 – 07/25/19

2. Merck: 2016-063: A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (KEYNOTE-177). PI 10/05/16 – 10/04/19

3. (KEYNOTE-240)Lilly: 2016-041: Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo plus Cisplatin and Gemcitabine as First-Line Treatment in Patients with Advanced or Metastatic Biliary Tract. PI 04/19/16 – 04/18/19

4. Gilead: 2016-038: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5745 Combined with mFOLFOX6 as First Line Treatment in Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. PI 09/13/16 – 09/12/19

5. CancerHalozyme: 2016-011: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination with nab-Paclitaxel Plus Gemcitabine Compared with Placebo Plus nab-Paclitaxel and Gemcitabine in Subjects with Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal. PI 04/18/16 – 04/17/19

6. AdenocarcinomaMerck: 2016-008: A Phase II Study of Pembrolizumab Monotherapy in Third-line Previously Treated Subjects with Advanced/Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus or Advanced/Metastatic Siewert Type I Adenocarcinoma of the Esophagogastric Junction (KEYNOTE -180). PI 03/07/16 – 03/06/19

7. MacroGenics: 2015-161: A Phase 1b/2, Open Label, Dose Escalation Study of Margetuximab in Combination with Pembrolizumab in Patients with Relapsed/Refractory Advanced HER2+ Gastroesophageal Junction or Gastric Cancer. PI 02/23/16 – 02/22/19

8. Merck: 2015-153: A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs

Page 11: PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C ...igicc.org/wp-content/uploads/2019/05/Philip-Agop-Philip-CV.pdfPage 1 of 53 . PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C

Page 11 of 53

Physicians' Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy. PI 03/08/16 – 03/07/19

9. AstraZeneca: D4198C00001: 2015-152: A Phase II Open-Label, Multi-Center Study of MEDI4736 Evaluated as Single Agent or in Combination with Tremelimumab in Patients with Metastatic Pancreatic Ductal Adenocarcinoma. PI 02/24/16 – 02/23/19

10. Advaxis: ADXS001-06: 2015-108: Phase 2 Study of ADXS11-001 in Subjects with Persistent/Recurrent, Loco-Regional or Metastatic Squamous Cell Carcinoma of the Anorectal Canal. PI 01/08/16 – 01/07/19

11. Merck: 015-092 : A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin+5-Fluorouracil versus Placebo+Cisplatin+5-Fluorouracil as First-Line Treatment in Subjects with Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma. PI 09/10/15 – 09/09/18

12. Merck: 2015-092 : A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin+5-Fluorouracil versus Placebo+Cisplatin+5-Fluorouracil as First-Line Treatment in Subjects with Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma. PI 09/10/15 – 09/09/18

13. Acerta Pharma: 2015-091: A Phase 2 Proof-of-Concept Study of ACP-196 Alone and in Combination with Pembrolizumab in Subjects with Advanced or Metastatic Pancreatic Cancer. PI 09/08/15 – 09/07/18

14. Merck: 2015-056: A Phase III, Randomized, Open-label Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel in Subjects with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma who Progressed after First-line Therapy with Platinum and Fluropyrimidine. PI 07/15/15 – 07/14/18

15. Immunomedics: 2014-138: An International, Multi-Center, Double-Blind, Randomized, Phase III Trial of 90Y-Clivatuzumab Tetraxetan plus Low-Dose Gemcitabine Versus Placebo plus Low-Dose Gemcitabine in Patients with Metastatic (Stage IV) Pancreatic Adenocarcinoma Who Received at Least Two Prior Treatments (PANCRIT-1). PI 04/13/15 – 04/12/18

16. Merck: 2014-146: A Phase II Clinical Trial of Single Agent Pembrolizumab (MK-3475) in Subjects with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Who Have Failed Platinum and Cetuximab. PI 03/16/15 – 03/15/18

17. Celgene: 2014-114: Nab-Paclitaxel (Abraxane) plus Gemcitabine in Subjects with Locally Advanced Pancreatic Cancer (LAPC): An International Open-Label, Multicenter Phase 2 Study (LAPACT). PI 01/29/15 – 01/28/18

18. Taiho Pharma: 2014-145: An Open-Label Expanded Access Study of TAS-102 in Patients with Metastatic Colorectal Cancer Refractory to or Failing Standard Chemotherapy. PI 01/08/15 – 01/07/18

19. Incyte Corp: 2014-119: A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer. PI 12/23/14 – 12/22/17

20. Celgene: 2014-118: A Phase I, Multicenter, Open-Label, Dose-Escalation Study to Investigate the Safety and Pharmacokinetics of nab-Paclitaxel (ABI-007) plus Gemcitabine in Subjects with Advanced Pancreatic Cancer who have Cholestatic Hyperbilirubinemia Secondary to Bile Duct Obstruction. PI 12/08/14 – 12/07/17

21. Momenta: 2014-110: A Phase I/II, Two-Part, Multicenter Study to Evaluate the Safety and Efficacy of M402 in Combination with nab-Paclitaxel and Gemcitabine in Patients with Metastatic Pancreatic Cancer. PI 11/19/14 – 11/18/17

22. Columbia University Medical Center: 2014-049: Phase II Trial of Afatinib in Combination with Weekly Paclitaxel in the Second Line Treatment of HER2 Amplified Advanced Gastric, Gastroesophageal Junction and Esophageal Cancer. PI 1014/14 – 10/13/17

23. Celgene: ABI-007-PANC-003: 2014-021: A Phase 3, Multicenter, Open-label, Randomized Study of nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Subjects With Surgically. PI 05/29/14 – 05/28/17

24. Incyte Corporation: INCB 18424-362: 2014-032: A Randomized, Double-Blind, Phase 3 Study of the JAK1/2 Inhibitor, Ruxolitinib or Placebo in Combination With Capecitabine in

Page 12: PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C ...igicc.org/wp-content/uploads/2019/05/Philip-Agop-Philip-CV.pdfPage 1 of 53 . PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C

Page 12 of 53

Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Fai. PI 08/28/14 – 08/27/17 ($10,000)

25. Novartis: CBGJ398X2204: 2014-081: A Phase II Multicenter, Single Arm Study of Oral BGJ398 in Adult Patients with Advanced or Metastatic Cholangiocarcinoma with FGFR2 Gene Fusions or other FGFR Genetic. PI 05/27/14 – 05/26/17

26. Karyopharm: 2013-133: “A Phase Ib/II Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330, Gemcitabine and nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer”. PI 08/18/14 – 08/17/17.

27. Polaris: 2013-065: POLARIS 2009-001 : A Randomized, Double-Blind, Multi-Center Phase 3 Study of ADI-PEG 20 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Have Failed Prior Systemic Therapy. PI 06/11/13 – 06/10/16

28. Bayer, 2013-026: “A Randomized, Double Blind, Placebo-Controlled, Multicenter Phase III Study of Regorafenib in Patients with Hepatocellular Carcinoma (HCC) after Sorafenib”. PI 5/28/13 – 5/27/16. ($3,600)

29. XBiotech: 2013-014: 2012-PT023: A Pivotal Phase III Study to Evaluate Overall Survival using

MABp1 as a Monotherapy in Metastatic Colorectal Cancer Patients with Cachexia. PI 04/09/13 – 04/18/16

30. Biocompatibles UK Ltd: 2011-145: TS103: A Phase III Clinical Trial of Intra-arterial TheraSphere in the Treatment of Patients with Unresectable Hepatocellular Carcinoma (HCC). PI 06/21/12 – 06/20/16

31. Merck: 2011-116: Prevention of Nausea and Vomiting Secondary to FOLFIRINOX Chemotherapy in GI Cancer Patients. PI 05/22/12 – 05/21/16

32. Biocompatibles UK Lts: 2011-144: TS-102: A Phase III Clinical Trial Evaluating TheraSphere in Patients with Metastatic Colorectal Carcinoma of the Liver who have Failed First Line Chemotherapy. PI 05/22/12 – 05/21/16

33. Weill Cornell Medical College: 2013-035: An Open-Labeled, Multicenter Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma. PI 07/08/13 – 07/07/16

34. Roche, 2012-050: “A Randomized, Placebo-controlled, Double-blind, Multicenter Phase II Trial of Intravenious GC33 at 1600 mg Q2W in Previously Treated Patients with Unresectable Advanced or Metastatic Hepatocellular Carcinoma (HCC)”. PI 8/8/12 – 8/7/15. ($1,500)

35. Bayer, 2012-051: “An Open-Label Phase IIIb Study of Regorafenib in Patients with Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy”. PI 8/29/12 – 3/124/15. ($1,300)

36. InCyte Corp, 2011-138: “A Randomized Phase 2 Study of Ruxolitinib Efficacy and Safety in Combination with Capecitabine for Subjects with Recurrent or Treatment Refractory Metastatic Pancreatic Cancer (The RECAP trial)”. PI ($8850) 2/29/12 – 2/27/15.

37. Lilly, 2011-139: “A Randomized Phase 2 Placebo-Controlled Study of LY2495655 in Patients with Advanced or Metastatic Pancreatic Cancer Receiving Chemotherapy”. PI ($13,150) 3/15/12 – 3/14/16.

38. Abbott Laboratories: M12-375: 2011-110: A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABT-700, a Monoclonal Antibody, in Subjects with Advanced Solid Tumors. PI 11/01/11 – 10/31/15. ($35,000)

39. Novartis: CLGK974X2101: 2011-135: A Phase I, Open-Label, Dose Escalation Study of Oral LGK974 in Patients with Melanoma and Lobular Breast Cancer. PI 09/08/11 – 12/15/15. ($40,000)

40. NCI, “Cancer Center Support Grant” (Acct 300601). PI 12/1/11 – 11/30/12. $2,700,000 41. NCI, “Southwest Oncology Group” (Acct 300607). PI 1/1/12 – 12/31/12. $315,000 42. Onconova, 2011-103: “A Phase II/III, Multi-center, Randomized, Controlled Study to Compare the

Efficacy and Safety of Gemcitabine Alone vs ON 01910.Na Combined with Gemcitabine in Patients with Previously Untreated Metastatic Pancreatic Cancer”. PI ($6,100) 12/1/11 – 11/30/12.

43. Lilly: I4T-MC-JVBT: 2011-003: “Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product (IMC-1121B) versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach”. PI ($106,257) 05/23/11 – 05/22/15.

Page 13: PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C ...igicc.org/wp-content/uploads/2019/05/Philip-Agop-Philip-CV.pdfPage 1 of 53 . PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C

Page 13 of 53

44. Novartis, CRAD001C2324, 2007-074, “A Randomized Double-Blind Phase III Study of RAD001 10mg/d plus Best Supportive Care versus Placebo plus Best Supportive Care in the Treatment of Patients with Advanced Pancreatic Neuroendrocrine Tumor (NET).” PI ($3757) 06/01/08 – 11/11/15.

45. Nektar Therapeutics #08-PIR-03, 2007-027, “A Multicenter, Open-Label, Randomized, Phase 2 Study to Evaluate the Efficacy and Safety of NKTR-102 (PEG-Irinotecan) Versus Irinotecan in Patients with Second-Line, Irinotecan-Naïve, KRAS-Mutant, Colorectal Cancer with Metastatic or Locally Advanced Disease.” PI ($27057) 07/02/09 – 07/01/15.

46. BMS, CA182033: 2009-035: “A Randomized, Double-blind, Multi-center Phase III Study of Brivanib versus Sorafenib as First-line Treatment in Patients with Advanced Hepatocellular Carcinoma”. PI ($3650) 1/1/10 – 2/24/14.

47. Amgen: 20060540: 2011-015: “A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Trial of AMG 479 or Placebo in Combination with Gemcitabine as First-Line Therapy for Metastatic Adenocarcinoma of the Pancreas”. PI ($8100) 05/02/11 – 05/01/13.

48. NIH R21, “Analysis of EMT Markers in Pancreatic Cancer.” Co-Investigator. 08/10 – 07/12. 49. Henry Ford Health System, Program Project Grant supporting translational work in pancreatic

cancer, P01 CA097012, “Molecular Gene and Radiation Therapies for Cancer.” PI Svend O Freytag, PhD, Consultant Philip A Philip

50. GSK, MEK113487: 2010-146: “A Randomized, Double-Blind Placebo-Controlled Phase II Study of the MEK inhibitor GSK1120212 plus Gemcitabine vs. Placebo plus Gemcitabine in Subjects with Metastatic Pancreatic Cancer”. PI ($4757) 3/15/11 – 3/14/12.

51. Novartis, CAUY922A2202: 2010-054: “A Randomized, Open-Label, Multi-center Phase II Study to Compare AUY922 with Docetaxel or Irinotecan in Adult Patients with Advanced Gastric Cancer, who have Progressed after one line of Chemotherapy”. PI 02/22/10 – 12/31/11.

52. BMS, CA182034: 2009-036: “A Randomized, Double-blind, Multi-center Phase III Study of Brivanib plus Best Supportive Care (BSC) versus Placebo plus BSC in Subjects with Advanced Hepatocellular Carcinoma (HCC) who have Failed or are Intolerant to Sorafenib: The BRISK Study.” PI 05/29/09 – 05/29/11.

53. Chugai GC-001US, 2008-069, “A Phase I, Open-Label, Multi-center, Dose-escalation Study of the Safety, Tolerability and Pharmacokinetics of GC33, a Recombinant Humanized Antibody to glypican-3 Administered Weekly in Patients with Advanced or Metastatic Hepatocellular Carcinoma (HCC).” PI ($5750) 11/21/09 – 11/20/12.

54. Pfizer, SU011248, “A Phase III Randomized, Double-Blind Study of Sunitinib (SU011248) Sutent versus Placebo in patients with Progressive Advanced/Metastatic Well-Differentiated Pancreatic Islet Cell Tumors.” Co-Investigator 01/24/08 – 01/23/11.

55. GenVec, GV-001.004, 2007-062, “A Randomized Phase II/III Study of TNFerade TM Biologic with 5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer.” Co-Investigator ($6482) 01/09/08 – 01/08/12.

56. GlaxoSmithKline, MET111643, “A Phase 2 Study of GSK1363089 (XL880) Administered Orally to subjects with Metastatic Gastric Cancer.” Co-Investigator 01/14/08 – 01/13/10.

57. NCI, “A Phase II Trial of OSI-774 in patients with Hepatocellular or Biliary Carcinoma (P2C# MC0152, NCI Protocol# 5429).” PI 02/04/02 – 9/30/11.

58. Pfizer, A6181114, “An Open-Label Sunitinib Malate (SU011248) Continuation Protocol for Patients who have completed a prior Sunitinib Study and are judged by the Investigator to have the potential to benefit from Sunitinib Treatment.” PI 04/01/08 – 03/31/10.

59. Sanofi-Aventis, EFC10547, “A Multi-National, Randomized, Double-blind Study, Comparing the Efficacy of Aflibercept Once Every 2 Weeks versus Placebo in Patients Treated with Gemcitabine for Metastatic Pancreatic Cancer.” PI 04/01/08 – 03/31/10.

60. Genentech, 2006-129, “An Observational Study of Avastin (Bevacizumab) in Combination with Chemotherapy for First-Line Treatment of Metastatic Colorectal Adenocarcinoma (Genentech Protocol AVF2941n).” PI ($6300) 08/01/07 – 7/31/12.

61. NIH/NCI, “Cancer Center Support Grant” (Acct 335200). Co-Investigator 12/01/08 – 03/31/12. 62. KCI, Lilly, OSI, Archer Daniels, “Phase II Trial of Genistein, Erlotinib and Gemcitabine in

Pancreatic Cancer” Karmanos Cancer Center Career Development Grant. Co-Investigator 10/06/06 – 12/31/08.

Page 14: PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C ...igicc.org/wp-content/uploads/2019/05/Philip-Agop-Philip-CV.pdfPage 1 of 53 . PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C

Page 14 of 53

63. Genentech, “An observational study of Avastin (Bevacizumab) in combination with chemotherapy for treatment of metastatic or locally advanced and unresectable colorectal cancer, locally advanced or metastatic non-small cell lung (excluding predominant squamous cell histology), or locally recurrent or metastatic breast cancer (ARIES).” PI 08/28/07 – 07/31/08.

64. Bristol-Myers Squibb, CA163-116-005, “A Phase II, Open Label Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer.” PI 09/11/07 – 09/10/10.

65. Genentech Sanofi-Aventis, “Phase II Trial of Bevacizumab, Docetaxel, and Oxaliplatin in Gastric and Gastroesophageal Junction Cancer.” PI 05/12/06 – 12/31/09.

66. Internal Medicine Department Seed Money Grant, $25,000. “Differential Gene Expression Profiling between Primary and Secondary Tumor Sites in Patients with Pancreas Cancer.” P.I. 07/12/04 – 12/31/10.

67. Bristol-Myers Squibb, $105,486, “A Phase III Randomized, Multicenter Study of Cetuximab, Oxaliplatin, 5-FU, and Leucovorin vs. Oxaliplatin, %-FU, and Leucovorin in Patients with Previously Treated Metastatic, EGFR-positive Colorectal Carcinoma.” P.I. 5% effort, 7/12/04 – 12/31/10.

68. Sanofi Aventis, $334,650, “A Phase II Trial of Bevacizumab, Docetaxel, and Oxaliplatin in Gastric and Gastroesophageal Junction Cancer.” P.I., 4% effort, 12/1/04 – 12/31/08.

69. OSI Pharmaceuticals, $38,828, “A Randomized, Open Label, Phase II Study of OSI-7904L vs. 5-FU/LV as First-line Treatment in Patients with Unresectable, Locally Advanced or Metastatic Adenocarcinoma of the Biliary Tract.” P.I. 5% effort, 7/30/04 – 12/31/10.

70. Bristol-Myers Squibb, ImClone Systems, Inc, $105,955 “A Phase III Randomized, Open label, Multicenter Study of Irinotecan and Cetuximab vs. Irinotecan as Second-line Treatment in Patients with Metastatic EGFR-Positive Colorectal Carcinoma.” 3/15/04 – 3/14/09.

71. Lilly, $115,516, “A Phase II Trial of Gemcitabine and Genistein In Metastatic Breast Cancer Patients with Biomarker Assays.” P.I. Philip Agop Philip, 5% effort. 2/18/04 – 2/28/06.

72. Detroit Medical Center Institute for Oncology and Allied Diseases ($15,000), “Combined Targeting of Cyclooxygenase-2 and NF-B Pathways in Pancreas Cancer.” P.I. 1/1/03-12/31/03.

73. Pfizer and Roche, #440E-ONC-0020-348, $190,300, “A Phase II Study of Capecitabine, Celecoxib, and Irinotecan in Patients with Metastatic Colorectal Cancer.” P.I. 5% effort. 1/4/02 – 12/31/06.

74. Eli Lilly #B93-US-X347, (direct cost = $6,814, indirect cost = $956, total = $84,000). “A Phase II Study of Gemcitabine, Celecoxib, and Cisplatin in Patients with Metastatic Pancreas Cancer.” PI 01/04/02 – 12/31/06.

75. Lilly Research Laboratories Protocol #B9E-MC-S247 (direct cost = $6,520, indirect cost = $1,598, total = $26,868). “A Phase II Trial of Full-Dose Gemcitabine with Concurrent Radiation Therapy in Patients with Resectable or Unresectable Non-Metastatic Pancreatic Cancer.” P.I. Philip Agop Philip. March 1, 2002 through February 28, 2003.

76. Pfizer, #440E-ONC-0020-348 (direct cost = $21,356, indirect cost = $3,844, total = $184,800). “A Phase II Study of Capecitabine, Celecoxib, and Irinotecan in Patients with Metastatic Colorectal Cancer.” P.I. January 4, 2002 through October 31, 2004.

77. Aventis Pharmaceuticals (total = $348,000). “Phase II Study of Neoadjuvant Docetaxel and Vinorelbine with or without Trastuzumab in Patients with Operable Stage I-IIIB Breast Cancer.” P.I. November 1, 2001 through March 31, 2003.

78. Sanofi-Synthelabo Research #EFC-4585 (direct cost = $1,271, indirect cost = $229, total = $120,000). “Multicenter, Open-Label, Randomized, Two-Arm Study of Irinotecan (CPT-11) Versus the Combination of Oxaliplatin + Irinotecan (CPT-11) as Second-Line Treatment of Metastatic Colorectal Carcinoma – EFC-4585.” P.I. May 4, 2001 through May 31, 2003.

79. Sanofi-Synthelabo Research #EFC 4584 Z-2320 (direct cost = $48,729, indirect cost = $8,771, total = $120,000). “Multicenter, Open-Label, Randomized, Two-Arm Study of Irinotecan (CPT- 11) Versus the Combination of Oxaliplatin + Irinotecan (CPT-11) as Second-Line Treatment of Metastatic Colorectal Carcinoma – EFC-4585.” P.I. March 1, 2001 through May 31, 2003.

80. Tularik, Inc. #T-2004, (direct cost = $13,030, indirect cost = $2,345, total = $75,000). “A Phase I/II Open-Label Study of T138067 – Sodium in Patients with Advanced, Surgically Unrespectable Hepatocellular Carcinoma.” P.I. October 25, 2000 through September 30, 2002.

Page 15: PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C ...igicc.org/wp-content/uploads/2019/05/Philip-Agop-Philip-CV.pdfPage 1 of 53 . PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C

Page 15 of 53

81. Genentech & Bristol-Myers Squibb (total = $160,000). “Phase II Study of Herceptin and taxol in Esophageal or Gastro-esophageal Junction Cancers.” P.I. May 14, 2000 through January 31, 2002.

82. NIH ($1,250,350). “Labeled Thymidine: Development as a PET Imaging Agent.” P.I. Anthony F. Shields. Philip Agop Philip (Consultant). April 1, 2000 through March 31, 2004.

83. Lilly Research Laboratories Protocol #B9E-MC-X251 (direct cost = $81,779, indirect cost = $14,721, total = $125,000). “Study of Gemzar, Cisplatin and 5-Fluororacil in the Treatment of Advanced Pancreatic Cancer.” P.I. September 1, 1999 through August 31, 2002.

84. Zeneca (total = $4,400), “A Double-Blind, Randomized Multicenter Trial Comparing T.” P.I. June 1, 1999 through August 20, 1999.

85. Zeneca Pharmaceuticals #9238IL/0025 (direct cost = $4,237, indirect cost = $763, total = $5,000). “A Double-Blind, Randomized Multicenter Trial Comparing the Efficacy and Tolerability of 250

86. mg of FASLODEX (Long-Acting ICI 182,780) with 250 mg of NOLVADEX (Tamoxifen) in Postmenopausal Women with Advanced Breast Cancer.” P.I. February 1, 1999 through December 31, 1999.

87. Bristol-Myers-Squibb (total = $5,000). “Correlation Studies in Advanced Stomach/Esophageal Cancers.” P.I. October 1, 1997 through July 31, 1998.

88. Department of Defense (total = $314,989). “Role of RAD6, a DNA Repair Gene, in Tumor Progression and Drug Resistance.” P.I. Malathy Shekhar Ph.D., Philip Agop Philip. 5% effort, May 1, 1999 through April 30, 2002.

89. Bristol-Myers Squibb (direct cost = $33,898, indirect cost = $6,102, total = $40,000). “Phase I Study of Gemcitabine (GEMZAR) and UFT/Leucovorin.” P.I., September 1, 1998 through December 31, 2002.

90. Karmanos Cancer Institute, Virtual Discovery Grant, (total = $75,000). “Evaluation of the Mechanisms and Magnitude of Radiation-Induced Cardiac Toxicity in Left-Sided Breast Cancer Patients.” Co-investigator, April 1, 1998 through August 31, 1999.

91. Eli Lilly PO#4500007955/#B9E-MC-X148 (direct cost = $43,433, indirect cost = $7,817, total = $51,250). “Phase I Study of Gemzar and UFT/Leucovorin in Solid Tumors.” March 1, 1998 – Dec

31, 2002. 92. NCI, 2U10 CA 14028-25, (total = $227,088). “Southwest Oncology Group.” P.I., L.E. Flaherty, Philip

Agop Philip, 5% effort. January 1, 1998 through December 31, 2002. 93. Eli-Lilly PO #4500007890/#B9E-MC-X103, (direct cost = $10,169, indirect cost = $1,831, total =

$12,000). “Study of Gemcitabine in Patients with Advanced Breast Cancer who Relapsed After High-Dose Chemotherapy and Autologous Bone Marrow Transplantation.” December 1, 1997 through December 31, 2002.

94. Lilly Research Laboratories #B9E-MC-X097, (direct cost = $20,212, indirect cost = $3,638, total = $23,850). “Study of Gemcitabine and Liposomal Doxorubicin (Doxil) in Patients with Advanced Breast Cancer.” P.I.

95. “Phase II Study of Gemzar and Doxil in Patients with Liposomal Doxorubicin in Advanced Breast Cancer.” P.I. September 15, 1997 through September 14, 1998.

96. Eli-Lilly (total = $75,000). “Phase II Study of Gemcitabine in Patients with Breast Cancer Who Relapse After High-Dose Chemotherapy and Autologous Bone Marrow Transplant.” P.I. September 1, 1997 through November 30, 1998.

97. Lilly Research Laboratories Protocol #B9E-MC-X027, (direct cost = $55,085, indirect cost = $9,915, total = $65,000). “A Study of Gemcitabine and Cisplatin in The Treatment of Advanced or Metastatic Pancreatic Cancer.” April 1, 1997 through August 31, 2001.

98. Rhone-Poulenc Rorer Pharmaceuticals, Inc., (direct cost = $100,501, indirect costs = $18,091, total = $118,592). “A Phase II Study of the Combination of Taxotere, Doxorubicin and Infusional 5-FU in the Treatment of Locally Advanced Breast Cancer.” P.I. January 1, 1997 through December 31, 2000.

99. Affiliated Internists, (total = $24,000). “A Study of the Influence of Cellular Expression of Carcinogen-Metabolizing Enzymes on the Presence of Mutated p53 in Peri-tumoral Mucosal Cells in Patients with Head and Neck Cancer.” P.I., Philip Agop Philip. June 1997.

100. NIH – ROI CA61526-02, (total = $91,304). “New Drug Combinations for Breast Cancer.” P.I., P. M. LoRusso, Philip Agop Philip, 5% effort. August 1, 1993 through May 31, 1998.

101. NCI-2U10 CA 14028-24, (total = $218,354). Southwest Oncology Group. P.I., L.E. Flaherty, Philip Agop Philip, 5% effort. January 1, 1978 through December 31, 1998.

Page 16: PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C ...igicc.org/wp-content/uploads/2019/05/Philip-Agop-Philip-CV.pdfPage 1 of 53 . PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C

Page 16 of 53

102. Harper Hospital Medical Staff Trust Fund Role, (direct cost = $19,400/indirect cost = 0/closed), Funded July 1, 1996 through April 30, 1997. “Role of cytochrome P-450 3A4 enzyme in the pharmacokinetics of cyclophosphamide and cytotoxic metabolite formation in patients with cancer.” P.I. July 1, 1996 through April 30, 1997.

103. National Institutes of Health/National Institute of Environmental Health Sciences, (total = $10,000). “A study of differences in the expression of xenobiotic metabolizing enzymes in the oral mucosa of African-Americans and Caucasians.” P.I. April 1, 1995 through March 31, 1997.

104. Sequus Pharmaceuticals, Inc., (total = $5,000). “Doxil and Cyclophosphamide/Phase I Study.” PI, October 1996.

PUBLICATIONS Original Observations in Peer-Reviewed Journals: 1. Puccini A, Dr. Axel Grothey , Dr. Derek Raghavan , Dr. Richard M. Goldberg , Dr. Joanne

Xiu , Dr. W. Michael Korn , Dr. Benjamin A. Weinberg , Dr. Jimmy Hwang , Dr. Anthony F. Shields , Dr. John L. Mashall , Dr. Philip A. Philip , Dr. Heinz-Josef Lenz. Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers. Molecular Cancer Research, In Press.

2. Javle M, Lowery M, Shroff RT, Weiss KH, Springfeld C, Borad MJ, Ramanathan RK, Goyal L, Sadeghi S, macarulla T, El-Khoueiry A, Kelley RK, Borbath I, Choo SP, Oh DY, Philip PA, Chen LT, Reungwetwattana T, Van CutsemE, Yeh KH, Ciombor K, Finn RS, Patel A, Sen S, Porter D, Isaacs R, Zhu AX, Abou-Alfa GK, Bekaii-Saab T. Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. J Clin Oncol. 2018 Jan 20;36(3):276-282. doi: 10.1200/JCO.2017.75.5009. Epub 2017 Nov 28.

3. Veer ET, L van Rijssen LB, Besselink, MD MSc PhD2; Rosa M.A. Mali, BSc1; Prof.Jordan D. Berlin, MD3; Prof. Stefan Boeck, MD4; Prof. Franck Bonnetain, MD PhD5,†; Ian Chau, MD6; Prof. Thierry Conroy, MD7; Prof. Eric Van Cutsem, MD PhD8; Gael Deplanque, MD PhD9; Prof. Helmut Friess, MD10; Prof. Bengt Glimelius, MD PhD11; Prof. David Goldstein, MD PhD12; Prof. em. Richard Herrmann, MD PhD13; Roberto Labianca, MD PhD14; Prof. Jean-Luc Van Laethem, MD PhD15; Teresa Macarulla, MD PhD16; Jonathan H.M. Van der Meer, MD2; Prof. John P Neoptolemos, MD PhD17; Takuji Okusaka, MD PhD18; Prof. Eileen M. O’Reilly, MD19; Uwe Pelzer, MD PhD20; Prof. Philip A Philip, MD PhD21; Marcel J. van der Poel, MD2; Michele Reni, MD22; Prof. Werner Scheithauer, MD23; Prof. Jens T. Siveke, MD24; Prof. Chris Verslype, MD PhD25; Prof. Olivier R.C. Busch2, MD PhD; Johanna W. Wilmink, MD PhD1; Martijn G.H. van Oijen, PhD1; van Laarhoven HWM, MD PhD1.. COnsensus statement on Mandatory Measurements in PAncreatic Cancer Trials for systemic treatment of unresectable disease (COMM-PACT). The Lancet Oncology, Volume 19, No. 3, e151–e160, March 2018

4. Tesfaye AA, Kamgar M, Azmi A, Philip PA. The evolution into personalized therapies in pancreatic ductal adenocarcinoma: challenges and opportunities. Expert Rev Anticancer Ther. 2018 Feb;18(2):131-148. doi: 10.1080/14737140.2018.1417844. Epub 2017 Dec 19. PubMed PMID: 29254387..

5. Berlin JD1, Feng Y, Catalano P, Abbruzzese JL, Philip PA, McWilliams RR, Lowy AM, Benson Iii AB, Blackstock AW. An Intergroup Randomized Phase II Study of Bevacizumab or Cetuximab in Combination with Gemcitabine and in Combination with Chemoradiation in Patients with Resected Pancreatic Carcinoma: A trial of the ECOG-ACRIN Cancer Research Group (E2204). Oncology, 2017 Oct 18. doi: 10.1159/000480295. [Epub ahead of print]

6. Azmi AS, Li Y, Muqbil I, Aboukameel A, Senapedis W, Baloglu E, Landesman Y, Shacham S, Kauffman MG, Philip PA, Mohammad RM. Exportin 1 (XPO1) inhibition leads

Page 17: PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C ...igicc.org/wp-content/uploads/2019/05/Philip-Agop-Philip-CV.pdfPage 1 of 53 . PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C

Page 17 of 53

to restoration of tumor suppressor miR-145 and consequent suppression of pancreatic cancer cell proliferation and migration. Oncotarget. 2017 Jul 17;8(47):82144-82155. doi: 10.18632/oncotarget.19285. eCollection 2017 Oct 10. PubMed PMID: 29137251; PubMed Central PMCID: PMC5669877.

7. Salem ME, Weinberg BA, Xiu J, El-Deiry WS, Hwang JJ, Gatalica Z, Philip PA, Shields AF, Lenz HJ, Marshall JL. Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers. Oncotarget. 2017 Sep 21;8(49):86356-86368. doi: 10.18632/oncotarget.21169. eCollection 2017 Oct 17. PubMed PMID: 29156800; PubMed Central PMCID: PMC5689690.

8. Separovic D, Shields AF, Philip PA, Bielawski J, Bielawska A, Pierce JS, Tarca AL. Altered Levels of Serum Ceramide, Sphingosine and Sphingomyelin Are Associated with Colorectal Cancer: A Retrospective Pilot Study. Anticancer Res. 2017 Mar;37(3):1213-1218. PubMed PMID: 28314284.

9. Mohammad RM, Li Y, Muqbil I, Aboukameel A, Senapedis W, Baloglu E, Landesman Y, Philip PA, Azmi AS. Targeting Rho GTPase effector p21 activated kinase 4 (PAK4) suppresses p-Bad-microRNA drug resistance axis leading to inhibition of pancreatic ductal adenocarcinoma proliferation. Small GTPases. 2017 Jun 22:0.doi 10.1080/21541248.2017.1329694. [Epub ahead of print] PubMed PMID: 28641032.

10. Lenz HJ, Philip P, Saunders M, Kolevska T, Mukherjee K, Samuel L, Bondarde S, Dobbs T, Tagliaferri M, Hoch U, Hannah AL, Berkowitz M. Randomized study of etiririnotecan pegol versus irinotecan as second-line treatment for metastatic colorectal cancer. Cancer Chemother Pharmacol. 2017 Dec;80(6):1161-1169. doi: 10.1007/s00280-017-3438-y. Epub 2017 Oct 17. PMID: 29043412.

11. Weinberg BA, Philip PA, Salem ME. Evolving standards of care for resected pancreatic cancer. Hematol Oncol. 2017 Feb;15(2):141-150.

12. Aboukameel A, Muqbil I, Senapedis W, Baloglu E, Landesman Y, Shacham S, Kauffman M, Philip PA, Mohammad RM, Azmi AS. Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma. Mol Cancer Ther. 2017 Jan;16(1):76-87. doi: 10.1158/1535-7163.MCT-16-0205. PMID:28062705

13. Yoon HH, Bendell JC, Braiteh FS, Firdaus I, Philip PA, Cohn AL, Lewis N, Anderson DM, Arrowsmith E, Schwartz JD, Gao L, Hsu Y, Xu Y, Ferry D, Alberts SR, Wainberg ZA. Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial. Ann Oncol. 2016 Dec;27(12):2196-2203.doi: 10.1093/annonc/mdw423. Epub 2016 Oct 20. PubMed PMID: 27765757.

14. M Katz; Q Shi; S Ahmad; J Herman; R Marsh; E Collisson; L Schwartz; W Frankel; R Martin; W Conway; M Truty; H Kindler; A Lowy; T Saab; P Philip M Talamonti; D Cardin; N LoConte; P Shen, J Hoffman; A Venook, Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer Alliance for Clinical Trials in Oncology Trial A021101. JAMA Surg. doi:10.1001/jamasurg.2016.1137

15. Chung V, McDonough S, Philip PA, Cardin D, Wang-Gillam A, Hui L, Tejani MA, Seery TE, Dy IA, Al Baghdadi T, Hendifar AE, Doyle LA, Lowy AM, Guthrie KA, Blanke CD, Hochster HS. Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial. JAMA Oncol. 2016 Dec 15. doi: 10.1001/jamaoncol.2016.5383. PMID:27978579

16. Artac M, Korkmaz L, El-Rayes B, Philip PA. An update on the multimodality of localized rectal cancer. Crit Rev Oncol Hematol. 2016 Dec;108:23-32. doi: 10.1016/j.critrevonc.2016.10.004. Review. PMID:27931837

17. Diab M, Muqbil I, Mohammad RM, Azmi AS, Philip PA. The Role of microRNAs in the Diagnosis and Treatment of Pancreatic Adenocarcinoma. J Clin Med. 2016 Jun 16;5(6). pii: E59. doi:

Page 18: PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C ...igicc.org/wp-content/uploads/2019/05/Philip-Agop-Philip-CV.pdfPage 1 of 53 . PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C

Page 18 of 53

10.3390/jcm5060059. Review. PMID:27322337 18. Sohal DP, Mangu PB, Khorana AA, Shah MA, Philip PA, O'Reilly EM, Uronis HE, Ramanathan

RK, Crane CH, Engebretson A, Ruggiero JT, Copur MS, Lau M, Urba S, Laheru D. Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016 Aug 10;34(23):2784-96. doi: 10.1200/JCO.2016.67.1412. PMID:27247222

19. Philip PA. Targeting macrophages to treat pancreatic cancer. Lancet Oncol. 2016 May;17(5):552-3. doi: 10.1016/S1470-2045(16)00151-0. No abstract available. PMID:27055730

20. Sukari A, Muqbil I, Mohammad RM, Philip PA, Azmi AS. F-BOX proteins in cancer cachexia and muscle wasting: Emerging regulators and therapeutic opportunities. Semin Cancer Biol. 2016 Feb;36:95-104. doi: 10.1016/j.semcancer.2016.01.002. Review. PMID:26804424

21. Suresh R, Ali S, Ahmad A, Philip PA, Sarkar FH. The Role of Cancer Stem Cells in Recurrent and Drug-Resistant Lung Cancer. Adv Exp Med Biol. 2016;890:57-74. doi: 10.1007/978-3-319-24932-2_4. Review. PMID:26703799.

22. Azmi AS1, Muqbil I1, Wu J1, Aboukameel A1, Senapedis W2, Baloglu E2, Bollig-Fischer A1, Dyson G1, Kauffman M2, Landesman Y2, Shacham S2, Philip PA1,Mohammad RM1,3Targeting the Nuclear Export Protein XPO1/CRM1 Reverses Epithelial to Mesenchymal Transition. Sci Rep. 2015 Nov 5;5:16077. doi: 10.1038/srep16077.

23. Philip PA. Systemic Therapy of Pancreatic Cancer: Better Science, Faster Progress. Oncology (Williston Park). 2015 Nov;29(11):821, 826. PMID: 26573061

24. O'Neil BH, Scott AJ, Ma WW, Cohen SJ, Leichman L, Aisner DL, Menter AR, Tejani MA, Cho JK, Granfortuna J, Coveler L, Olowokure OO, Baranda JC1, Cusnir M, Phillip P, Boles J, Nazemzadeh R, Rarick M,Cohen DJ, Radford J, Fehrenbacher L, Bajaj R, Bathini V, Fanta P, Berlin J, McRee AJ, Maguire R,Wilhelm F, Maniar M, Jimeno A, Gomes CL, Messersmith WA. A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer. Ann Oncol. 2015 Oct 21. pii: mdv477.

25. Shaib WL, Martin LK, Choi M, Chen Z, Krishna K, Kim S, Brutcher E, Staley C 3rd, Maithel SK, Philip P, Abdel-Misih S, Bekaii-Saab TS, El-Rayes BF. Hyperthermic Intraperitoneal Chemotherapy Following Cytoreductive Surgery Improves Outcome in Patients With Primary Appendiceal Mucinous Adenocarcinoma: A Pooled Analysis From Three Tertiary Care Centers.<http://www.ncbi.nlm.nih.gov/pubmed/26070916> Oncologist. 2015 Jun 12.

26. Suresh R, Ali S, Ahmad A, Philip PA, Sarkar FH. The Role of Cancer Stem Cells in Recurrent and Drug-Resistant Lung Cancer. Adv Exp Med Biol. 2016;890:57-74. doi: 10.1007/978-3-319-24932-2_4. PMID: 26703799

27. Ali S, Suresh R, Banerjee S, Bao B, Xu Z, Wilson J, Philip PA, Apte M, Sarkar FH. Contribution of microRNAs in understanding the pancreatic tumor microenvironment involving cancer associated stellate and fibroblast cells. Am J Cancer Res. 2015 Feb 15;5(3):1251-64. PMID: 26046003

28. Azmi AS, Muqbil I, Wu J, Aboukameel A, Senapedis W, Baloglu E, Bollig-Fischer A, Dyson G, Kauffman M, Landesman Y, Shacham S, Philip PA, Mohammad RM. Targeting the Nuclear Export Protein XPO1/CRM1 Reverses Epithelial to Mesenchymal Transition. Sci Rep. 2015 Nov 5;5:16077. doi: 10.1038/srep16077.PMID: 26536918

29. Philip PA, Lutz MP. Targeting Epidermal Growth Factor Receptor-Related Signaling Pathways in Pancreatic Cancer. Pancreas. 2015 Oct;44(7):1046-52. PMID: 26355547

30. Strosberg JR, Fisher GA, Benson AB, Anthony LB, Arslan B, Gibbs JF, Greeno E, Iyer RV, Kim MK, Maples WJ, Philip PA, Wolin EM, Cherepanov D, Broder MS. Appropriateness of systemic treatments in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors. World J Gastroenterol. 2015 Feb 28;21(8):2450-9. doi: 10.3748/wjg.v21.i8.2450. Review. PMID: 25741154

31. Choi M, Kollepara S, Heilbrun L, Smith D, Shields AF, Philip PA. PET Scans as a Predictive Marker of Survival in Advanced Colorectal Cancer. Clinical Colorectal Cancer. 2014 Oct 23. pii: S1533-0028(14)00104-2. doi: 10.1016/j.clcc.2014.10.001. PMID: 25481195.

32. J Strosberg, G Fisher, A Benson, L Anthony, B Arslan, J Gibbs, E Greeno, R Iyer, M Kim, W Maples, P Philip, E Wolin, D Cherepanov, M Broder. Appropriateness of systemic treatments in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors. World Journal of Gastroenterology. World J Gastroenterol. 2015 Feb 28;21(8):2450-9. doi: 10.3748/wjg.v21.i8.2450

Page 19: PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C ...igicc.org/wp-content/uploads/2019/05/Philip-Agop-Philip-CV.pdfPage 1 of 53 . PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C

Page 19 of 53

PMID: 25741154 33. Ali S, Ahmad A, Aboukameel A, Ahmed A, Bao B, Banerjee S, Philip PA, Sarkar FH. Deregulation

of miR-146a expression in a mouse model of pancreatic cancer affecting EGFR signaling. Cancer Lett. 2014 Aug 28;351(1):134-42. doi: 10.1016/j.canlet.2014.05.013. Epub 2014 May 16. PMID: 24839931

34. Konski A, Meyer JE, Joiner M, Hall MJ, Philip P, Shields A, McSpadden E, Choi M, Adaire B, Duncan G, Meropol NJ, Cescon TP, Cohen SJ. Multi-institutional phase I study of low-dose ultra-fractionated radiotherapy as a chemosensitizer for gemcitabine and erlotinib in patients with locally advanced or limited metastatic pancreatic cancer. Radiother Oncol. 2014 Oct;113(1):35-40. doi: 10.1016/j.radonc.2014.08.014. Epub 2014 Oct 20. PMID: 25441058.

35. Philip PA, Chansky K, LeBlanc M, Rubinstein L, Seymour L, Ivy SP, Alberts SR, Catalano PJ, Crowley J. Historical controls for metastatic pancreatic cancer: benchmarks for planning and analyzing single-arm phase II trials. Clin Cancer Res. 2014 Aug 15;20(16):4176-85.

36. Philip PA, Goldman B, Ramanathan RK, Lenz HJ, Lowy AM, Whitehead RP, Wakatsuki T, Iqbal S, Gaur R, Benedetti JK, Blanke CD. Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: Phase ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727). Cancer. 2014 July 16. Doi: 10.1002/cncr.28744 PMID: 25041791.

37. Sarkar S, Dubaybo H, Ali S, Goncalves P, Kollepara SL, Sethi S, Philip PA, Li Y. Down-regulation of miR-221 inhibits proliferation of pancreatic cancer cells through up-regulation of PTEN, p27(kip1), p57(kip2), and PUMA. Am J Cancer Res. 2013 Nov 1;3(5):465-77. PubMed PMID: 24224124.

38. Johnson PJ, Qin S, Park JW, Poon RT, Raoul JL, Philip PA, Hsu CH, Hu TH, Heo J, Xu J, Lu L, Chao Y, Boucher E, Han KH, Paik SW, Robles-Aviña J, Kudo M, Yan L, Sobhonslidsuk A, Komov D, Decaens T, Tak WY, Jeng LB, Liu D, Ezzeddine R, Walters I, Cheng AL. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol. 2013 Oct 1;31(28):3517-24. doi: 10.1200/JCO.2012.48.4410. Epub 2013 Aug 26. PubMed PMID: 23980084.

39. Salem ME, Jain N, Dyson G, Taylor S, El-Refai SM, Choi M, Shields AF, Critchfield J, Philip PA. Radiographic parameters in predicting outcome of patients with hepatocellular carcinoma treated with yttrium-90 microsphere radioembolization. ISRN Oncol. 2013 Sep 15;2013:538376. doi: 10.1155/2013/538376. PubMed PMID: 24167742; PubMed Central PMCID: PMC3791818.

40. Rougier P, Riess H, Manges R, Karasek P, Humblet Y, Barone C, Santoro A, Assadourian S, Hatteville L, Philip P. Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Phase III Study Evaluating Aflibercept in Patients Receiving First-Line Treatment with Gemcitabine for Metastatic Pancreatic Cancer. Eur J Cancer. 2013 Aug:49(12):2633-42. PMID: 23642329.

41. Katz MH, Marsh R, Herman JM, Shi Q, Collison E, Venook AP, Kindler HL, Alberts SR, Philip P, Lowy AM, Pisters PW, Posner MC, Berlin JD, Ahmad SA. Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design. Ann Surg Oncol 2013 Aug;20(8):2787-95. doi: 10.1245/s10434-013-2886-9. Epub 2013 Feb 23.

42. Strosberg JR, Fisher GA, Benson AB, Malin JL; GEPNET Treatment Consensus Panel, Cherepanov D, Broder MS, Anthony LB, Arslan B, Fisher GA, Gibbs JF, Greeno E, Iyer RV, Kim MK, Maples W, Philip PA, Strosberg J, Wolin EM. Systemic treatment in unresectable metastatic well-differentiated carcinoid tumors: consensus results from a modified delphi process. Pancreas. 2013 Apr;42(3):397-404. doi: 10.1097/MPA.0b013e31826d3a17. PubMed PMID: 23211372.

43. Zhu AX, Gold PJ, El-Khoueiry A, Abrams TA, Morikawa H, Ohishi N, Ohtomo T, Philip PA. First-in-Man Phase I Study of GC33, A Novel Recombinant Humanized Antibody against Glypican-3, in Patients with Advanced Hepatocellular Carcinoma. Clin Cancer Res. Jan 29 2013;19:920-928, PubMed PMID: 23362325.

44. Ali AS, Ahmad A, Ali S, Bao B, Philip PA, Sarkar FH. The role of cancer stem cells and miRNAs in defining the complexities of brain metastasis. J Cell Physiol. 2013 Jan;228(1):36-42. doi: 10.1002/jcp.24127. Review. PubMed PMID:22689345; PubMed Central PMCID: PMC3443527.

45. Bauer TM, El-Rayes BF, Li X, Hammad N, Philip PA, Shields AF, Zalupski MM, Bekaii-Saab T. Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced

Page 20: PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C ...igicc.org/wp-content/uploads/2019/05/Philip-Agop-Philip-CV.pdfPage 1 of 53 . PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C

Page 20 of 53

pancreatic cancer who receive gemcitabine-containing chemotherapy: A pooled analysis of 6 prospective trials. Cancer. 2013 Jan 15;119(2):285-92. doi: 10.1002/cncr.27734. Epub 2012 Jul 11. PubMed PMID: 22786786.

46. Azmi AS, Aboukameel A, Bao B, Sarkar FH, Philip PA, Kauffman M, Shacham S, Mohammad RM. Selective Inhibitors of Nuclear Export Block Pancreatic Cancer Cell Proliferation and Reduce Tumor Growth in Mice. Gastroenterology. 2012 Oct 23. doi:pii: S0016-5085(12)01552-1. 10.1053/j.gastro.2012.10.036. PubMed PMID: 23089203.

47. Ali S, Saleh H, Sethi S, Sarkar FH, Philip PA. MicroRNA profiling of diagnostic needle aspirates from patients with pancreatic cancer. Br J Cancer. 2012 Oct 9;107(8):1354-60. doi:10.1038/bjc.2012.383. Epub 2012 Aug 28. PubMed PMID: 22929886; PubMed Central PMCID: PMC3494446.

48. Qazi AM, Gruzdyn O, Semaan A, Seward S, Chamala S, Dhulipala V, Sethi S, Ali-Fehmi R, Philip PA, Bouwman DL, Weaver DW, Gruber SA, Batchu RB. Restoration of E-cadherin expression in pancreatic ductal adenocarcinoma treated with microRNA-101. Surgery. 2012 Oct;152(4):704-11; discussion 711-3. doi:10.1016/j.surg.2012.07.020. Epub 2012 Sep 1. PubMed PMID: 22943841.

49. Claudino WM, Goncalves PH, di Leo A, Philip PA, Sarkar FH. Metabolomics in cancer: a bench-to-bedside intersection. Crit Rev Oncol Hematol. 2012 Oct;84(1):1-7. doi: 10.1016/j.critrevonc.2012.02.009. Epub 2012 March 18 PMID: 22429650.

50. Rocha Lima CM, Lin EH, Kim GP, Giguere JK, Marshall J, Zalupski M, Papageorgio C, Auber ML, Kaleta R, McHenry MB, Trifan OC, Philip PA. A phase 2 trial of ixabepilone plus cetuximab in first-line treatment of metastatic pancreatic cancer. Gastrointest Cancer Res. 2012 Sep;5(5):155-60. PubMed PMID: 23112883; PubMed Central PMCID: PMC3481147.

51. Almhanna K, El-Rayes B, Sethi S, Dyson G, Heilbrun L, Philip PA, Sarkar F. Association between COX-2 expression and effectiveness of COX-2 inhibitors in a phase II trial in patients with metastatic colorectal adenocarcinoma. Anticancer Res. 2012 Aug;32(8):3559-63. PubMed PMID: 22843946.

52. Soubani O, Ali AS, Logna F, Ali S, Philip PA, Sarkar FH. Re-expression of miR-200 by novel approaches regulates the expression of PTEN and MT1-MMP in pancreatic cancer. Carcinogenesis. 2012 Aug;33(8):1563-71. doi:10.1093/carcin/bgs189. Epub 2012 May 27. PubMed PMID: 22637745.

53. Ali AS, Ali S, Ahmad A, Bao B, Philip PA, Sarkar FH. Expression of microRNAs: potential molecular link between obesity, diabetes and cancer. Obes Rev. 2011 Dec;12(12):1050-62. doi: 10.1111/j.1467-789X.2011.00906.x. Epub 2011 Jul 19. Review. PubMed PMID: 21767342.

54. Kim GP, Mahoney MR, Szydlo D, Mok TS, Marshke R, Holen K, Picus J, Boyer M, Pitot HC, Rubin J, Philip PA, Nowak A, Wright JJ, Erlichman C. An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma. Invest New Drugs. 2012 Feb;30(1):387-94. PMID: 20839030.

55. Banerjee S, Padhye S, Azmi A, Wang Z, Philip PA, Kucuk O, Sarkar FH, Mohammad RM. Review on molecular and therapeutic potential of thymoquinone in cancer. Nutr Cancer. 62(7):938-46, 2011.

56. El-Rayes BF, Philip PA, Sarkar FH, Shields AF, Ferris AM, Hess K, Kaseb AO, Javle MM, Varadhachary GR, Wolff RA, Abbruzzese JL. A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer. Invest New Drugs. 2011 Aug;29(4):694-9. Epub 2010 Jan 27. PMID: 20107864.

57. Bao B, Ali S, Kong D, Sarkar SH, Wang Z, Banerjee S, Aboukameel A, Padhye S, Philip PA, Sarkar FH. Anti-tumor activity of a novel compound-CDF is mediated by regulating miR-21, miR-200, and PTEN in pancreatic cancer. PLoS One. 2011 Mar 9;6(3):e17850. PMID: 21408027; PMCID: PMC3052388.

58. Philip PA. Locally advanced pancreatic cancer: where should we go from here? J Clin Oncol. 2011 Nov 1;29(31):4066-8. Epub 2011 Oct 3. PMID: 21969514.

59. Philip PA, Mahoney MR, Holen KD, Northfelt DW, Pitot HC, Picus J, Flynn PJ, Erlichman C. Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer. Cancer. 2012 May 1;118(9):2424-30. doi:10.1002/cncr.26556. Epub 2011 Sep 27. PubMed PMID: 21953248.

60. Azmi AS, Ali S, Banerjee S, Bao B, Maitah MN, Padhye S, Philip PA, Mohammad RM, Sarkar FH. Network modeling of CDF treated pancreatic cancer cells reveals a novel c-myc-p73 dependent

Page 21: PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C ...igicc.org/wp-content/uploads/2019/05/Philip-Agop-Philip-CV.pdfPage 1 of 53 . PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C

Page 21 of 53

apoptotic mechanism. Am J Transl Res. 2011 Aug 15;3(4):374-82. Epub 2011 Jul 26. PMID: 21904657; PMCID:PMC3158739.

61. Azmi AS, Banerjee S, Ali S, Wang Z, Bao B, Beck FW, Maitah M, Choi M, Shields TF, Philip PA, Sarkar FH, Mohammad RM. Network modeling of MDM2 inhibitor-oxaliplatin combination reveals biological synergy in wt-p53 solid tumors. Oncotarget. 2011 May;2(5):378-92. PMID: 21623005; PMCID: PMC3248191.

62. Ali AS, Ali S, Ahmad A, Bao B, Philip PA, Sarkar FH. Expression of microRNAs:potential molecular link between obesity, diabetes and cancer. Obes Rev. 2011 Dec;12(12):1050-62. doi: 10.1111/j.1467-789X.2011.00906.x. Epub 2011 Jul 19. Review. PMID: 21767342.

63. Hammad N, Heilbrun LK, Gupta S, Tageja N, Philip P, Shields AF, Smith D, El-Rayes B. Squamous Cell Cancer of the Anal Canal in HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy. Amer Journal of Clinc Onc. 2011 Apr; 34(2):135-139.

64. Philip PA. Are we ready for neoadjuvant therapy in potentially resectable pancreatic cancer? Oncology (Williston Park). 2011 Feb;25(2):189-90, 192. PMID: 21456391.

65. Philip PA. Developing targeted therapies in pancreatic cancer. Lancet Oncol. 2011 Mar;12(3):206 PMID: 21306954.

66. Azmi AS, Philip PA, Beck FW, Wang Z, Banerjee S, Wang S, Yang D, Sarkar FH, Mohammad RM. MI-219-zinc combination: a new paradigm in MDM2 inhibitor-based therapy. Oncogene. 2011 Jan 6;30(1):117-26. PMID: 20818437

67. Bin Bao; Shadan Ali; Dejuan Kong; Sanila H Sarkar; Zhiwei Wang; Sanjeev Banerjee; Amro Aboukameel; Subhash Padhye; Philip A Philip; Fazlul H. Sarkar. Anti-tumor activity of a novel compound-CDF is mediated by regulating miR-21, miR-200, and PTEN in pancreatic cancer. PloS ONE. 2011, Mar 9;6(3):317850. PMID: 21408027

68. Lubner S, Mahoney M, Kolesar J, LoConte N, Kim P, Pitot H, Philip P, Picus J, Ping Yong W, Horvath L, VanHazel G, Erlichman C, Holen K. Report of a multicenter phase 2 trial testing a combination of biweekly Bevacizumab and daily erlotinib in patients with unresectable biliary cancer (BC): A Phase 2 Consortium (P2C) study. Journal of Clinical Oncology, 28:3491-3497, 2010.

69. Philip PA, Benedetti J, Goldman B, Lowy A, Blanke C. Reply to S. Boeck et al. JCO published online Dec 13, 2010; DOI:10.1200/JCO.2010.32.0101.

70. Moinpour CM, Vaught NL, Goldman B, Redman MW, Philip PA, Millwood B, Lippman SM, Seay TE, Flynn PJ, O’Reilly EM, Rowland KM, Wong RP, Benedetti J, Blanke CD. Pain and emotional well-being outcomes in Southwest Oncology Group-directed intergroup trial S0205: a phase III study comparing gemcitabine plus cetuximab versus gemcitabine as first-line therapy in patients with advanced pancreas cancer. J Clin Oncol. 2010 Aug 1;28(22):3611-6. PMID: 20606094

71. Azmi AS, Wang Z, Philip PA, Mohammad RM, Sarkar FH. Emerging Bcl-2 inhibitors for the treatment of cancer. Expert Opin Emerg Drugs. 2010 Sept 3. PMID: 20812891

72. Azmi AS, Wang Z, Philip PA, Mohammad RM, Sarkar FH. Proof of concept: network and systems biology approaches aid in the discovery of potent anticancer drug combinations. Mol Cancer Ther. 2010 Dec;9(12):3137-44. PMID: 21041384

73. Ali S, Almhanna K, Chen W, Philip PA, Sarkar FH. Differentially expressed miRNA’s in the plasma may provide a molecular signature for aggressive pancreatic cancer. Am J Transl Res. 2010 Sept 28;3(1):28-47. PMID: 21139804

74. Kim GP, Mahoney MR, Szydlo D, Mok TS, Marshke R, Holen K, Picus J, Boyer M, Pitot HC, Rubin J, Philip PA, Nowak A, Wright JJ, Erlichman C. An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma. Invest New Drugs. 2010 Sept 14. PMID: 20839030

75. Philip PA, Benedetti J, Corless CL, Wong R, O’Reilly EM, Flynn PJ, Rowland KM, Atkins JN, Mirtsching BC, Rivkin SE, Khorana AA, Goldman B, Fenogliio-Preiser CM, Abbruzzese JL, Blanke CD. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol. 2010 Aug 1;28(22):3605-10. PMID: 20606093

76. Azmi AS, Philip PA, Almhanna K, Beck FW, Sarkar FH, Mohammad RM. MDM2 inhibitors for pancreatic cancer therapy. Mini Rev Med Chem. 2010 June;10(6):518-26. PMID:

Page 22: PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C ...igicc.org/wp-content/uploads/2019/05/Philip-Agop-Philip-CV.pdfPage 1 of 53 . PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C

Page 22 of 53

20377522 77. Banerjee S, Azmi AS, Padhye S, Singh MW, Baruah JB, Philip PA, Sarkar FH, Mohammad RM.

Structure-activity studies on therapeutic potential of Thymoquinone analogs in pancreatic cancer. Pharm Res. 2010 June;27(6):1146-58. PMID: 20422266

78. Azmi AS, Philip PA, Zafar SF, Sarkar FH, Mohammad RM. PAR-4 as a possible new target for pancreatic cancer therapy. Expert Opin Ther Targets. 2010 June;14(6):611-29. PMID: 20426700

79. Li Y, Vandenboom TG, Wang Z, Kong D, Ali S, Philip PA, Sarkar FH. miR-146a suppresses invasion of pancreatic cancer cells. Cancer Res. 2010 Feb 15;70(4):1486-95. PMID: 20124483

80. Philip PA. Novel targets for pancreatic cancer therapy. Surg Oncol Clin N Am. 2010 Apr;19(2):419-29. PMID: 20159523.

81. Hammad N, Heilbrun L, Philip P, Shields A, Zalupski M, Venkatramanamoorthy R, El-Rayes B. CA19-9 as a predictor of tumor response and survival in patients with advanced pancreatic cancer treated with gemcitabine based chemotherapy. Asia-Pacific Journ of Clin Onc. 2010; 6:98-105.

82. Banerjee S, Padhye S, Azmi A, Wang Zhiwei, Philip P, Kucuk O, Sarkar F, Mohammad R. Review of Molecular and Therapeutic Potential of Thymoquinone in Cancer and its Chemosensitizing effect in Gemcitabine Resistant Pancreatic Cancer Cells. Nutrition and Cancer. 2010, 62(7), 938-946.

83. El-Rayes B, Pallavi J, Severson R, Almhanna K, Philip P, Shields A, Zalupski M, Heilbrun L. Impact of Race, Age, and Socioeconomic status on Participation in Pancreatic Cancer Clinical Trials. Pancreas. 2010 Oct;39(7):967-71. PMID: 20467351

84. Azmi AS, Aboukameel A, Banerjee S, Wang Z, Mohammad M, Wu J, Wang S, Yang D, Philip AP, Sarkar FH, Mohammad MR. MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 function. European Journal of Cancer. 2010 Apr;46(6):1122-31. PMID: 20156675

85. El-Rayes B, Zalupski M, Bekai-Saab T, Heilbrun L, Hammad N, Patel B, Urba S, Shields A, Vaishampayan U, Dawson S, Almhanna K, Smith D, Philip P. A Phase II study of Bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesohageal junction cancers. Annals of Oncology. 2010 Oct;21(10):1999-2004. PMID: 20332133

86. Sachin Gupta, Venkata Parsa, Volkan Adsay, Lance Heilbrun, Daryn Smith, Anthony Shields, Donald Weaver, Philip Philip, Bassel El-Rayes. Clinicopathological analysis of primary epithelial appendiceal neoplasms: A single institution experience. Medical Oncology. 2010 Dec ;27(4) :1073-8. PMID: 19851895.

87. Azmi AS, Philip AP, Wang Z, Banerjee S, Zafar S, Goustin A, Almhanna K, Yang D, Wang S, Sarkar FH , Mohammad RM. Reactivation of p53 by Novel MDM2 Inhibitors: Implications for Pancreatic Cancer Therapy. Current Cancer Drug Targets. 2010; May;10(3):319-31. PMID: 20370686

88. Nazik Hammad, Sachin Gupta, Nishant Tageja, Philip A. Philip, Anthony Shields, Daryn Smith, Lance K. Heilbrun, Bassel F. El-Rayes. Squamous Cell Cancer of the Anal Canal in HIV Infected Patients receiving highly active Antiretroviral Therapy. Am J Clin Oncol. 2010. PMID 20523206

89. Maen Abdelrahim, Santhi Konduri, Riyaz Basha, Philip A. Philip, Cheryl H. Baker. Angiogenesis: An update and potential drug approaches (Review). Int J Oncol 36(1):5-18, 2010. PMID: 19956828.

90. Ahmed O Kaseb, Amr Hanbali, Matthew Cotant, Manal M. Hassan, Ira Wollner, Philip A. Philip. Vascular Endothelial Growth Factor in the Management of Hepatocellular Carcinoma. Cancer, 115:4895-4906, 2009

91. Almhanna K, Philip PA. Safety and Efficacy of Sorafenib in the Treatment of Hepatocellular Carcinoma. OncoTargets and Therapy. 2009 Feb 18:2:261-7. PMID: 20616913

92. PA Philip, M Mooney, D Jaffe, G Eckhardt, M Moore, N Meropol, L Emens, E O’Reilly, M Korc, L Ellis, J Benedetti, M Rothenberg, C Willett, M Tempero, A Lowy, J Abbruzzese, D Simeone, S Hingorani, J Berlin, J Tepper. Consensus Report of the National Cancer Institute Clinical Trials Planning Meeting on Pancreas Cancer Treatment. J Clin Oncol 2009 Nov 20;27:5660-5669. PMID: 19858397.

93. Okunieff P, Kachnic LA, Constine LS, Fuller CD, Gaspar LE, Hayes DF, Hooks J, Ling C,

Page 23: PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C ...igicc.org/wp-content/uploads/2019/05/Philip-Agop-Philip-CV.pdfPage 1 of 53 . PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C

Page 23 of 53

Meyskens FL, Philip PA, Raben D, Smalley SR, Swanson GP, Teicher BA, Thomas CR, Vikram B, Zelefsky MJ, Baker LH. SWOG Radiation Therapy Workshop 2008. Clin Cancer Res. 2009 Sept 15;15(18):5663-70. PMID: 19723641

94. Mohammad Mobayed, Lance K. Heilbrun, Anthony F. Shields, Tara Washington, Raghu Venkatramanamoorthy, Philip A. Philip, Bassel F. El-Rayes. Safety and Feasibility of Carboplatin and Paclitaxel followed by Fluoropyrimidine Analogs and Radiation as Adjuvant Therapy for Gastric Cancer. Case Reports in Oncology 41 Journal, 2:220-228, 2009.

95. Yiwei Li, Timothy G. VandenBoom II, Dejuan Kong, Zhiwei Wang, Shadan Ali, Philip A. Philip, Fazlul H. Sarkar. Up-regulation of miR-200 and let-7 by Natural Agents Leads to the Reversal of epithelial-to-Mesenchymal Transition in Gemcitabine-Resistant Pancreatic Cancer Cells. Cancer Res. August 15;69(16):6704-12, 2009.

96. Kim GP, Sargent DJ, Mahoney MR, Rowland K, Philip PA, Mitchell EP, Mathews AP, Fitch TR, Goldberg RM, Alberts SR, Pitot HC. A randomized Phase III Non-Inferiority Trial of Irinotecan (CPT-11) Versus Oxaliplatin (OXAL)/5-Fluorouracil (5-FU)/Leucovorin (CF) in Patients With Advanced Colorectal Carcinoma Previously Treated With 5-FU, N9841. J Clin Oncol. 2009 June 10; 27(17).

97. Gadgeel SM, Ali S, Philip PA, Wozniak A, Sarkar FH. Genistein enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitors and inhibits nuclear factor kappa B in nonsmall cell lung cancer cell lines. Cancer. 2009 May 15;115(10):2165-76. PubMed PMID: 19288574.

98. Alis S, Al-Sukhun S, El-Rayes, BF, Sarkar FH, Heilbrun LK, Philip PA. Protein Kinases C Isozymes are differentially expressed in human breast carcinomas. Life Science. 2009 May 22;84(21-22):766-71. Epub 2009 Mar 24.

99. Hammad, N, Philip, PA, El-Rayes, BF, Nassar, H, Hong, K. Two patients with elevated alpha fetoprotein levels and liver lesions in the absence of Hepatocellular carcinoma. Community Oncology. 2009 March:6(3):1-4.

100. Ali AS, Ali S, El-Rayes BF, Philip PA, Sarkar FH. Exploitation of protein kinase C: a useful target for cancer therapy. Cancer Treat Rev. 2009 Feb;35(1):1-8. PMCID: 18778896.

101. Patel BB, Yu Y, Du J, Levi E, Philip PA, Majumdar A. Age-Related Increase in Colorectal Cancer Stem Cells in Macroscopically Normal Mucosa of Patients with Adenomas: A Risk Factor for Colon Cancer. Biochem Biophys Res Commun. 2009 Jan 16, 378(3):344-7.

102. Philip PA, Targeting angiogenesis in pancreatic cancer. Lancet. 2008 Jun 21:371(9630):2062-4. 103. Vandenboom TG, Li Y, Philip PA, Sarkar FH. MicroRNA and Cancer: Tiny Molecules with Major

Implications. Curr Genomics. 2008 Apr;9(2):97-109. PubMed PMID: 19440450; PubMed Central PMCID: PMC2674802.

104. Philip PA. Improving treatment of pancreatic cancer. Lancet Oncol. 2008 Jan;9(1):7-8. 105. Isacoff WH, Philip PA. Clinical management of long-term cancer survivors. J Clin Oncol. 2008 Jan

1;26(1):162-4. 106. Small W Jr, Berlin J, Freedman GM, Lawrence T, Talamonti MS, Mulcahy MF, Small W Jr,

Chakravarthy AB, Konski AA, Zalupski MM, Philip PA, Kinsella TJ, Merchant NB, Hoffman JP, Benson, AB,Nicol S, Xu RM, Gill JF, McGinn CJ. Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial. J Clin Oncol. 2008 Feb 20;26(6):942-7.

107. El-Rayes, BF, Zalupski MM, Manza SG, Rusin B, Ferris AM, Vaishampayan U, Heilbrun LK, Venkatramanamoorthy R, Shields AF, Philip PA. Phase II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer. Cancer Chemotherapy and Pharmacology, 2008 Feb;61(2):283-9.

108. Rahman KM, Ali S, Aboukameel A, Sarkar SH, Wang Z, Philip PA, Sakr WA, Raz A. Inactivation of NF-kappaB by 3,3'-diindolylmethane contributes to increased apoptosis induced by chemotherapeutic agent in breast cancer cells. Mol Cancer Ther.2007 Oct;6(10):2757-65.

109. Ciuleanau T, Diculescu M, Hoepffner NM, Trojan J, Sailer V, Zalupski M, Hermnn T, Roth A, Chick J, Brock K, Albert D, Philip PA. A randomized phase II study of OSI-7904L versus 5-fluorouracil (FU)/leucovorin (LV) as first-line treatment in patients with advanced biliary cancers.

Page 24: PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C ...igicc.org/wp-content/uploads/2019/05/Philip-Agop-Philip-CV.pdfPage 1 of 53 . PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C

Page 24 of 53

Investigational New Drugs, 2007, Invest New Drugs. 2007 Aug;25(4):385-90. 110. Schneider BJ, El-Rayes B, Muler JH, Philip PA, Kalemkerian GP, Griffith KA, Zalupski MM.

Phase II trial of carboplatin, gemcitabine, and capecitabine in patients with carcinoma of unknown primary site. Cancer, 2007 Aug 15;110(4):770-5.

111. Philip PA, Mahoney MR, Allmer, C, Thomas J, Pitot HC, Kim G, Donehower RC, Fitch T, Picus J, and Erlichman C. Targeting of epidermal growth factor receptor in patients affected by biliary tract carcinoma. Journal of Clinical Oncology, 1145-1146, 2007.

112. Desai SP, El-Rayes BF, Ben-Josef E, Greenson JK, Knoll JA, Huang EH, Griffith KA, Philip PA, McGinn CJ, Zalupski MM. A Phase II study of preoperative capecitabine and radiation therapy in patients with rectal cancer. American Journal of Clinical Oncology, 2007 Aug;30(4):340-5.

113. Isacoff WH, Bendetti JK, Barstis JJ, Jazieh A-R, MD, Macdonald JS, Philip PA. Infusional 5-Flurouracil, Leucovorin, Mitomycin-C, and Dipyridamole in Patients with Locally Advanced Unresectable Pancreatic Adenocarcinoma: A Phase II Trial of the Southwest Oncology Group (SWOG). Journal of Clinical Oncology, 2007 Aug 15;110(4):770-5.

114. El-Rayes BF, Zalupski M, Shields AF, Lorusso P, Philip PA. A phase I study of gemcitabine and uracil-ftorfar (UFT)/ leucovorin. American Journal of Clinical Oncology, 2007 Apr;30(2):101-5.

115. El-Rayes BF, Gadgeel S, Shields AF, Manza S, LoRusso P, Philip PA. Phase I study of bryostatin 1 and gemcitabine. Clinical Cancer Research, 12(23): 7059-7062, 2006.

116. Lu H, Wang JJ, Chan KK, Philip PA. Stereoselectivity in metabolism of ifosfamide by CYP3A4 and CYP2B6. Xenobiotica, 36:367-385, 2006.

117. Thatai LC, Vishnubhotla P, Biernat L, Flaherty L, LoRusso P, Simon M, Stephens D, Vereeke K, Abrams J, Bouwman D, Philip PA. A phase II study of docetaxel, doxorubicin and infusional 5-fluorouracil in the treatment of patients with locally advanced breast cancer. American Journal of Clinical Oncology, 29(5):484-489, 2006.

118. Philip PA, Mahoney MR, Allmer, C, Thomas J, Pitot HC, Kim G, Donehower RC, Fitch T, Picus J, and Erlichman C. Phase II Study of Erlotinib in Patients With Advanced Biliary Cancer. Journal of Clinical Oncology, 24:3069–3074, 2006.

119. Cote ML, Wenzlaff AS, Philip PA, Schwartz AG. Secondary cancers after a lung carcinoid primary: a population-based analysis. Lung Cancer, 52:273 – 279, 2006.

120. Hochster HS, Haller DG, de Gramont A, Berlin JD, Philip PA, Moore MJ, Ajani JA. Consensus report of the International Society of Gastrointestinal Oncology on therapeutic progress in advanced pancreatic cancer. Cancer, 2006 Jul 17.

121. El-Rayes BF, LoRusso P, Philip PA. A Phase I Study of Flavopiridol and Docetaxel. American Investigational New Drugs, 24:305-310, 2006.

122. Talamonti MS, Small W, Mulcahy MF, Wayne J, Attaluri V, Colleti L, Zalupski MM, Hoffman J, Freedman GM, Kinsella T, Philip PA, TS, McGinn CJ. A multiinstitutional Phase II trial of Preoperative Full-dose Gemcitabine and Concurrent Radiation for Patients with Potentially Resectable Pancreatic Carcinoma. Annals of Surgical Oncology, 13(2): 1-9, 2006.

123. Ali S, El-Rayes BF, Sarkar FHY, Philip PA. Simultaneous targeting of the epidermal growth factor receptor and cycliixygenase-2 pathways for pancreatic cancer therapy. Mol Cancer Ther. 2005 Dec; 4 (12):1943-51.

124. Ali S, El-Rayes BF, Aranha O, Sarkar FH, Philip PA. Sequence dependent potentiation of gemcitabine by flavopiridol in human breast cancer cells. Breast Cancer and Treatment,

125. 90: 25-31, 2005. 126. Banerjee S, Zhang Y, Ali S, Bhuiyan M, Wang, Chiao PJ, Philip PA, Abbruzzese J, Sarkar

FH. Molecular evidence for increased anti-tumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer. Cancer Research, 65(19): 9064-72, 2005.

127. El-Rayes B, Zalupski M, Vaishampayan U, Shields AF, Heilbrun, Philip PA. Phase II study of gemcitabine, cisplatin and celecoxib in patients with metastatic pancreas cancer. Investigational New Drugs, 23(6): 583-90, 2005.

128. Philip PA, MR, Mahoney, C Allmer, J Thomas, HC Pitot, EA Johnson, G Kim, R

Page 25: PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C ...igicc.org/wp-content/uploads/2019/05/Philip-Agop-Philip-CV.pdfPage 1 of 53 . PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C

Page 25 of 53

Donehower, T Fitch, PM. Fracasso, F Dawkins, C Erlichman. Phase II Study of Erlotinib (OSI-774) in Patients with Advanced Hepatocellular Cancer. Journal of Clinical Oncology, 23(27): 6657-63, 2005.

129. El-Rayes BF, Ibrahim D, Shields AF, LoRusso P, Zalupski M, Philip PA. Phase I study of liposomal doxorubicin (Doxil) and cyclophosphamide in solid tumors. Investigational New Drugs, 23(1): 57-62, 2005.

130. El-Rayes BF, Shields A, Zalupski M, Heilbrun LK, Jain V, Terry D, Ferris AM, Philip PA. 131. A phase II trial of carboplatin and paclitaxel in adenocarcinoma of unknown primary.

American Journal of Clinical Oncology, 28(2):152-6. 2005. 132. El-Rayes BF, Ali S, Sarkar FH, Philip PA. Cyclooxygenase-2-dependent and independent

effects of celecoxib in pancreatic cancer cell lines. Molecular Cancer Therapeutics, 3(11): 1421-1426, 2004.

133. Ali S, El-Rayes BF, Heilbrun LK, Sarkar F, Ensley JF, Kucuk O, Philip PA. Cytochrome P450 and glutathione transferase expression in squamous cell cancer. Clinical Cancer Research, 2004 Jul 1; 10(43): 4412-6.

134. Li Y, Ellis K-L, Ali S, El-Rayes BF, Nedeljkovic-Kurepa A, Kucuk O, Philip PA, Sarkar F. Apoptosis inducing effect of chemotherapeutic agents is potentiated by soy isoflavone genstein, a natural inhibitor of NF-kB in BxPC-3 pancreatic cancer cell line. Pancreas, 28(4): e90-95, 2004.

135. El-Rayes BF, Shields A, Zalupski M, Heilbrun LK, Jain V, Terry D, Ferris AM, Philip PA. 136. A phase II trial of carboplatin and paclitaxel in advanced esophageal cancer. Annals of

Oncology, 15: 960-965, 2004. 137. E Ben-Josef, AF Shields, U Vaishampayan, V Vaitkevicius, BF El-Rayes, P McDermott, J

Burmeister, B Todd, PA Philip. Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer. International Journal of Radiation Biology and Physics, 2004 Jun; 15(6): 960-5.

138. Simon M S, Du W, Flaherty L, Philip PA, Lorusso P, Mirec C, Smith D, Brown D. Factors associated with breast cancer clinical trials participation and enrolment at a large academic medical center. Journal of Clinical Oncology, 2004 Jun 1; 22(11): 2046-52.

139. Puscheck, EP, Philip, PA, Jeyendran, RS. Male fertility preservation and cancer treatment. Cancer Treatment Reviews, 30:173-178, 2004.

140. Li Y, Ali S, Philip PA, Sarkar FH. Direct Comparison of Microarray Gene Expression Profiles between Non-amplification and a Modified cDNA Amplification Procedure Applicable for Needle Biopsy Tissues. Cancer Detection and Prevention, 27:405-411, 2003.

141. El-Rayes BF, Zalupski M, Shields A, Vaishampayan U, Heilbrun LK, Adsay V, Philip PA. A Phase II study of gemcitabine, cisplatin and infusional 5-flourouracil in advanced pancreatic cancer. Journal of Clinical Oncology, 21:2920-2925, 2003.

142. Pernick NL, Adsay V, Carolin KA, Philip PA, Sipiesrski S, Bouwman D, Kosir MA White M, Visscher DW. Histopathologic Evidence of Tumor Regression in the Axillary Lymph Nodes of Newman LA. Patients Treated with Preoperative Chemotherapy Correlates with Breast Cancer Outcome. Annals of Surgical Oncology, 10:734-739, (Accompanying Editorial by B O Anderson, pp 713-715), 2003.

143. Ali S, Aranha O, Li Y, Pettit G, Sarkar FH, Philip PA. Sensitization of Human Breast Cancer Cells to Gemcitabine by Protein Kinase C Modulator Bryostatin 1. Cancer Chemotherapy and Pharmacology, 52:235-246, 2003.

144. Gadgeel, S., Shields, A.F., Labadidi, S., Zalupski, M., Heilbrun, L., Chaplen, R., Philip, P.A. A Phase II Study of Paclitaxel and Carboplatin in Patients with Advanced Stomach Cancer. American Journal of Clinical Oncology. 26:37-41, 2003.

145. El-Rayes BF, Ali S, Heilbrun LK, Lababidi S, Bouwman D, Visscher D, Philip PA. Cytochrome P450 and Glutathione Transferase Expression in Human Breast Cancer. Clinical Cancer Research, 9: 1705-1709, 2003.

146. Al-Sukhun, S., Zalupski, M.M., Ben-Joseph, E., Vaitkevicius, V.K., Philip, P.A., Soulen, R, Weaver, D., Adsay, V., Heilbrun, L., Levin, K., Forman, J., Shields, A.F. Chemo-Radiotherapy in the Treatment of Regional Pancreatic Carcinoma: A Phase II Study. Am J Clin Oncol, 26(6): 543-

Page 26: PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C ...igicc.org/wp-content/uploads/2019/05/Philip-Agop-Philip-CV.pdfPage 1 of 53 . PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C

Page 26 of 53

649.2003. 147. Pernick, N.L., Sarkar, F.H., Philip, P.A., Arlauskas, P., Shields, A.F., Vaitkevicius, V.K., Dugan,

M.C., Adsay, N.V. Clinicopathologic Analysis of Pancreatic Adenocarcinoma in African Americans and Caucasians. Pancreas, 26:28-32, 2003.

148. El-Rayes, B.F., Berenji, K., Schuman, P., Philip, P.A. Breast Cancer in Women with Human Immunodeficiency Virus Infection: Implications for Diagnosis and Therapy. Five Case Reports and a Review of the Literature. Breast Cancer Research and Treatment. 76;111-116, 2002.

149. Vaishampayan, U.N., Ben-Josef, E., Philip, P.A., Vaitkevicius, V.K., Du, W., Levin, K., Shields, A.F. A Single Institution Experience with Concurrent Capecitabine and Radiation Therapy in Gastrointestinal Malignancies. International Journal of Radiation Oncology and Biologic Physics. 53:675-79, 2002.

150. Mohammad, R.M., Adsay, N.V., Philip, P.A., Pettit, G.R., Vaitkevicius, V.K., Sarkar, F.H. Bryostatin 1 Induces Differentiation and Potentiates the Antitumor Effect of Auristatin PE in a Human Pancreatic Tumor (PANC-1) Xenograft Model. Anti-Cancer Drugs. 12:735-40, 2001.

151. Merati, K., Siadaty, M.S., Sarkar, Andea, A., Sarkar, F, Mohammad, R.M., Philip, P.A., Shields, A.F., Vaitkevicius, V., Grignon, D.J., Volkan, A.N. Expression of Inflammatory Modulator COX-2 in Pancreatic Ductal Adenocarcinoma and its Relationship to Pathologic and Clinical Parameters. American Journal of Clinical Oncology. 24:447-52, 2001.

152. Philip, P.A., Zalupski, M. M., Vaitkevicius, V.K., Arlauskas, P., Chaplen, R., Heilbrun, L. K., Adsay, V., Weaver, D., Shields, A.F. Phase II Study of Gemcitabine and Cisplatin in the Treatment of Advanced Pancreatic Cancer. Cancer. 92:569-77, 2001.

153. Zonder, J.A., Shields, A.F., Zalupski, M., Chaplen, R., Heilbrun, L.K., Philip, P.A. A Phase II Trial of Bryostatin 1 in the Treatment of Metastatic Colorectal Cancer. Clinical Cancer Research. 7:38-42, 2001.

154. O’Byrne, K.J., Philip, P.A., Saunders, M.P., Propper, D.J., Braybrooke, J.P., Salisbury, A.J., Taylor, M.A., Ganesan, T.S., Talbot, D.C. and Harris, A.L. Modulation of 5-Fluorouracil and Folinic acid with Hydroxyurea in the Treatment of Metastatic Colorectal Carcinoma. Annals of Oncology. 10(8): 981-83, 1999.

155. Philip, P.A., Ibrahim, D., Zalupski, M., Arlauskas, P., Shields, A. Gemcitabine and UFT Plus Oral Calcium Folinate: Phase I Study. Oncology. 13(7), SUPPL. NO. 3:116-19, 1999.

156. Philip, P.A., Rea D, Mitchell K, Carmichael J, Harris AL, Talbot DC. A pilot study of increasing 157. dose-intensity of epirubicin and ifosfamide in patients with small cell lung cancer by using

recombinant granulocyte colony stimulating factor. Clinical Oncology, 11:84-89, 1999. 158. Philip, P.A., Ali-Sadat, S., Kocarek, T., Akhtar, A., Doehmer, J., Chan, K.K. Use of V79 cells with 159. stably transfected cytochrome P450 cDNAs in studying the metabolism of cytotoxic drugs. Cancer

Chemotherapy and Pharmacology, 43: 59-67, 1999. 160. Shields, A.F., Philip, P.A., LoRusso, P.M., Ferris, A.M., Zalupski, M.M. Phase II study of CI-958 in

colorectal cancer. Cancer Chemotherapy and Pharmacology, 43:162-164, 1998. 161. Macaulay, V.M., O’Byrne, K.J., Green, J.A., Philip, P.A., McKinely, L., LaCreta, F.P., Winograd,

B., Ganesan, T.S., Harris, A.L. and Talbot, D.C. Phase I study of the Mitomycin C analogue BMS-181174. British Journal of Cancer, 77(11): 2020-2027, 1998.

162. Zalupski, M.M., Shields, A.F., Philip, P.A., Kraut, M.J., LoRusso, P.M., Heilbrun, L.K., Vaitkevicius, V. Evaluation of pyrazoloacridine in patients with advanced pancreatic carcinoma. Investigational New Drugs, 16: 93-96, 1998.

163. Macaulay, V.M., O’Byrne, K.J., Green, J.A., Philip, P.A., McKinely, L., LaCreta, F.P., Winograd, B., Ganesan, T.S., Harris, A.L. and Talbot, D.C. Phase I study of the Mitomycin C analogue BMS-181174. British Journal of Cancer, 77(11): 2020-2027, 1998.

164. Philip P.A., Zalupski M.M., Gadgeel, S., Hussain, M., Shields, A.F. A Phase II study of carboplatin and paclitaxel in the treatment of patients with advanced esophageal and gastric cancer. Seminars in Oncology, 24:S19-S26, 1997.

165. Philip, P.A., Flaherty, L.E. Interleukin-2 in the treatment of malignant melanoma. Seminars in Oncology, 24:532-538, 1997.

166. Zalupski, M.M., Philip, P.A., LoRusso, P.M., Shields, A.F. Phase II study of pyrazoloacridine in patients with advanced colorectal carcinoma. Cancer Chemotherapy and Pharmacology, 40:225-227, 1997.

Page 27: PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C ...igicc.org/wp-content/uploads/2019/05/Philip-Agop-Philip-CV.pdfPage 1 of 53 . PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C

Page 27 of 53

167. Philip P.A., Souliotis V.L., Harris A.L., Salisbury A., Tates A.D., Mitchell K., Van Delft J. H.M., Ganesan T.S., Kyrtopoulos S.A. Methyl DNA adducts, DNA repair and HPRT mutations in peripheral white blood cell from patients with malignant melanoma treated with dacarbazine and hydroxyurea. Clinical Cancer Research, 2:303-310, 1996.

168. Carmichael J, Philip P.A., Forfar C, Harris AL. An open study to assess the safety, tolerance and pharmacokinetics of an intravenous infusion of granisetron given at 3 mg over 30 s in patients receiving chemotherapy for malignant disease. Cancer Chemotherapy and Pharmacology, 37:134-138, 1995.

169. Carmichael J., Possinger K., Philip P.A., Beykirch M., Kerr H., Walling J., Harris A.L. Advanced Breast Cancer: A phase II trial with Gemcitabine. Journal of Clinical Oncology, 13:2731-2736, 1995.

170. Philip P.A. and Ajani J. Has combined modality therapy improved the outlook in carcinoma of the esophagus? Oncology, 8:37-42, 1994.

171. Philip, P.A., Carmichael J., Tonkin T., Ganesan T.A., Harris A.L. A Phase II study of high-dose hydroxyurea and dacarbazine (DTIC) in the treatment of metastatic malignant melanoma. European Journal of Cancer, 30A: 1027-1029, 1994.

172. Philip, P.A., Kaklamanis, L., Ryley, N., Wolf, R., Harris, A.L., Stratford, I., Carmichael, J. Expression of Xenobiotic-Metabolizing Enzymes in Primary and Secondary Hepatic Tumors in Man. International Journal of Radiation Oncology Biology Physics. 29:277-83, 1994. 173. Philip, P.A., Rea, D., Thieves, P., Carmichael, J., Stuart, N.S.A., Rockett, H., Talbot, D.C.,

Ganesan, T., Pettit, G.R., Balkwill, F., Harris, A.L. Phase I Study of Bryostatin 1: Assessment of Interleukin 6 and Tumor Necrosis Factor α Induction In Vivo (see Editorial Comments). Journal of National Cancer Institute. 85:1812-18, 1993.

174. Philip, P.A., Campbell, C.H., Carmichael, J., Rea, D., Mitchell, K., Taylor, D.J., Stuart, N.S.A, Dennis, I., Rajagopalan, B., Ganesan, T., Radda, K., Harris, A.L. A Phase I Study of the Left-Shifting Agent BW12C79 Plus Mitomycin C and the Effect on the Skeletal Muscle Metabolism Using 31P Magnetic Resonance Spectroscopy. Cancer Research. 53:5649-53, 1993.

175. Philip, P.A., Kaklamanis, L., Carmichael, J., Tonkin, K., Morrison, H., Gatter, K., Harris, A.L. The Influence of High Dose Hydroxyurea on the Incorporation of 5-Iodo-2-Deoxyuridine (IUdR) by Human Bone Marrow and Tumor Cells In Vivo. British Journal of Cancer, 67:644-49, 1993.

176. Philip, P.A., Carmichael, J., Tonkin, K., Buamah, P.K., Britton, J., Dowsett, M., Harris, A.L. Hormonal Treatment of Pancreatic Carcinoma: A Phase II Study of LHRH Agonist Goserelin Plus Hydrocortisone. British Journal of Cancer. 67:379-82, 1993.

177. Stuart, N.S.A., Philip, P.A., Harris, A.L., Tonkin, K., Houlbrook, S., Kirk, J., Lien, E.A., Carmichael, J. High-dose Tamoxifen as an Enhancer of Etoposide Cytotoxicity. Clinical Effects and In Vitro Assessment in P-Glycoprotein Expressing Cell Lines. British Journal of Cancer. 66:833-39, 1992.

178. Rustin, J.R., Stratford, M.R., Lamont, A., Bleehen, N., Philip, P.A., Howells, N., Watfa, R.R., Slack, J.A. Phase I Study of Intravenous 4-Hydroxyanisole. European Journal of Cancer. 28A(8/9): 1362-64, 1992.

179. Philip, P.A., Joel, S., Monkman, S.C., Dolega-Ossowski, E., Tonkin, K., Carmichael, J., Idle, J.R., Harris, A.L. A Phase I Study on the Reversal of Multidrug Resistance (MDR) in Vivo: Nifedipine Plus Etoposide. British Journal of Cancer. 65:267-270, 1992.

180. Philip, P.A., Rustin, G.J.S., Ledermann, J.A., Begent, R.H.J., Bagshawe, K.D. Weekly Etoposide, Methotrexate, and Actinomycin D, Alternating with Cyclophosphamide Plus Vincristine (EMA/CO); A Phase II Study in Advanced Gastric Carcinoma. Clinical Oncology. 3:214-16, 1991.

181. Philip, P.A., Carmichael, J., Harris, A.L. Convulsions and Cortical Blindness Following Therapy with Cisplatin. British Medical Journal. 302:416, 1991.

182. Philip, P.A., Bagshawe, K.D., Searle, F., Newlands, E.S., Begent, R.H.J., Adam, T. In Vivo Uptake of 131I-5-Iodo-2-Deoxyuridine by Malignant Tumors in Man. British Journal of Philip A.

Cancer. 63:134-35, 1991. 183. Kelly, M.P., Rustin, G.J.S., Ivory, C., Philip, P.A., Bagshawe, K.D. Respiratory Failure Due to

Choriocarcinoma: A Study of 103 Dyspnoeic Patients. Gynaecologic Oncology. 38:149-154, 1990. 184. Philip, P.A., James, C.A., Rogers, H.J. The Influence of Cimetidine on Debrisoquine 4-

Page 28: PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C ...igicc.org/wp-content/uploads/2019/05/Philip-Agop-Philip-CV.pdfPage 1 of 53 . PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C

Page 28 of 53

Hydroxylation in Extensive Metabolizers. European Journal of Clinical Pharmacology. 36:319-21, 1989.

185. Philip, P.A., Rogers, H.J. Effect of Cancer Chemotherapy on Dapsone N-acetylation in Man. Cancer Chemotherapy and Pharmacology. 23:395-96, 1989.

186. Hitchins, R.N., Philip, P.A., Wignall, B., Newlands, E.S., Begent, R.H.J., Rustin, G.J.S., Bagshawe, K.D. Bone Disease in Testicular and Extragonadal Germ Cell Tumors. British Journal of Cancer. 58:793-96, 1988.

187. Philip, P.A., James, C.A., Lewis, L.D., Rogers, H.J. Relationship Between Ifosfamide Plasma Clearance and the Debrisoquine Oxidation Status. Cancer Chemotherapy and Pharmacology. 22:321-24, 1988.

188. Philip, P.A., Fitzgerald, D.L., Cartwright, R.A., Peake, M.D., Rogers, H.J. Polymorphic N-acetylation Capacity in Lung Cancer. Carcinogenesis. 9:491-3, 1988.

189. Philip, P.A., James, C.A., Rogers, H.J. Determination of Debrisoquine Metabolic Ratio From Hourly Urine Collections in Healthy Volunteers. British Journal of Clinical Pharmacology. 24:827- 29, 1987.

190. Philip, P.A., Rogers, H.J., Harper, P.G. Acetylation and Oxidation Phenotypes in Malignant Lymphoma. Cancer Chemotherapy and Pharmacology. 20:235:238, 1987.

191. Philip, P.A., Rogers, H.J., Millis, R.R., Rubens, R.D., Cartwright, R.A. Acetylator Status and its Relationship to Breast Cancer and Other Diseases of the Breast. European Journal of Cancer and Clinical Oncology. 23:1701-06, 1987.

192. Ledermann, J.A., Crawford, S.M., Philip, P.A., Bagshawe, K.D. Curable Metastatic Cancer in Young Women. British Medical Journal. 295: 399-452, 1987.

193. Philip, P.A., Gayed, S.L., Roger, H.J., Crome, P. Influence of Age, Sex and Body Weight on the Dapsone Acetylation Phenotype. British Journal of Pharmacology. 23:709-713, 1987.

194. Philip, P.A., Roberts, M.S., Rogers, H.J. A Rapid Method for the Determination of Acetylation Phenotype Using Dapsone. British Journal of Clinical Pharmacology. 17:465-69, 1984.

195. Cartwright, R.A, Philip, P.A., Rogers H.J., Glashan, R.W. Genetically Determined Debrisoquine Oxidation Capacity in Bladder Cancer. Carcinogenesis. 5: 1191-92, 1984.

Invited Review Articles 1. Alian OM, Philip PA, Sarkar FH, Azmi AS. Systems biology approaches to pancreatic cancer

detection, prevention and treatment. Curr Pharm Des. 2014;20(1):73-80. PMID: 23530496. 2. Sethi S, Ali S, Kong D, Philip PA, Sarkar FH. Clinical implication of microRNAs in molecular

pathology. Clin Lab Med. 2013 Dec;33(4):773-86. doi: 10.1016/j.cll.2013.08.001. Epub 2013 Oct 9. PMID: 24267185.

3. Sethi S, Ali S, Philip PA, Sarkar FH. Clinical advances in molecular biomarkers for cancer diagnosis and therapy. Int J Mol Sci. 2013 Jul 16;14(7):14771-84. doi: 10.3390/ijms140714771. PMID: 23863689

4. Alian OM, Philip PA, Sarkar FH, Azmi AS. Systems Biology Approaches to Pancreatic Cancer Detection, Prevention and Treatment. Curr Pharm Des. 2013 Mar 19. PMID: 23530496.

5. Choi, M, Critchfield J, Philip P. Combining sorafenib with chemoembolization for hepatocellular cancer. Community Oncology. 2011 May 8(5):216-19. PMID:

6. Almhanna K, Philip PA. Defining New Paradigms for the Treatment of Pancreatic Cancer. Curr Treat Options Oncol. 2011 Jun; 12(2):111-25. PMID: 21461670

7. Philip PA. Novel Targets for Pancreatic Cancer Therapy, Surg Oncol Clin N Am 19 (2010) 419–429 8. Heinemann V, Philip PA, Pelzer U. Accomplishmants in 2008 in the treatment of metastatic

pancreatic cancer. Gastrointestinal Cancer Research, 3(5 supplement 2): S43-S47, 2009. 9. Khaldoun Almhanna, Philip A Philip, Safety and efficacy of sorafenib in the treatment of

Hepatocellular carcinoma. OncoTargets and Therapy. Nov 2009:2 261-267. 10. Philip PA, First and second-line treatment of metastatic pancreatic adenocarcinoma: the conundrum

continues. Gastrointest Cancer Res. 2009 Jan;3(1):37-9. PubMed PMID: 19343138; PubMed Central PMCID: PMC2661127.

11. El-Rayes BF, Ali S, Philip PA, Sarkar FH. Protein kinase C: a target for therapy in pancreatic cancer. Pancreas 2008 May;36(4):346-52. PubMed PMID:18437080.

Page 29: PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C ...igicc.org/wp-content/uploads/2019/05/Philip-Agop-Philip-CV.pdfPage 1 of 53 . PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C

Page 29 of 53

12. Louvet C, Philip PA. Accomplishments in 2007 in the Treatment of Metastatic Pancreatic Cancer. Gastrointestinal Cancer Research, 2(3): S37-S41, 2008.

13. Philip PA. Targeted Therapies for Pancreatic Cancer. Gastrointestinal Cancer Research, 2(4): S16-S19, 2008.

14. El-Rayes BF, Gadgeel S, Ali S, Philip PA, Sarkar FH. Erlotinib. Encyclopedia of Cancer, Berlin: Springer (2008).

15. Goldberg RM, Marshall JL, Ajani JA, Philip PA, O’Reilly EM, Venook AP. Section IV: Significance of Recent Study Results and Future Research Directions in Gastrointestinal Oncology. Gastrointest Cancer Res. 2007 Nov;1(6 Suppl):s13-6. PubMed PMID: 19330058; PubMed Central PMCID: PMC2659796.

16. Kachnic LA, Ajani JA, Philip PA. Section II : Current Approaches to Treating Localized Gastrointestinal Cancers. Gastrointest Cancer Res. 2007 Nov;1(6 Suppl):s4-7. PubMed PMID: 19330059; PubMed Central PMCID: PMC2659792.

17. Choi M and Philip PA. Liver Directed Therapies in Hepatocellular Cancer. Community Oncology, 2007.

18. Philip PA. A New Era in the Treatment of Metastatic Colorectal Cancer. American Journal of Clinical Oncology Review, 5:10, suppl 8, pages 10-11, 2006.

19. Philip PA. Is EGFR Testing Necessary for Using Cetuximab in Patients with Advanced Colorectal Cancer? American Journal of Clinical Oncology Review.

20. Philip PA. Experience with Docetaxel in the Treatment of Gastric Cancer. Seminars in Oncology. 32(suppl 4): S24-S38), 2005. [also authored the Introduction on pages 1 and 2 of the same issue].

21. Philip PA. Current Strategies in Previously Untreated Patients with Advanced Colorectal Cancer. Physicians’ Education Resource, 7(3): 3-6, 2003.

22. El-Rayes B, Philip PA. Systemic Therapy of Advanced Pancreas Cancer. Hematology and Oncology, 1(7): 430-434, July 2003.

23. El-Rayes, B., Shields A.F., Vaitkevicius, V, Philip, P.A. Developments in the Systemic Therapy of Pancreatic Cancer. Cancer Investigation. 21:73-86, 2003.

24. El-Rayes, B., Philip, P.A. Systemic Therapy for Advanced Pancreatic Cancer. Expert Review of Anticancer Therapy. 2:426-436, 2002.

25. El-Rayes, B., Adsay, V., Philip, P.A. Pancreatic cancer: the evolving role of systemic therapy. Expert Opinion on Pharmacotherapy. 2:1939-1947, 2002.

26. Philip, P.A. Gemcitabine Platinum Combinations in Pancreatic Cancer. Cancer. 95:908-911, 2002. 27. Philip, P.A., Flaherty, L. Biochemotherapy of Melanoma. Current Opinion in Clinical Oncology.

2(4): 314-321, 2000. 28. Gurjal, A., Philip, P.A., IL-2 in Cancer. Emerging Drugs: The Prospect for Improved Medicines.

5(3): 273-285, 2000. 29. Zonder, J., Philip, P.A. Pharmacology and Clinical Experience with Bryostatin 1: A Novel

Anticancer Drug. Expert Opinion on Investigational Drugs. 8(12): 2189-2199, 1999. 30. Philip, P.A. Interleukin-2 and Malignant Melanoma. Expert Opinion on Investigational Drugs.

7:361-372, 1998. 31. Philip, P.A., Ajani, J. Gastro-Intestinal Malignancies in the Elderly. Cancer Bulletin, 47:218-223,

1995. 32. Philip, P.A., Harris, A.L. Potential for Protein Kinase C Inhibitors in Cancer Therapy. In,

Chemotherapy: Concepts, Mechanisms, and New Targets for Chemotherapy. Ed; FM Muggia. 6:3-27, November 1995, Kluwer Academic Publishers, Boston, MA.

33. Philip, P.A., Harris, A.L. Molecular Aspects of Breast Carcinoma. Royal Society of Medicine. Current Medical Literature. pp 3-7, 1992.

Book Editorship

1. Lowy, A. M., Leach, S. D., Philip, P. A. Pancreatic Cancer. Springer Science. 2008 Books Chapters

1. Diab M and Philip PA. Uncommon cancers of the pancreas. In, Textbook of Uncommon Cancer, Edited by Derek Raghavan et al. Wiley, 2017, DOI: 10.1002/9781119196235.ch29

Page 30: PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C ...igicc.org/wp-content/uploads/2019/05/Philip-Agop-Philip-CV.pdfPage 1 of 53 . PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C

Page 30 of 53

2. Diab M and Philip PA. Ch 6. Current and Emerging Therapies in Pancreatic Cancer. In Current and Emerging Therapies in Pancreatic Cancer. Eds T Bakaai-Saab and B El-Rayes. Springer (2017).

3. T Pandit and P Philip. Emerging Systemic and Targeted Therapies. In Multimodality Management of Borderline Resectable Pancreatic Cancer [Hardcover]. Matthew H.G. Katz (Editor), Syed A. Ahmad (Editor), Springer, 2015.

4. Salem M and Philip PA, "Emerging Systemic and Targeted Therapies", In Multimodality Management of Borderline Resectable and Locally Advanced Pancreatic Cancer, In, Springer, edited by Drs. Matthew Katz and Syed Ahmad. 2015.

5. Ali S, Sethi S, Ali AS, Philip P, Sarkar F. Molecular Pathogenesis of Breast Cancer and the Role of MicroRNAs In miRNAs and Target Genes in Breast Cancer Metastasis. Springer. ISBN 978-3-319-08161-8 (2014), pp. 7-22.

6. H Mahaseth, B El-Rayes, P Philip. Treatment of Advanced Pancreatic Cancer, In, World Science Publishing Co. Pte. Ltd., Editor, Bassel El-Rayes. (2014) Singapore. ISBN: 978-981-4618-98-4.

7. A Ahmed, AS Ali, S Ali, A Ahmad, PA Philip, FH Sarkar. MicroRNAs in Breast Cancer Research: Progress and Promise. A. Ahmad (ed.), Breast Cancer Metastasis and Drug Resistance, 399 DOI: 10.1007/978-1-4614-5647-6_22, Ó Springer Science+Business Media New York 2013.

8. Philip, P. A., Heilbrun, L. K., Abrams, J. Pitfalls in Clinical Trials and Future Directions. In, Pancreatic Cancer. Springer Science. (2008), pp. 723-731.

9. Flaherty, L.E., Philip, P.A. Biochemotherapy of Melanoma. In, Melanoma: Biologically Targeted Therapeutics. Ed., Ernest C Borden. Humana Press Inc., Totowa, New Jersey. (2002), pp. 259-285.

10. Philip, P.A., Molecular Biology in the Diagnosis, Follow-up and Therapeutic Evaluation of Colorectal Cancer. In, Genetic Diagnosis in Medicine. Ed., J. Garcia-Foncillas, M.E. Armengod, J.M. Echevarria, A. Blasbond. University of Navarra Press, Pamplona. 1998.

11. Philip, P.A., Ajani, J. Esophageal Cancer. In, Medical Oncology, a Comprehensive Review. Ed., Richard Pazdur. PRR, Huntington, New York. (1995), pp. 225-234.

12. Philip, P.A., Milliken, R. Prostate Cancer. In, Medical Oncology, a Comprehensive Review. Ed., Richard Pazdur. PRR, Huntington, New York. (1995), pp. 419-432.

13. Philip, P.A., Ajani, J. Gastric Cancer. In, Medical Oncology a Comprehensive Review. Ed., Richard Pazdur. PRR, Huntington, New York. (1995), pp. 235-246.

14. Talbot, D.C., Philip, P.A. Drug Resistance. In, Treatment of Cancer. 3d edition. Eds. Price P. and Sikora K. Chapman and Hall, London. 1995, pp. 109-119.

15. Philip, P.A., Harris, A.L. Malignant Disease in Pregnancy. In, Oxford Textbook of Medicine, 3d Edition. Eds. Weatherall D., Ledingham J.G.G., Warell D.A. Oxford University Press, Oxford. pp. 1806-1808 (1995).

Book Reviews

1. Gastrointestinal Malignancies Series: Emerging Cancer Therapeutics V1 I1 M. Wasif Saif, MD, MBBS, Jame Abraham, MD, FACP Published 04/2010 196 pp Hardback ISBN13 9781933864907 – Reviewed for Gastrointestinal Cancer Research (2011)

2. A Molecular Medicine Resource, Elsevier, Inc. – Reviewed for Community Oncology, March, 2006. Educational Materials

1. Philip, PA. Audio lecture on Gastric Cancers, the Audio-Digest Oncology Board Review course, 2015. 2. P Philip, M Talamonti, R Alasadi, Improving Treatment Outcomes and Sharing Decision Making in

Pancreatic Cancer. CME Released: 08/26/2014 3. Philip, P.A., Internet-based Physician’s Information and Education Resource (PIER), “Pancreas Cancer

Module,” American College of Physicians - American Society of Internal Medicine, 2004 - 2006. Other Publications

1. Philip PA, “Colon Cancer” Hope Magazine, Karmanos Cancer Instiute Publication, Sept 2017 2. Philip PA, Promiisng Treatments in Pancreatic Cancer, Gastrointestinal Cancers Symposium Daily

News, ASCO GI, 2017 3. Exploration Health Television, Gastric cancer, http://explorationhealth.tv/programs/gastric-cancer/

Page 31: PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C ...igicc.org/wp-content/uploads/2019/05/Philip-Agop-Philip-CV.pdfPage 1 of 53 . PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C

Page 31 of 53

2016 4. Commentary in Hemonc Today, http://www.healio.com/hematology-oncology/gastrointestinal-

cancer/news/online/%7Bed5b2690-2f21-481a-8364-a298debc5238%7D/combination-therapy-may-extend-os-in-metastatic-pancreatic-cancer, 2016

5. Article on pancreatic cancer in CURE, magazine, 2016 6. Philip PA, What you need to know about, STOMACH CANCER, Hope Magazine, November 2016 7. Strosberg JR, Fisher GA, Benson AB, Malin JL, Cherepanov D, Broder MS; Philip PA was panelist.

“Systemic Treatment in Unresectable Metasatic Well-Differentiated Carcinoid Tumors: Consensus Results from a Modified Delphi Process”, Pancreas, Dec 2, 2012 (Epub ahead of print).

8. Philip PA. “Top Oncology Stories for 2010”, Pancreas Cancer. OncologySTAT editors, Lee Schwartzberg and Axel Grothey, January 2011.

9. Progress Provides HOPE. http://awomanshealth.com/progress-provides-hope/, 2011 10. Philip PA. Key Practical Strategies in Pancreatic Cancer: Improving Treatment Disparities and

Clinical Trial Accrual. MedscapeCME Oncology. Posted: 09/30/2010 on www.medscape.com 11. Philip, PA. Update on the GI ASCO Symposium, Pancreas Cancer. Available at

http://www.medscape.com/viewarticle/468972, 2004. 12. Philip, PA. “Improvements in Gastric Cancer Therapy Options,” Medscape Conference Coverage. June

30, 2003. Available at http://www.medscape.com/viewarticle/457605. 13. Ph.D. Thesis (1988). “Studies in Polymorphic Drug Metabolism in Cancer,” University of London,

Philip A. Philip. Published Abstracts

14. P Philip, J Lacy, S Dowden, J Sastre, V Bathini, D Cardin, W Ma, A Sobrero, S Koski, C Borg, G

Tonini, F Rivera, J Hwang, J Knoble, T Baghdadi, W Saif, E Meiri, L Kayitalire, J Li, P Hammel. LAPACT: An open-label, multicenter phase II trial of nab-paclitaxel (nab-P) plus gemcitabine (Gem) in patients (pts) with locally advanced pancreatic cancer (LAPC). Abstract No TPS477 presented at GI ASCO, San Francisco, CA. January 2016. J Clin Oncol 34, 2016 (suppl 4S; abstr TPS477)

15. U Verma, Y Arriaga, J Lenz, C Henderson, J Fuloria, T Cartwright, A Khojasteh, P Stella, M Saltzman, A Cohn, P Philip, C Kappeler, J Kalmus, A Grothey, E Cutsem, H Hochster, F Arena. Regorafenib for previously treated metastatic colorectal cancer (mCRC): A subgroup analysis of 364 patients in the USA treated in the international, open-label phase IIIb CONSIGN study. Abstract No 735 presented at GI ASCO, San Francisco, CA. January 2016. J Clin Oncol 34, 2016 (suppl 4S; abstr 735)

16. H Riess, V Kunzmann, P Philip, T Seufferlein, D McGovern, P Chen, A Romano, R Ramanathan. A phase I safety and pharmacokinetic (PK) study of nab-paclitaxel (nab-P) plus gemcitabine (Gem) for patients (pts) with advanced pancreatic cancer (APC) who have cholestatic hyperbilirubinemia (CH) secondary to bile duct obstruction. Abstract No TPS474 presented at GI ASCO, San Francisco, CA. January 2016. J Clin Oncol 34, 2016 (suppl 4S; abstr TPS474)

17. M Tempero, D Cardin, D Goldstein, E O'Reilly, P Philip, H Riess, T Macarulla, L Yung, M Li, BD. Lu, A Biankin. APACT: Phase III randomized trial of adjuvant treatment with nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem alone in patients (pts) with resected pancreatic cancer (PC). Abstract No TPS473 presented at GI ASCO, San Francisco, CA. January 2016. J Clin Oncol 34, 2016 (suppl 4S; abstr TPS473)

18. M Javle, R Shroff, A Zhu, S Sadeghi, S Choo, M Borad, M Lowery, A El-Khoueiry, T Macarulla, P Philip, Do-Youn Oh, E Van Cutsem, Kun-Huei Yeh, R Isaacs, C McGarry, S Sen, T Bekaii-Saab. A phase 2 study of BGJ398 in patients (pts) with advanced or metastatic FGFR-altered cholangiocarcinoma (CCA) who failed or are intolerant to platinum-based chemotherapy. Abstract No 335 presented at GI ASCO, San Francisco, CA. January 2016. J Clin Oncol 34, 2016 (suppl 4S; abstr 335)

19. D Sohal, S McDonough, S Ahmad, N Gandhi, M Beg, A Wang-Gillam, K Guthrie, A Lowy, P

Page 32: PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C ...igicc.org/wp-content/uploads/2019/05/Philip-Agop-Philip-CV.pdfPage 1 of 53 . PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C

Page 32 of 53

Philip, H Hochster. SWOG S1505: A randomized phase II study of perioperative mFOLFIRINOX vs. gemcitabine/nab-paclitaxel as therapy for resectable pancreatic adenocarcinoma. Abstract No TPS4151presented at GI ASCO, San Francisco, CA. January 2016. J Clin Oncol 34, 2016 (suppl; abstr TPS4151)

20. M Salem, J Xiu, S Khan, H Wang, B Smaglo, W El-Deiry, J Hwang, M Pishvaian, E Lou, A Shields, P Philip, Z Gatalica, S Reddy, J Marshall. Comparative molecular analyses of esophageal cancer: Adenocarcinoma vs. squamous cell carcinomas and impact on outcome. Abstract No 4035 presented at GI ASCO, San Francisco, CA. January 2016. J Clin Oncol 34, 2016 (suppl; abstr 4035)

21. M Salem, J Marshall, R Feldman, M Pishvaian, W El-Deiry, J Hwang, E Lou, H Wang, Z Gatalica, S Reddy, A Shields, P Philip. Comparative molecular analyses of pancreatic cancer (PC): KRAS wild type vs. KRAS mutant tumors and primary tumors vs. distant metastases. Abstract No 4121 presented at GI ASCO, San Francisco, CA. J Clin Oncol 34, 2016 (suppl; abstr 4121)

22. J Marshall, J Xiu, W El-Deiry, J Hwang, Z Gatalica, M Pishvaian, P Philip, S Reddy, A Shields, M Salem. Comparative molecular analyses of colon versus rectal tumors. Abstract No 3552 presented at GI ASCO, San Francisco, CA. J Clin Oncol 34, 2016 (suppl; abstr 3552)

23. W El-Deiry, J Xiu, E Obeid, R Mehra, I Astsaturov, J Wagner, A Lev, M Baumeister, A Shields, M Salem, J Hwang, N Vijayvergia, C Denlinger, E Dotan, H Borghaei, M Pishvaian, P Philip, J Marshall, S Cohen, Z Gatalica, S Reddy. Tumor profiling of liver metastases (LM) from CRC, NSCLC, pancreatic (PC), breast (BC) and gastroesophageal (GE) tumors to reveal differences versus primary tumors including in cMET, MYC, CDK4, Her2, b-catenin and PD1. Abstract No 11604 presented at GI ASCO, San Francisco, CA. J Clin Oncol 34, 2016 (suppl; abstr 11604)

24. M Overman, C Lopez, A Benson, S Neelapu, N Mettu, A Ko, V Chung, J Nemunaitis, J Reeves, J Bendell, P Philip, R Dalal, M Fardis, J Greer, X Wang, S Inamdar, B Lannutti, W Rothbaum, R Izumi, M Javle. A randomized phase 2 study of the Bruton tyrosine kinase (Btk) inhibitor acalabrutinib alone or with pembrolizumab for metastatic pancreatic cancer (mPC). Abstract No 4130 presented at GI ASCO, San Francisco, CA. J Clin Oncol 34, 2016 (suppl; abstr 4130)

25. K Lilley, P Naylor, O Sadiq, S Stern, K Mathur, A Devara, K Ravindran, R Anand, S Haider, R Morton, S Benjaram, P Philip, M Ehrinpreis and M Mutchnick. Racial Disparity in Hepatocellular Carcinoma Patients Diagnosed in an Urban Medical Center (ID # 2321275), presented at the 2015 AASLD Annual Meeting.

26. M Choi , G Dyson, S Petit, A Thakur, H Mahaseth, A Shields, P Philip, L Lum. Phase I study of Anti-CD3 x anti-EGFR Armed Activated T-cells for Treatment of Advanced Colorectal or Pancreatic Cancer. Proceedings of ASCO GI Symposium, San Francisco, January 2015.

27. M Tempero, D Cardin, A Biankin, D Goldstein, M Moore, E O’Reilly, P Philip, H Riess, T Macarulla, L Yung, X Wei, B Lu. APACT: A phase III trial of nab-paclitaxel (nab-P) plus gemcitabine (Gem) vs Gem alone for resected pancreatic cancer (PC). Abstract presented at ASCO, June 2014.

28. Kollepara S, Choi M, Heilbrun L, Smith D, Shields AF, Philip PA. PET scan as a prognostic marker in advanced colorectal cancer. Abstract No 442 presented at GI ASCO, San Francisco, CA. January 2014.

29. Salem M, Al-hajeili M, Dyson G, Stanski N, Jain T, Mahaseth H, Choi M, Shields AF, Philip PA. Clinicopathologic features of patients with KRAS wild-type pancreatic adenocarcinoma. Abstract No 192 presented at GI ASCO, San Francisco, CA. January 2014.

30. Konski A, Meyer J, Philip PA, Shields AF, Hall M, Choi M, Duncan G, Adaire B, McSpadden E, Cohen S. A phase I study of hyperfractionated low-dose radiotherapy as a chemotherapy sensitizer in combination with gemcitabine and erlobtinib in advanced pancreatic cancer. Abstract No 268 presented at GI ASCO, San Francisco, CA. January 2013.

31. Tan J, Choi M, Philip PA, Dyson G, Shields AF, Kim R. The outcome of patients with advanced hepatocellular carcinoma in pre- and post-sorafenib eras using the SEER database. Abstract No 276 presented at GI ASCO, San Francisco, CA. January 2013.

32. Salem M, Arun M, Dyson G, Saad C, Arbabi C, Jain T, Taylor S, Kunz S, Choi M, Shields AF, Philip PA. Characteristics of colorectal cancer in patients younger than 40 years compared to older patients. Abstract No 371 presented at GI ASCO, San Francisco, CA. January 2013.

33. Osourji I, Dyson G, Yerasuri D, Philip PA, Shields AF, Choi M. Prognostic factors for metastatic

Page 33: PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C ...igicc.org/wp-content/uploads/2019/05/Philip-Agop-Philip-CV.pdfPage 1 of 53 . PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C

Page 33 of 53

colorectal cancer with and without bevacizumab therapy. Abstract No e14163 presented at ASCO Annual Meeting, Chicago, IL. May 2012.

34. Goncalves P, Ruch J, Byer J, Shields AF, Choi M, Kim R, Zalupski M, Philip PA. Multi-institutional experience using 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) in patients with pancreatic cancer. Abstract No e1459 presented at ASCO Annual Meeting, Chicago, IL. May 2012.

35. Josep Tabernero, Carmen Joseph Allegra, Philippe R Rougier, Giorgio Scagliotti, Philip Agop Philip, Radek Lakomy, Rodryg Ramlau, Sylvie Assadourian, Soazig Chevalier, Eric Van Cutsem. Meta-analysis of anti-VEGF class adverse events from three double-blind (db), placebo (pbo)-controlled phase III trials with IV aflibercept (Afl). Abstract No 3579 presented at 2012 ASCO Annual Meeting, Chicago, IL, June, 2012.

36. Philip Agop Philip, Bryan H. Goldman, Ramesh K. Ramanathan, Heinz-Josef Lenz, Andrew M. Lowy, Robert P. Whitehead, Syma Iqbal, Rakesh Gaur, Jacqueline K. Benedetti, C. D. Blanke. Dual blockade of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor-1 (IGF-1R) signaling in metastatic pancreatic cancer: Phase I/randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG-0727). Abstract No 4109 presented at 2012 ASCO Annual Meeting, Chicago, IL, June, 2012.

37. Tait LM, Meyer JE, McSpadden E, Cheng J, Philip PA, Scott WJ, Baciewicz F, Meropol NJ, Shields AF, Crawford K, Cohen SJ, Wozniak AJ, Gadgeel SM, Choi M, Konski AA. Cardiac toxicity associated with dose and gender in patients undergoing chemoradiation for esophageal carcinoma. Abstract No 112 presented at 2012 Gastrointestinal Cancers ASCO Symposium, San Francisco, CA. January, 2012.

38. Asfar S. Azmi, Ammar Sukari, Philip A. Philip, Mohammad RM. Zinc is Essential for the Efficacy of p53 Reactivating Drugs. AACR Annual Meeting, Orlando, FL, April 2011.

39. Lauren Marie Tait, Joshua E. Meyer, Erin McSpadden, Jonathan D. Cheng, Philip Agop Philip, Walter J. Scott, Frank Baciewicz, Neal J. Meropol, Anthony Frank Shields, Kevin Crawford, Steven J. Cohen, Antoinette J. Wozniak, Shirish M. Gadgeel, Minsig Choi, Andre A. Konski. Cardiac toxicity associated with dose and gender in patients undergoing chemoradiation for esophageal carcinoma. Abstract #88955. Proceedings Annual GI Symposium, San Francisco, CA, 2012.

40. Philip A Philip, Hussain Saleh, Shadan Ali, Wei Chen, Paulette Palazzolo, Seema Sethi, Fazlul H Sarkar. MicroRNA analysis of fine needle aspirates from pancreatic cancer. Abstract #88107. Proceedings Annual GI Symposium, San Francisco, CA, 2012.

41. Philip A. Philip, Bryan Goldman, Ramesh K. Ramanathan, Heinz-Josef Lenz, Andrew M. Lowy, Robert P. Whitehead,Syma Iqbal, Rakesh Gaur, Jacqueline K. Benedetti, Charles D. Blanke. Phase I and randomized phase II trial of gemcitabine, erlotinib, and IMC-A12 (cixutumumab) versus gemcitabine plus erlotinib as first line treatment in patients with metastatic pancreatic cancer (SWOG-0727). Abstract #87986. Proceedings Annual GI Symposium, San Francisco, CA, 2012.

42. Shadan Ali, Amro Aboukameel, Sanjeev Banerjee, Bin Bao, Philip A. Philip, Fazlul H. Sarkar. In vivo sensitization of Pancreatic Tumors to Gemcitabine and Erlotinib by Isoflavone. APA Annual Meeting, Chicago, 2011.

43. Shadan Ali, Khaldoun Almhanna, Wei Chen, Philip A. Philip, Fazlul H. Sarkar. Differentially expressed miRNAs in the plasma may provide a molecular signature for aggressive pancreatic cancer. AACR Annual Meeting, Orlando, FL, 2011.

44. M. E. Christensen, P. Paximadis, A. F. Shields, P. A. Philip, D. W. Weaver, A. A. Konski. Mixed photon and neutron radiotherapy given concurrently with chemotherapy in unresectable pancreatic cancer. Abstract #328. Proceedings Annual GI Symposium, San Francisco, CA, 2011.

45. M. Choi, G. Dyson, P. A. Philip, A. F. Shields. Clinical outcome of advanced colorectal cancer patients pre- and post-bevacizumab therapy using the SEER database. Abstract #6083. Proceedings Annual ASCO Meeting, Chicago, IL, 2011.

46. A. X. Zhu, P. J. Gold, A. B. El-Khoueiry, T. A. Abrams, H. Morikawa, T. Ohtomo, P. A. Philip. A phase I study of GC33, a recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma (HCC). Abstract #4085. Proceedings Annual ASCO Meeting, Chicago, IL, 2011.

47. P. Paximadis, D. Elliott, A.F. Shields, P.A. Philip, D.W. Weaver, M. Joiner, A. A. Konski. High LET (Linear Energy Transfer) Radiation Therapy in Recurrent, Metastatic, or

Page 34: PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C ...igicc.org/wp-content/uploads/2019/05/Philip-Agop-Philip-CV.pdfPage 1 of 53 . PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C

Page 34 of 53

Unresectable Rectal Cancer. Proceedings Annual GI Symposium, San Francisco, CA, 2011. 48. A Azmi, P Philip, M Choi, AF Shields, FH Sarkar, FM Mohammad. Unveiling the Role of Network

and Systems Biology in Pancreatic Cancer Drug Discovery. AACR Annual Meeting, Orlando, FL, April 2011:4910.

49. J Berlin, PJ Catalano, Y Feng, AM Lowy, AW Blackstock, PA Philip, RR McWilliams, JL Abbruzzese, AB Benson, ECOG 2204: An intergroup randomized phase II study of cetuximab (Ce) or bevacizumab (B) in combination with gemcitabine (G) and in combination with capecitabine (Ca) and radiation (XRT) as adjuvant therapy (Adj Tx) for patients with completely-resected pancreatic adenocarcinoma. ASCO Meeting Abstracts June 2010.

50. P.A. Philip, B.H. Goldman, R.K. Ramanathan, H. Lenz, A.M. Lowy, R.P. Whitehead, S. Iqbal, V.M. Chung, J.K. Benedetti, C.D. Blanke. SWOGS0727: A randomized phase II trial of combination gemcitabine plus erlotinib plus IMC-A12 (cixutumumab) versus gemcitabine plus erlotinib as first-line treatment in patients (pts) with metastatic pancreatic cancer. ASCO Meeting Abstracts June 2010:TPS223:50948.

51. P.A. Philip, B.H. Goldman, R.K. Ramanathan, H.J. Lenz, A.M. Lowy, R.P. Whitehead, S. Iqbal, V.M. Chung, J.K. Benedetti, C. Blanke. Phase I trial of combination gemcitabine, erlotinib (NSC-718781), and IMC-A12 (NSC-742460) as first-line treatment in patients with metastatic pancreatic cancer: Southwest Oncology Group study S0727. GI ASCO Meeting Abstracts January 2010:233.

52. B. F. El-Rayes, N. Hammad, P. A. Philip, A. F. Shields, L. K. Heilbrun. A phase II study of Bevacizumab, docetaxel and oxaliplatin in gastric and gastroesophageal junction (GEJ) cancer. ASCO Meeting Abstracts June 2009:4563.

53. Gupta S, Shields A, Heilbrun L, El-Rayes B, Philip P. 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) as a biomarker in metastatic colorectal cancer. GI ASCO Meeting, January 2009.

54. M. Mobayed, B. El-Rayes, P. A. Philip, L. Heilbrun. Activity and safety of carboplatin and paclitaxel followed by capecitabine and radiation as adjuvant therapy for gastric cancer (GC). GI ASCO Meeting Abstracts January 2008:61.

55. N. K. LoConte, K. D. Holen, M. R. Mahoney, D. W. Szydlo, J. Picus, W. Maples, H. Pilot, P. A. Philip, J. P. Thomas, C. E. Erlichman. Interim report of a multicenter phase II clinical trial testing a combination of biweekly Bevacizumab and daily erlotinib in patients with metastatic bile tract carcinoma: A Phase II Consortium (P2C) study. GI ASCO Meeting Abstracts January 2008:256.

56. N. Hammad, P. A. Philip, A. F. Shields, J. L. Abruzzese, A. O. Kaseb, M. M. Javie, G. R. Varadhachary, R. A. Wolff, F. H. Sarkar, B. F. El-Rayes. A phase II study of isoflavone (Novasoy), gemcitabine, and eriotinib in locally advanced (LA) or metastatic pancreatic cancer. GI ASCO Meeting Abstracts January 2008:262.

57. B. F. El-Rayes, N. Hammad, P. A. Philip, A. F. Shields, L. K. Heilbrun. A phase II study of Bevacizumab, docetaxel and oxaliplatin in gastric and gastroesophageal junction (GEJ) cancer. ASCO Meeting Abstracts June 2008:15608.

58. P. Jasti, B. F. El-Rayes, L, K. Heilbrun, P. A. Philip, M. M. Zalupski, A. F. Shields, R. Venkatramanamoorthy, R. Severson. A comparison of advanced pancreatic cancer patients treated on clinical trials with those from a SEER registry over an 18 year period. ASCO Meeting Abstracts June 2008:4628.

59. K. D. Holen, M. R. Mahoney, N. K. LoConte, D. W. Szydlo, J. Picus, W. J. Maples, G. P. Kim, H. C. Pitot, P. A. Philip, J. P. Thomas, C. E. Erlichman. Efficacy report of a multicenter phase II trial testing a biologic-only combination of biweekly Bevacizumab and daily erlotinib in patients with unresectable biliary cancer (BC): A Phase II Consortium (P2C) study. ASCO Meeting Abstracts June 2008:4522.

60. M. Mobayed, P. A. Philip, A. F. Shields, L. Heilbrun, T. Washington, U. Vaishampayan, R. Venkatramanamoorthy, B. F. El-Rayes. ASCO Meeting Abstracts Jun 20 2007: 15162 Activity and safety of carboplatin and paclitaxel followed by capecitabine and radiation as adjuvant therapy for gastric cancer (GC).

61. L. K. Heilbrun, A. Khanna, R. Venkatramanamoorthy, A. F. Shields, P. A. Philip, M. M. Zalupski, B. F. El-Rayes. ASCO Meeting Abstracts Jun 20 2007: 15094. CA 19–9 as a predictor of tumor response and survival in patients with pancreatic cancer treated with gemcitabine and cisplatin based chemotherapy.

Page 35: PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C ...igicc.org/wp-content/uploads/2019/05/Philip-Agop-Philip-CV.pdfPage 1 of 53 . PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C

Page 35 of 53

62. P. A. Philip, J. Benedetti, C. Fenoglio-Preiser, M. Zalupski, H. Lenz, E. O'Reilly, R. Wong, J. Atkins, J. Abruzzese, C. Blanke. ASCO Meeting Abstracts Jun 20 2007: 4509. Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG S0205 study.

63. A.B. El-Khoueiry, C. Rankin, H.J. Lenz, P. Philip, S.E. Rivkin, C.D. Blanke. SWOG 0514: A phase II study of sorafenib (BAY 43-9006) as single agent in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinomas. ASCO Meeting Abstracts. June 20 2007: 4639.

64. Basturk O, Cheng JD, El-rayes B, Philip P, Thirabanjasak D, Adsay NV. High grade goblet cell carcinoid is an aggressive neoplasm often asscoaited with abdominal carcinomatosis and ovarian metastses: Clinico-Pathologic analysis of 22 cases. Archives of Pathology and Laboratort Medicine, 131:1433A, 2007.

65. S. M. Gadgeel, S Ali, P Philip, A Wozniak, and F Sarkar. Epidermal growth factor receptor (EGFR) mutational status of non-small cell lung cancer cells (NSCLC) may determine the outcome of dual blockade of EGFR and cyclooxygenase-2 (COX-2). AACR Meeting Abstracts, Apr 2006; 2006: 294.

66. S. M. Gadgeel, S. Ali, P. Philip, A. Wozniak, F. Sarkar. Dual blockade of epidermal growth factor receptor (EGFR) and cyclooxygenase 2 (COX 2) may be dependent upon the EGFR mutational status in non-small cell lung cancer (NSCLC) cell lines. ASCO Proceedings, Ab #7170, 2006.

67. J. Grandhi, P. A. Philip, T. Washington, A. F. Shields, U. Vaishampayan, L. K. Heilburn, R. Venkatramanamoorthy, B. F. El-Rayes. A retrospective review of anal squamous cell carcinoma in HIV positive and HIV negative negative patients. ASCO Proceedings, Ab #4153, 2006.

68. W. Sun, J. Schwartz, A. Zhu, P. A. Philip, J. Metz, M. B. Thomas, Liver Cancer Research Group. Feasibility of multi-institutional live cancer registry. ASCO Proceedings, Ab #4146, 2006.

69. T. J. Hobday, K. Holen, R. Donehower, J. Camoriano, G. Kim, J. Picus, P. Philip, R. Lloyd, M. Mahoney, C. Erlichman.A phase II trial of gefitinib in patients (pts) with progressive metastatic neuroendocrine tumors (NET): A Phase II Consortium (P2C) study. ASCO Proceedings, Ab #4043, 2006.

70. B. F. El-Rayes, A. F. Shields, U. Vaishampayan, L. K. Heilbrun, M. M. Zalupski, P. A. Philip. A dose attenuated schedule of irinotecan and capecitabine in combination with celecoxib in advanced colorectal cancer. ASCO Proceedings, Ab #3584, 2006.

71. B. Patel, L. Heilburn, A. Khanna, R. Venkatramanamoorthy, A. Shields, P. Philip, M. Zalupski, B. El-Rayes. CA 19-9 as a predictor of response and survival in patients with pancreatic cancer treated with gemcitabine and cisplatin based chemotherapy. ASCO Proceedings, 2005, Ab #4189.

72. B. J. Schneider, J. Muler, P. Philip, G. Kalemkerian, B. El-Rayes, K. Griffith, M. Zalupski A phase II trial of carboplatin, gemcitabine and capecitabine in patients with carcinoma of unknown primary site (CUP). ASCO Proceedings, 2005, Ab #4090.

73. B. F. El-Rayes, M. M. Zalupski, A. F. Shields, L. K. Heilbrun, T. Bekaii-Saab, U. Vaishampayan, P. A. Philip. A phase II trial of celecoxib, irinotecan, and capecitabine in metastatic colorectal cancer. ASCO Proceedings, 2005, Ab #3677.

74. K. M. Rowland, H. C. Pitot, D. J. Sargent, P. A. Philip, E. P. Mitchell, J. A. Mailliard, R. M. Goldberg, S. R. Alberts. Results of 3rd line therapy on N9841: a randomized phase III trial of oxaliplatin/5-fluorouracil (5FU)/leucovorin (FOLFOX4) versus irinotecan (CPT-11) in patients (pts) with advanced colorectal cancer (CRC) previously treated with prior 5FU chemotherapy. ASCO Proceedings, 2005, Ab #3519.

75. HC. Pitot, K. M. Rowland, D. J. Sargent, P. A. Philip, E. P. Mitchell, R. M. Goldberg, S. R. Alberts; N9841: A randomized phase III equivalence trial of irinotecan (CPT-11) versus oxaliplatin/5-fluorouracil (5FU)/leucovorin (FOLFOX4) in patients (pts) with advanced colorectal cancer (CRC) previously treated with 5FU. ASCO Proceedings, 2005, Ab #3506

76. Philip PA, Mahoney MR, Thomas JP, Pitot HC, Donehower R, Kim GP, Picus J, Fitch TR, Geyer SM, Erlichman C. Phase II trial of OSI-774 in patients with hepatocellular and biliary

Page 36: PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C ...igicc.org/wp-content/uploads/2019/05/Philip-Agop-Philip-CV.pdfPage 1 of 53 . PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C

Page 36 of 53

cancer. Proceedings of 2004 Gastrointestinal Cancers Symposium, Ab #174, page 173, 2004. 77. Ben-Josef, Shields A, Vaishampayan U, Vaitkevicius V, McDermott P, Burmeister J,

Bossenberger T, Philip PA. Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer. Proceedings of 2004 Gastrointestinal Cancers Symposium, Ab #163, page 122, 2004.

78. El-Rayes, FB, Ali S, Sarkar F, Philip PA. Targeting the epidermal growth factor receptor (EGFR) and cyclooxygenase 2 (COX-2) pathways in pancreatic cancer. Proceedings of 2004 Gastrointestinal Cancers Symposium, Ab #126, page 104, 2004.

79. McGinn CJ, Talamonti MS, Small W, Freedman GM, Berlin J, Kinsella TJ, Philip PA, Zalupski MM, Mulcahy MF, Meropol NJ, Chakraverthy A, Brell J, Balter JM, Normolle D, Benson AB, Lawrence TS. A Phase II trial of full-dose gemcitabine with concurrent radiation therapy in patients with resectable or unresectable non-metastatic pancreatic cancer. Proceedings of 2004 Gastrointestinal Cancers Symposium, Ab #96, 2004.

80. Vishnubhotla, PS, Alsukhn S, Washington T, Freidman L, Flaherty L, Simon B, Yu B, Philip PA. Capecitabine is safe and tolerable in combination with radiation therapy in breast cancer. Breast Cancer Research and Treatment, Vol 82, Suppl 1, A169, 2003.

81. P. A. Philip, M. R. Mahoney, J. P. Thomas, H.C. Pitot, R. Donehower, G. P. Kim, J. Picus, T. R. Fitch, S. M. Geyer, C. Erlichman; OSI-774 (Tarceva) in patients (pts) with unresectable or metastatic hepatocellular carcinoma (HCC): A multi-center Phase 2 Consortium (P2C) study. Proceedings of the Molecular Targets and Cancer Therapeutics international conference, 2003.

82. P. A. Philip, M. R. Mahoney, J. P. Thomas, H.C. Pitot, R. Donehower, G. P. Kim, J. Picus, T. R. Fitch, S. M. Geyer, C. Erlichman. Proceedings of the Molecular Targets and Cancer Therapeutics international conference, 2003.

83. P. A. Philip, S. M. Geyer, J. P. Thomas, H. C. Pitot, R. Donehower, G. P. Kim, J. Picus, T. R. Fitch, M. R. Mahoney, C. Erlichman Tolerability of OSI-774 (Tarceva) in locally advanced or metastatic hepatocellular cancer (HCC) and biliary (BILI) carcinomas: an interim report. Proceedings of the American Society of Clinical Oncology (ASCO), #1461, 2003.

84. B. F. El-Rayes, S. Ali, F. Sarkar, P. A. Philip. Protein kinase C (PKC): A target for therapy in pancreatic cancer. Proceedings of the American Society of Clinical Oncology (ASCO), #1091, 2003.

85. D. Ibrahim, B. F. El-Rayes, S. M. Gadgeel, P. Lorusso, P. A. Philip. A phase I study of the protein kinase C modulator bryostatin-1 and gemcitabine. Proceedings of the American Society of Clinical Oncology (ASCO), #930, 2003.

86. B. Patel, B. F. El-Rayes, S. M. Gadgeel, P. Lorusso, P. A. Philip. A phase I study of flavopiridol and docetaxel. Proceedings of the American Society of Clinical Oncology (ASCO), #932, 2003.

87. L.A. Newman, N.L. Pernick, P. Philip, K. Carolin, D. Bouwman, M. Kosir, M. White and D.W. Visscher. Histopathologic Evidence of Tumor Regression in the Axillary Lymph Nodes of Patients Treated with Preoperative Chemotherapy Predicts Breast Cancer Outcome. Annals of Surgery, 2002.

88. O Kucuk, J McMichael, A Hatfield, M Holmes, H Razook, N Yousif, M Kraut, P Philip, A Shields, J Abrams. A new method of dose modification using a computerized decision support system to accurately predict the contribution of each drug to the toxicity of chemotherapy regimen. Proceedings of the American Society of Clinical Oncology (ASCO), #2590, 2002.

89. Philip, P.A., Zalupski, M., El-Rayes, B., Adsay, V., Heilbrun, L., Vaitkevicius, V.K., Shields, A.F. Phase II Study of Gemcitabine, Cisplatin and Infusional 5-Fluorouracil in Patients with Metastatic Pancreatic Cancer. Proceedings of the American Society for Clinical Oncology (ASCO), 2002.

90. Al-Sukhun, S.A., Ali, S., Heilbrun, L., Lababidi, S., Philip, P.A. Protein Kinases C Isozymes are Differentially Expressed in Human Breast Carcinoma. Proceedings of the American Association of Cancer Research, 2002.

91. Philip, P.A., Shadan, Ali, Kraut, M.J., Sarkar, F. Flavopiridol Sensitizes Human Breast Cancer Cells to Gemcitabine. Annual Meeting of the American Association for Cancer Research, April, 2001.

92. Philip, P.A., Shields, A.F., Zalupski, M., El-Rayes, B., Adsay, V., Heilbrun, L., Arlauskas, P.L., Vaitkevicius, V.K. Gemcitabine, Cisplatin, and 5-Fluorouracil in Advanced Pancreas Cancer. Proceedings of ASCO, Volume 20, Abst 2341, 2001.

93. E. Ben-Joseph, E., Vaishampayan, U.N., Vaitkevicius, V.K., Levin, K..J., Philip, P.A.,

Page 37: PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C ...igicc.org/wp-content/uploads/2019/05/Philip-Agop-Philip-CV.pdfPage 1 of 53 . PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C

Page 37 of 53

Shields, A.F. A Single Institution Experience with Concurrent Capecitabine and Radiation Therapy in Gastrointestinal Malignancies. Proceedings of ASCO, Volume 20, Abst 2324, 2001.

94. Dohmen, B.M., Shields, A.F., Dittmann H, Fersis N, Eschmann SM, Philip P, Reimold M, Machulla HJ, Bares. Use of [18F]FLT for breast cancer imaging. Proceedings of the Society of Nuclear Medicine Meeting, June 2001, Toronto.

95. Philip, PA, Ensley, J., Heilbrun, L., Ali, S. Expression of Cytochrome P-450 Enzymes and Glutathione S-transferase P1 in Peritumoral Tissue From Patients with Head and Neck Cancers and its Relationship to the Tumoral Expression of p16. Proceedings of the Annual Meeting of the AACR, San Francisco, 2000.

96. Pernick, N.L., Sarkar, F., Arlauskas, P.L., Philip, P.A., Shields, V.K., Vaitkevicius, V.K., Adsay, V. FAS and FAS Ligand Expression in Pancreatic Adenocarcinoma. Pancreas, 4(21), 2000.

97. Philip, P.A., Shields, A.F., Zalupski, M.M., Foster, B., Arlauskas, P., Adsay, V., Vaitkevicius, V.K. Phase II Study of Gemcitabine, 5-Fluorouracil and Cisplatin in Patients With Advanced Pancreatic Cancer. Pancreas, 4(21), 2000. Feng, J., Vaitkevicius, V., Shields, A., Philip, P., Adsay, V. Perineural Invasion in Pancreatic Adenocarcinoma. Proceedings of 89th Annual Meeting, United States and Canadian Academy of Pathology, New Orleans, March 2000. Philip, P.A., Ensley, J. Heilbrun, L., Ali, S. Expression of Cytochrome p-450 Enzymes and Glutathione S-Transferase Pi in Tumoral Tissue From Patients with Head and Neck Cancers and its Relationship to the Tumoral Expression of p16. Proceedings of AACR, 2000.

98. Philip, P.A., Pernick, N.L., Vaishampayan, U., Simon, M., LoRusso, P., Chaplen, Biernat, L., Flaherty, L. Phase II Study of Doxorubicin, Docetaxel, and 5-Fluorouracil (FAT) in Patients with Locally Advanced Breast Cancer. Proceedings of ASCO, 2000.

99. Feng, J., Vaitkevicius, V.K., Shields, A.F., Philip, P.A., Adsay, V. Perineural Invasion in Pancreatic Adenocarcinoma. Modern Pathology, 13(1), #1075, 2000.

100. Andea, A., Philip, P.A., Shields, A.F., Vaitkevicius, V.K., Adsay, V. Is "Tail Carcinoma" a Different Entity? A Comparative Analysis of Resected Adenocarcinomas From the Head and Tail of Pancreas. Modern Pathology, 13(1), #1054, 2000.

101. Philip, P.A., Gadgeel, S., Hussain, M., Zalupski, M.M., Shields, A.F. Phase II Study of Carboplatin and Paclitaxel in Patients with Advanced Upper Gastrointestinal Cancers. Seminars in Oncology, Feb 1999, 141.

102. Philip, P.A., Heilbrun, L., Lababidi, S., Vischer, D., Ali, S. Expression of Cytochrome P450 (CYP) Enzymes in Malignant and Morphologically Normal Human Breast Tissues. Proceedings of Annual Meeting of AACR, Philadelphia, Penn., April 1999.

103. Philip, P.A., Li, Y., Alonso, M., Manji, H., Sarkar, F., Ensley, J., Ali, S. Sensitization of Human Breast Cancer Cells to Gemcitabine by Bryostatin 1. Proceedings of Annual Meeting of AACR, Philadelphia, Penn., April 1999.

104. Philip, P.A., Zalupski, M., Vaitkevicius, V.K., Arlauskas, P., Shields, A.F. Phase II Study of Gemcitabine and Cisplatin in Advanced or Metastatic Pancreatic Cancer. Proceeding of the Annual Meeting of ASCO, Atlanta, Georgia, May 1999.

105. Biernat, L., Flaherty, L., Philip, P., Simon, M. A Phase II Study of the Combination of Taxotere, Doxorubicin, and Infusional 5-FU (TDF) in the Treatment of Locally Advanced Breast Cancer (LABC)- Preliminary Toxicity Data. Abs. # 550, Breast Cancer Research and Treatment 50 (3), 1998.

106. Philip, P.A., Ali-Sadat, S., Alonso, M., Manji, H., Sarkar, F., Ensley, J. Bryostatin 1 Sensitizes Human Breast Cancer Cells to Gemcitabine (Gemzar). Abs. # 523, Breast Cancer Research and Treatment, 50 (3), 1998.

107. Philip, P.A., Gadgeel, S., Shields, A., Zalupski, M., Hussain, M. Phase II Study of Paclitaxel and Carboplatin in Patients with Advanced Gastric and Esophageal Cancers. Proceedings of ASCO, 1998.

108. Owainati, A., Zalupski, M., Shields, A., Hussain, M., Philip, P.A. Phase I Study of Liposomal Doxorubicin (Doxil) and Cyclophosphamide in Solid Tumors. Proceedings of ASCO, 1998.

109. Philip, P.A., et al. Expression of Cytochrome P450 Enzymes in the Oral Mucosa of African- Americans (AA) and Caucasians (CC). Proceedings of AACR, 1998.

Page 38: PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C ...igicc.org/wp-content/uploads/2019/05/Philip-Agop-Philip-CV.pdfPage 1 of 53 . PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C

Page 38 of 53

110. Philip, PA, et al. Interactions of Bryostatin 1 with Tamoxifen, Paclitaxel, and Doxorubicin in Human Breast Cancer Cells. Proceedings of AACR, 1998.

111. Philip, P.A., Ali-Sadat, S., Chen, K.K., Kocarek, T., Doehmer, J. Influence of Differential Metabolism of Cyclophosphamide (CPA) on Cytotoxicity in MCF-7 and V-79 cells. Proceedings of AACR, 1997.

112. Philip, P.A., et al. Expression of cytochrome P450 enzymes in the oral mucosa of African-Americans (AA) and Caucasians (CC). Proceedings of AACR, 1998.

113. Philip, P.A., et al. Interactions of bryostatin 1 with tamoxifen, paclitaxel, and doxorubicin in human breast cancer cells. Proceedings of AACR, 1998.

114. Philip P.A., Ali-Sadat S, Chen, K.K., Kocarek, T., Doehmer, J. Influence of differential metabolism of cyclophosphamide (CPA) on cytotoxicity in MCF-7 and V-79 cells. Proc. AACR, 1997.

115. Philip P.A., Ali-Sadat, S., Kocarek, T., Doehmer, J. The use of the V79 cells stably transfected with cytochrome P-450 cDNAs in studying the metabolism of cyclophosphamide and ifosfamide. Proc. ASCO, Abstract #A1588, 1996.

116. Philip P.A., Ali-Sadat, S., Kocarek, T., Doehmer, J. In vitro metabolism of cytotoxic drugs using V79 cells stably transfected with human cytochrome P-450 cDNAs. Proceedings of AACR, Abstract #2515, 1996.

117. O'Byrne K.J., Philip P.A., et al. Modulation of 5-Fluorouracil and folinic acid with hydroxyurea in the treatment of metastatic colorectal cancer. Proceedings of ASCO, 14:172, 372A, 1995.

118. O'Byrne K.J., Philip P.A., et al. 5-Fluorouracil and folinic acid modulation with hydroxyurea in the treatment of metastatic colorectal cancer. BACR Spring meeting, Nottingham/England, April 2-5, 1995. British Journal of Cancer, Supplement, p. 10, A3.1.

119. Philip P.A., and Hsieh J.T. Correlation between an apoptosis-associated gene (TRPM-2) and apoptotic cell death induced by Adriamycin in a rat prostatic epithelial cell line (NbE). AACR special conference in cancer research: Basic and clinical aspects of prostate cancer, Palm Springs, CA, December 8-12, 1994.

120. Vallis K., Philip P.A., Rockett H., et al. Multidrug resistance reversal with toremifene in renal cell cancer. British Journal of Cancer, Supplement XXI, Vol 69, 1994.

121. O'Byrne K.J., Philip P.A., Stuart N.S.A. et al. Increased dose-intensity of epirubicin and ifosfamide in small cell lung cancer using r-metHuG-CSF. British Journal of Cancer, Supplement XXI, Vol 69, 1994.

122. Philip P.A., et al. 5-fluorouracil, a-interferon, cisplatin (FAP) and methotrexate (MTX) in patients (pts) with transitional cell carcinoma (TCC): results of a phase I trial. Proceedings of ASCO 13, A796, 1994.

123. Talbot D.C., Green J.A., Mitchell K., Smith K., Philip P.A., Stuart N., et al. Phase I study of the mitomycin C analogue BMY 25067. European Journal of Cancer. 29A. Supplement 6. S120, 1993.

124. Philip P.A., Talbot D., Rea D., et al. Phase I study of protein kinase C partial agonist, bryostative-1. EORTC Early Drug Development Meeting, June 23-26, 1993. Rotterdam, the Netherlands.

125. Philip P.A., et al. Expression of xenobiotic-metabolizing enzymes (XMEs) by primary and secondary hepatic tumors in man. Eighth International Congress on Chemical Modifiers, Kyoto, Japan, June 1993.

126. Carmichael J., Possinger K., Philip P.A., et al. Difluorodeoxycytidine (gemcitabine): A phase II study in patients with advanced breast cancer. Proceedings of ASCO, 12, 1993.

127. Philip P.A., et al. Hydroxyurea increases the formation of O6-methylguanine (OMG) DNA adducts in lymphocytes from melanoma patients treated with dacarbazine (DTIC). The influence of dacarbazine on the induction of DNA mutations. Proceedings of ASCO, 12, 1993.

128. Philip P.A., et al. High-dose hydroxyurea increases the formation of O6-methylguanine but not N7-methylguanine DNA adducts in lymphocytes from melanoma patients treated with dacarbazine without induction of HPRT mutations or micronuclei formation. EORTC/PAMM winter meeting in Brest/France, January 14-16, 1993.

129. Philip P.A., et al. Phase I trial of bryostatin-1. Influence on the plasma

Page 39: PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C ...igicc.org/wp-content/uploads/2019/05/Philip-Agop-Philip-CV.pdfPage 1 of 53 . PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C

Page 39 of 53

concentrations of interleukin-6 and tumor necrosis factor-a. Proceedings of the AACR, 34, 1993. 130. Rea D., Harris A.L., Philip P.A., et al. Essential fatty acids in the treatment of metastatic

carcinoma of the colon. British Association of Cancer Research (BACR) spring meeting in March 1992, University of Southampton, Southampton, England.

131. Philip P.A., Modulation of drug resistance with antimetabolites: the influence of high-dose hydroxyurea (HU) on the repair of cisplatin induced DNA damage. British Association of Cancer (BACR) spring meeting in March 1992, University of Southampton, Southampton, England, March 1992.

132. Philip P.A., et al. Hormonal therapy in pancreatic carcinoma: A phase II study of LHRH agonist goserelin plus hydrocortisone. British Association of Cancer Research (BACR) spring meeting in University of Southampton, Southampton, England, March 1992.

133. Carmichael J., Philip P.A., Rea D., et al. Gemcitabine: an active drug in advanced breast cancer. Results of a phase II study. Proceedings of ASCO, 11, 1992.

134. Philip P.A. et al. A phase I/II study of left shifting agent BW12C and mitomycin C. Monitoring by magnetic resonance spectroscopy (MRS). Proceedings of the ASCO, 11, 1992.

135. Philip P.A., et al. Expression of drug metabolising enzymes (DME) in primary hepatic tumors in man. British Association of Cancer Research (BACR) Spring meeting at University of Southampton, Southampton, England, March 1992.

136. Lind M., Philip P.A., Margison J., et al. The effect of ifosfamide on antipyrine clearance in patients with non-small cell lung cancer. Proceedings of AACR, 32, 1991.

137. Philip P.A., Kaklamanis L., Morrison H., Gatter K.C., Carmichael J., Harris A.L. The influence of a continuous infusion of hydroxyurea (HU) on the uptake of 5-iodo-2-deoxyuridine (IUdR) by bone marrow and tumor cells in man. British Association of Cancer Research meeting in Manchester, England, April 1991.

PRESENTATIONS Invited and/or Refereed International or National Meetings 1. Speaker, “Advances in Pancreatic Cancer”, Roswell Park Cancer Center, Buffalo, November, 2017 2. Speaker, “Localized Pancreatic Cancer”, Annual Mayo Clinic Symposium on Pancreatic Cancer,

November, 2017 3. Speaker, Bridging Gaps in Oncology Symposium, NCI-Egypt, Cairo, Egypt, November, 2017 4. Visiting Professor, Kingdom of Saudi Arabia, November, 2017 5. Speaker, “Novel therapies in Pancreatic Cancer”, ISGIO, D.C., October, 2017 6. Speaker/Moderator, Annual Karmanos GI Cancers Symposium, October 2017 7. Course co-director/speaker/moderator, Pancreatic Cancer, Budapest, Hungary, September, 2017 8. Speaker, “Pancreatic Cancer”, Grand Rounds, St Joseph Hospital, Pontiac, MI, 08/2017 9. Speaker, South Carolina Oncology Society, Charleston, SC, August 2017 10. Speaker, “Pancreatic Cancer”, ESMO, World GI, Barcelona, Spain, June, 2017 11. Speaker, “GI malignancies”, MSHO’s ASCO Review, June 2017 12. Speaker, Molecular Therapeutics Annual Meeting, June 2017 13. Speaker, Grand Rounds, Allegheny General Hospital, Pittsburgh, May 2017 14. Panelist, Healing NET Foundation, Aspen, Colorado, Feb 2017 15. Speaker, Winship Cancer Center, Emory University, Atlanta, Feb 2017 16. Speaker, “Pancreatic cancer”, ASCO GI, San Francisco, January 2017 17. Poster Walk, ASCO GI, San Francisco, January 2017 18. Moderator, “Novel treatments”, ASCO GI, San Francisco, January 2017 19. Speaker, 6th International Gastrointestinal Cancer Conference (IGICC), Antalya, Turkey, “Novel

Therapies for Gastric Cancers”, Dec 2-4, 2016 20. Speaker, 5th Emirates Oncology Conference, Abu Dhabi, UAE, Nov 17-19, 2016 21. Keynote Speaker and Chairman, Bridging Gaps in Oncology, Sponsored by NCI Cairo University,

Egypt, Nov 9-11, 2016 22. Course Director and Lecturer, Annual KCI GI Cancers Symposium, Troy, MI, October, 2016. 23. Speaker, Surgery Committee, SWOG, Sept 15, 2016 24. Speaker, Cancer Treatment Centers of America, Newnan, Georgia, Sept 23, 2016

Page 40: PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C ...igicc.org/wp-content/uploads/2019/05/Philip-Agop-Philip-CV.pdfPage 1 of 53 . PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C

Page 40 of 53

25. Lecture, Beaumont Hospital, Royal Oak, “Neuroendocrine Cancer”, July 26, 2016 26. Lecture, Michigan Society of Hematology and Oncology (MSHO) ASCO Update Conference, Troy,

MI, June 25, 2016 27. Speaker, UAMS/Winthrop P. Rockefeller Cancer Institute, Little Rock, AR, May 11, 2016 28. Keynote Speaker, Ohio State University Gastrointestinal Cancer Symposium, April 9, 2016 29. Grand Rounds, Karmanos Cancer Institute, Detroit, MI, “Pancreatic cancer: multidisciplinary

management”, Feb 18, 2016 30. Two lectures and organizing committee, 5th International Gastrointestinal Cancers Conference

(5.IGICC), Istanbul, Turkey, December 2015 31. Lecture on Neuroendocrine tumors, 16th Annual Hampton Roads Oncology Educational Conference,

Duke Cancer Network / Virginia Oncology Associates Conference, November 14, 2015. 32. Talk, Gibbs Cancer Center & Research Institute, South Carolina, November, 2015 33. Lecture, Pancreatic Cancer Forum, Ospedale San Raffaele, Milano, Italy, November 2015 34. Talk, Pancreatic Cancer Conference in Scottsdale, Arizona, October 23-24, 2015. 35. Medical Grand Rounds, “Update on Pancreatic Cancer”, Henry Ford Hospital, Detroit, Oct 22, 2015 36. Course Director and Lecturer, Annual KCI GI Cancers Symposium, Troy, MI, October, 2015. 37. Talk, Satellite Symposium on Pancreatic Cancer, ESMO, Vienna, Austria, September, 2015 38. Seminar, Pancreatic Cancer, WSU Department of Pharmacology, October 1, 2015 39. Grand Rounds, Cleveland Clinic, Cleveland, OH, Sept 18, 2015 40. Two Talks, Joint meeting of Turkish Oncology Association with ASCO, Istanbul, Turkey, Sept 2015 41. Talk, New agents/strategies on the horizon in pancreatic cancer, 17th World Congress on

Gastrointestinal Cancers, Barcelona, Spain, July 2015 42. Talk, Update of GI Cancers, ASCO Annual review, Dearborn, MI, organized by MSHO, 6/2015 43. Talk, Pancreatic Cancer, Molecular Therapeutics Program, WSU Annual Research Symposium,

Wednesday, June 17, 2015 44. Talk on colorectal cancers, Miami Cancer Conference, Miami, Fl, Jan 25, 2015 45. Presenter, 4th International Gastrointestinal Cancers Conference, Istanbul, Turkey, Dec 12-14, 2014. 46. Lecture, colorectal cancer, Mary Washington Fredericksburg Hospital, VA, Dec 5, 2014. 47. Keynote Speaker, Pancreatic Cancer Forum, Sponsored by the Klinicum Der Universitat Munchen,

Munich, Germany, November 27-29, 2014. 48. Course Director and Lecturer, Annual KCI GI Cancers Symposium, Troy, MI, November 22, 2014. 49. Lecture, University of Kansas Multidisciplinary Cancer Symposium, Kansas City, KS, Nov 15,

2014. 50. Lecture, Advances in colorectal cancer, Aultman Hospital, Canton, OH, November 7, 2014. 51. Lecture, Texas A&M Grand Rounds, College Station, TX, November 14, 2014. 52. Lecture, colorectal cancers, Gwinnett Hospital, Lawrenceville, GA, October 30, 2014 53. Presenter, Dr. Neil Love’s Year in Review Symposium, New York, NY, October 11, 2014. 54. Lecture, MSHO Hem Onc Review, Crowne Plaza, Novi, MI, September 30, 2014. 55. Lecture, platinum compounds in pancreatic cancer, Regional Summit Meeting on Pancreatic Cancer,

Chicago, IL, September 13, 2014. 56. Presenter, California Cancer Consortium Conference, Pasadena, CA, August 9, 2014. 57. Lecture, ASCO Update, The Henry, Dearborn, MI, June 21, 2014. 58. Lecture, PER symposium on pancreatic cancer, Chicago, IL, May 31, 2014. 59. Course Director and Lecturer, NANET Regional Conference, Marriott Hotel Troy, Troy, MI, May

17, 2014. 60. Presenter, 1st Inaugural Pancreatic Cancer Symposium, Scottsdale, AZ, February 22, 2014. 61. Lecture, PER symposium on pancreatic cancer, Satellite symposium, ASCO GI, San Francisco, CA,

January 17, 2014. 62. Visiting Professor, Hamad Health Corporation Cancer Center, Doha, Qatar, January 5, 2014. 63. Course Director and Lecturer, Annual KCI GI Cancers Symposium, Troy, MI, November 9, 2013. 64. Lecture, Annual Pancreatic Disease Symposium, University of Cincinnati, Cincinnati, OH,

November 2, 2013. 65. Lecture, Educational Meeting on Pancreatic Cancer, Pancreatic Cancer Action Network, Livonia,

MI, October 10, 2013. 66. Discussant, Think Tank, Science of Pancreatic Cancer, Banbury Center, Cold Spring

Page 41: PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C ...igicc.org/wp-content/uploads/2019/05/Philip-Agop-Philip-CV.pdfPage 1 of 53 . PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C

Page 41 of 53

Harbor Laboratory, Cold Spring Harbor, NY, September 29, 2013. 67. Panel discussion, Research to Practice, Neil Love, Miami, FL, September 20, 2013. 68. Lecture and panel discussion, International Cancer Symposium, Goa, India, September 7, 2013. 69. Lecture, MSHO’s Annual ASCO Review course, Dearborn, MI, June 18, 2013. 70. Panel Presentation, Pancreas Cancer Discussion sponsored by Sky Foundation, The Townsend

Hotel, Birmingham, MI, June 10, 2013. 71. Lecture, 2013 Carcinoid/NET Patient Conference, Rochester, MI, June 8, 2013. 72. Lectures, 13th Pan Arab Cancer Congress, Amman, Jordan, April 24, 2013. 73. Lecture, Update in Hepatobiliary and Pancreatic Cancers International Conference, Riyadh, Saudi

Arabia, April 2, 2013. 74. Think Tank meeting on pancreatic cancer, Salk Institute, La Jolla, CA, February 28, 2013. 75. Talk and panelist, Neil Love’s Research to Practice Symposium, San Francisco, CA, January 25,

2013. 76. Abstract Discussant, Pancreatic Cancers Oral Presentation Session at ASCO’s 2013 Gastrointestinal

Cancers Symposium, January 25, 2013. 77. Lecture, “Update on Neuroendocrine Tumors”, KAU International Oncology Conference, King

Abdul-Aziz University, Jeddah, Kingdom of Saudi Arabia, January 15, 2013. 78. Course Director and Moderator, Karmanos Cancer Institute/Wayne State University, 7th Annual

State of the Art Treatment of Gastrointestinal Cancers Symposium, Troy, MI, November 10, 2012. 79. Lecture, 13th Annual Norman N. Krieger, MD Lecture in Geriatric Medicine, WSU, Novi, MI,

November 7, 2012. 80. Lecture, “Update on Colorectal Cancers”, Grand Rounds, Baptist Hospital, Pensacola, FL,

November 7, 2012. 81. Lecture, Grand Rounds, St. Louis, MO, November 3, 2012. 82. Lecture, Michigan State Medical Society Foundation Annual Scientific Meeting, Cancer

Surveillance and Survivorship, “Oncologist Perspective”, Troy, MI, October 26, 2012. 83. Lecture, ASCO Update, MSHO, Dearborn, June 16, 2012. 84. Lecture, "Incorporating Biologic Therapy and Molecular Testing in the Management of Metastatic

Colon Cancer", Rasco Symposium, University of Arkansas, Little Rock, AK, March 9, 2012. 85. Visiting Professor, School of Medicine, King Abdul-Aziz University, Jeddah, Kingdom of Saudi

Arabia, March 3, 2012. 86. Lecture, 9th Annual Miami Cancer Meeting, “Management of advanced HCC: multidisciplinary and

target approaches?” Miami, FL, January 27, 2012. 87. Grand Rounds, “Advances in Colorectal Cancer”, Cancer Center, Scottsdale, AZ, December 10,

2011. 88. Lecture and Moderator, “Neuroendocrine Tumors”, Karmanos Cancer Center Annual GI Oncology

Symposium, November 18th, 2011. 89. Lecture and Moderator, “Localized Pancreatic Cancer”, Seljuk Oncology Meeting, Seljuk

University, Konya, Turkey, October 29, 2011. 90. Visiting Professor, Cancer Hospital, Seljuk University Medical School, Konya, Turkey, October 27-

28, 2011. 91. Delphi Panel on Neuroendocrine, Minneapolis, October 18, 2011 92. Lecture, “Pancreatic Cancer update”, CRA Continuing Education Workshop, Southwest Oncology

Group, October 4, 2011. 93. Lecture, “Update on Managing Upper GI Cancers”, St Joseph Hospital, Pontiac, MI, August 17,

2011. 94. Grand Rounds, “Advances on Colorectal Cancer”, Deaconess Hospital, Evansville, MI, August 9,

2011. 95. Grand Rounds, “Advances in Colorectal Cancer”, VA Medical Center, Saginaw, MI, August 5,

2011. 96. Discussion, “Update on S0727 study in Pancreatic Cancer”, IMCA-12 investigator meeting, CTEP,

Chicago, IL, June 6th, 2011. 97. Lecture, “Colorectal Cancer prevention”, Saudi Cancer Society, Dammam, Saudi Arabia, May 2011. 98. Invited Talk, “Pancreatic Cancer, Treatment of Advanced Disease”, Southeastern Wisconsin Cancer

Conference, Milwaukee, March 19, 2011.

Page 42: PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C ...igicc.org/wp-content/uploads/2019/05/Philip-Agop-Philip-CV.pdfPage 1 of 53 . PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C

Page 42 of 53

99. Lecture, “Pancreatic Cancer, Learning from our Failures”, Emory University, Atlanta, Georgia, March 13, 2011.

100. Keynote Speech, “Translational Research from the Bench to the Clinic and from the Clinic into the Bench”, 1st Regional Conference on Cancer Molecular Targeted Therapy, City of Kuwait, Kuwait, February 17-19, 2011.

101. Lecture, “Molecular Targeted Therapy of Metastatic Pancreatic Cancer”, 1st Regional Conference on Cancer Molecular Targeted Therapy, City of Kuwait, Kuwait, February 17-19, 2011.

102. Lectures (2), “Colorectal Cancer”, “Lung Cancer”, International Iraqi Medical Association, Sharjah, UAE, January 18, 2011.

103. Presentation, “Improving Outcomes in HCC”, Educational Concepts Group, Nevada Cancer Institute, Las Vegas, NV, December 17, 2010.

104. Presentation, “Treatment Advances in Colorectal Cancer”, Medical Learning Institute, Walgreen Ultra Care, Northlake, IL, December 2, 2010.

105. Presentation, “Improving Outcomes in HCC”, Educational Concepts Group, Passion Fish Restaurant, Reston, VA, November 18, 2010.

106. Lecture, Advances in Colorectal Cancer Therapy”, Community Updates in Oncology 2010: A Focus on Gastrointestinal Cancers, Rocky Mountain Cancer Center, Boulder, CO, November 15, 2010.

107. Presentation, “Contemporary Therapy for Pancreatic Cancer”, University of Kansas Multidisciplinary Cancer Symposium, Kansas, October 16, 2010.

108. Presentation, “Improving Outcomes in HCC”, Educational Concepts Group, Smith & Wollensky, Chicago, IL, October 6, 2010.

109. Presentation, “Improving Outcomes in HCC”, Educational Concepts Group, New York School of Medicine, NY, October 5, 2010.

110. Presentation, “Treatment Advances in Colorectal Cancer”, Medical Learning Institute, Mckenzie Memorial Hospital, Sandusky, MI, September 22, 2010.

111. Presentation, “Treatment Advances in Colorectal Cancer”, Medical Learning Institute, Botsford Hospital, Farmington Hills, MI, September 20, 2010.

112. Grand Rounds, “Systemic Therapy for Gastrointestinal Malignancies: The Dawn of Multidisciplinary Care”, KCI Surgery Grand Rounds, September 15, 2010.

113. Lecture, “New Agents in Colorectal Cancers and Non-Colorectal Gastrointestinal Cancers”, Annual Symposium on Novel Anticancer Agents, Hilton Head, SC, September 11, 2010.

114. Presentation, “New Agents in Colorectal Cancers and Non-Colorectal Gastrointestinal Cancers”, 3rd Annual Novel Anticancer Agents for Practicing Physicians, San Antonio, TX, May 1, 2010.

115. Presentation, “Update on Treatment Options for Esophageal, Gastric and Pancreatic Cancers”, Colorectal Cancers and Non-Colorectal Gastrointestinal Cancers: Comprehensive Review, Atlanta, GA, April 10, 2010.

116. Lecture, University of Navarra School of Medicine, Pamplona, Spain, March 22, 2010. 117. Presentation, “Liver/Biliary Cancer” 13th Annual Charles William Rasco, III Symposium on

Colorectal Cancer and GI Malignancies, University of Arkansas, March 20, 2010. 118. Presentation, “Recent Progress in Pancreatic Cancers”, Current Trend in GI Malignancies, New

York, NY, March 13, 2010. 119. Lecture, “Neoadjuvant Therapy” and “Systemic Therapy” of Esophageal Cancers, King Faisal

Hospital, Riyadh, Saudi Arabia, March 9, 2010. 120. Lecture, “Treating Cancer, small but sure steps”, 7th GCC Medical Students Conference, King Abdul

Aziz University, Jeddah, Saudi Arabia, February 13, 2010. 121. Presentation, “Current Choices and Challenges in Personalizing the Management of Colorectal

Cancer”, McKenzie Memorial Hospital, Sandusky, MI, November 18, 2009. 122. Presentation, “Colorectal Cancer”, 10th Annual Lecture in Geriatric Medicine, Huron Valley-Sinai

Hospital, November 4, 2009. 123. Presentation, “Progress in the treatment of advanced colorectal cancer”, ProMedica Symposium,

Perrysburg, OH, October 9, 2009. 124. Presentation, “Hepatocellular Carcinoma: Novel Agents for Systemic Therapy”, 7th Annual Miami

Cancer Meeting, Miami, FL, October 3, 2009. 125. Presentations, “Nexavar: Proven in both Western and Asian population with HCC and varying

etiologies suitable for a broad range of patients” and “Nexavar: a reference standard in

Page 43: PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C ...igicc.org/wp-content/uploads/2019/05/Philip-Agop-Philip-CV.pdfPage 1 of 53 . PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C

Page 43 of 53

HCC treatment and the role in earlier stages of HCC”, 8th KACO Conference, Korea, June 12-13, 2009.

126. Presentation, “Pancreas Cancer: Are we doing any better?”, VA Lecture for Research Seminar Series, Detroit, MI, May 5, 2009.

127. Presentation, “Advances in HCC Management - Phase II and III studies in adjuvant settings”, 7th Pan Arab Congress of Digestive diseases – Satellite Symposium, Marrakech, Morocco, April 2-4, 2009.

128. Presentation, “Advances in Gastric/Esophageal Cancer”, Current Trends in GI Malignancies, New York, NY, March 14, 2009.

129. Presentation, “Systemic Treatment for HCC: Now and future directions”, Stockholm Liver Week, Stockholm, Sweden, February 3-6, 2009.

130. Presentation/Discussion, “A Doctor and Survivor Speak Out on Advances in Colon Cancer Treatment”, Mosaic of Colon Cancer Survivorship Program at Gilda’s Club, Royal Oak, MI, November 12, 2008.

131. Presentation, “Recent Advances in the Management of Breast Cancer: Latest Drug Therapies”, Saudi Arabia Cancer Foundation Conference, Saudi Arabia, October 25, 2008.

132. Grand Rounds, “Pancreatic Cancer”, Penn State College of Medicine, Hershey, PA, October 16, 2008.

133. Keynote Speaker, “Therapy of Colorectal Cancer with Liver Metastases”, 6th Annual Miami Cancer Meeting, Miami, FL, October 4, 2008.

134. Presentation, “Emerging Standards for Incorporating Targeted Therapies into the Treatment of HCC” Aultman Cancer Center’s Eighth Annual Cancer Conference, Canton, OH, September 27, 2008.

135. Case Presentation and Panel Discussion, “Localized and Metastatic Pancreatic Cancer: Metastatic First-Line”, International Society of Gastrointestinal Oncology Conference, Arlington, VA, September 25, 2008.

136. Presentation, “Targeted Therapies in Cancer Treatment: GI Cancers”, Michigan Society of Hematology and Oncology’s 2008 Oncology Update, Soaring Eagle Resort, Mt. Pleasant, MI, September 20, 2008.

137. Presentation, “Gastrointestinal Cancers”, Highlights from ASCO 2008, Sponsored by MSCHO, Dearborn, MI, June 28, 2008.

138. Grand Rounds, “Optimizing the management of gastric and gastro-esophageal junction cancers”, Henry Ford Hospital, Detroit, MI, May 23, 2008.

139. Chair of Educational Session, “Treating Localized Pancreatic Cancer: Are We Offering Patients the Best We Have?”, Annual Meeting of the ASCO, Chicago, IL, May 19, 2008.

140. Presentation, “Upper Gastrointestinal Overview 2007-2008: Practice Implications of the Newest Data”, Annual Meeting of the ASCO, Chicago, IL, May 19, 2008.

141. Grand Rounds, “Pancreas Cancer Research and GE Junction”, Mount Clemens Regional Medical Center, Mt. Clemens, MI, May 14, 2008.

142. Lecture, “The VEGF Pathway as a Therapeutic Target in Cancer”, Beaumont Cancer Center, Royal Oak, MI, March 24, 2008.

143. Presentation, “Karmanos Specific Treatments for Gastro-Esophageal Junction and Gastric Cancer” and “Treatment of Oligometastases”, ProMedica Cancer Institute Symposium, Toledo, OH, February 21, 2008.

144. Lecture, “Pitfalls of Clinical Trials in Pancreas Cancer”, State of the Science meeting in Pancreas Cancer, Bethesda, MD, December 1st, 2007.

145. Co-Chair of workshop, “Metastatic pancreas Cancer”, State of the Science meeting in Pancreas Cancer, Bethesda, MD, December 1, 2007.

146. Grand Rounds, “Angiogenesis as a target for cancer therapy”, Cancer Center, University of Alabama (UAB), Birmingham, AL, October 26th, 2007.

147. Lecture, “Advances in Pancreas Cancer”, International Society of Gastrointestinal Oncology Junior Faculty meeting, Arlington, VA, November 17th, 2007.

148. Lecture, “Carcinoid tumors”, Annual GI Symposium of KCI, Troy, MI, November 11th, 2007. 149. Lecture, “Advances in Pancreas Cancer”, GI Symposium, San Diego, CA, November 2nd, 2007.

Page 44: PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C ...igicc.org/wp-content/uploads/2019/05/Philip-Agop-Philip-CV.pdfPage 1 of 53 . PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C

Page 44 of 53

150. Lecture and Discussant, “Locally advanced Pancreas Cancer”, ASTRO annual meeting, Los Angeles, CA, October 29th, 2007.

151. Grand Rounds, “Angiogenesis as a target for cancer therapy”, Cancer Center, University of Alabama (UAB), Birmingham, AL, October 26th, 2007.

152. Lecture and Panel Discussion, “Pancreatic and Gastric Cancers”, GI Symposium, Bangkok, Thailand, October 11th, 2007.

153. Lecture and Panel Discussion, “Pancreas Cancer”, International Society of Gastrointestinal Oncology, Philadelphia, PA, September 27th, 2007.

154. Seminar, “Pancreas Cancer”, OSI Pharmaceuticals, Boulder, CO, September 19, 2007. 155. Lecture, “Management of Liver Metastases in Colorectal Cancer”, VA Hospitals Symposium,

Alexandria, VA, September 8th, 2007. 156. Lecture, “Pancreas Cancer: are we doing better?”, World Oncology Congress, San Francisco, CA,

September 7, 2007. 157. Lecture and Panel Discussion, “Novel Therapies in Upper GI Cancers”, CBCE, Newport Beach, CA,

July 14th, 2007. 158. Lecture, “Gastric Cancer”, St Joseph Hospital, Patterson, NJ, June 27th, 2007. 159. Lecture, “GI Cancers”, Annual Meeting to Review Oncology, Sponsored by the Michigan Society

for Hematology and Oncology (MSHO), Dearborn, MI, June 23d, 2007. 160. Lecture, “Advanced colorectal Cancer”, Tumor Board, St Joseph Hospital, Pontiac, June 13th, 2007. 161. Lecture, “ASCO 2007 Update on Colorectal Cancers”, Pittsburgh, PA, June 8th, 2007. 162. Chair of Educational Session, “Pancreas Cancer: from Bedside to the Clinic”, Annual Meeting of the

ASCO, Chicago, IL, June 3d, 2007. 163. Oral Presentation, “Phase III Trial of Gemcitabine plus Cetuximab versus Gemcitabine alone in

Advanced Pancreas Cancer”, Plenary Session of the Non-Colorectal GI, Annual Meeting of the ASCO, Chicago, IL, June 3d, 2007.

164. Presentation, “Phase III Trial of Gemcitabine plus Cetuximab versus Gemcitabine alone in Advanced Pancreas Cancer”, SWOG Spring Meeting’s Plenary Program, Chicago, IL, May 5th, 2007.

165. Lecture, “Colorectal Cancer Advances”, Qatari Cancer Society Annual Symposium, Doha, Qatar, April 29th, 2007.

166. Lecture and Discussant, International Society of Gastrointestinal Oncology, Pentagon City, VA, March 31st, 2007.

167. Lecture, “Colorectal Cancer”, Rush University, Chicago, IL, March 22nd, 2007. 168. Lecture, “Colorectal cancer with predominant liver metastases”, East Lansing, Breslin Cancer

Center, MI, March 9th, 2007. 169. Lecture, Symposium, “Adjuvant Therapy for Stage II Colon Cancers”, Battle Creek, MI, March 3d,

2007. 170. Lecture, Symposium, “Advances in Metastatic Colorectal Cancers”, Battlecreek, MI, March 3d,

2007. 171. Lecture, “Colorectal Cancer, Management of Liver Metastases”, western Michigan Cancer Center,

Kalamazoo, MI, February 23d, 2007. 172. Lecture, “Pancreatic Cancer, are we making any progress?” MD Anderson Cancer Center, Orlando,

FL, January 29, 2007. 173. Grand Rounds, “Multimodality Management of Liver Metastases from Colorectal Cancer,” Sparrow

Hospital, Lansing, MI, January 12th, 2007. 174. Lecture, “Gastroesophageal Cancers,” Cancer Center, Thomas Jefferson Hospital, Philadelphia, PA,

December 20th, 2006. 175. Grand Rounds, “Pancreas Cancer,” Cancer Center, Henry Ford Hospital, Detroit, MI, December 15th,

2006. 176. Lecture, “Chemotherapy,” Introduction to Oncology and Chemotherapy Course, Bridgehead

International, Princeton, New Jersey, November 30th, 2006. 177. Lecture, “Gastric and Gastroesophageal Junction Cancers,” State of the Art Treatment of

Gastrointestinal Cancers, Karmanos Cancer Institute and Wayne State University, Troy, MI, November 11, 2006.

178. Keynote Speaker, Targeted Molecular Therapy and Other Novel Approaches in

Page 45: PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C ...igicc.org/wp-content/uploads/2019/05/Philip-Agop-Philip-CV.pdfPage 1 of 53 . PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C

Page 45 of 53

Pancreatic Malignancy,” State of the Art Management of Hepatic and Pancreatic Malignancy, University of Florida and Jupiter Medical Center, Jupiter Beach, FL, November 4, 2006.

179. Lecture, “Multimodality Therapy of Liver Metastases from Colorectal Cancer,” 12th Annual Oncology Symposium, Multimodality Treatment of Colorectal Cancer, St. Mary’s Hospital, Saginaw, MI, October 28th, 2006.

180. Debate and Panel Discussions, “Early Endpoints in Pancreas Cancer Trials”, International Society of Gastrointestinal Oncology, Pentagon City, VA, September, 2006.

181. Tumor Board, “Pancreatic Cancer: Any steps forward,” St. Joseph Mercy Hospital, Ypsilanti, MI, August 2nd, 2006.

182. Grand Rounds, “Stage II Colon Cancer, Treat or Not to Treat,” North Michigan Hospital, Petoskey, MI, July 26th, 2006.

183. Tumor Board, “Management of Liver Metastases from Colorectal Cancer,” Memorial Hospital, South Bend, IN, July 19th, 2006.

184. Medical Grand Rounds, “Pancreatic Cancer,” Roswell Park Cancer Institute, Buffalo, NY, June 30, 2006.

185. Lecture, “Gastrointestinal Cancers,” Interpreting Clinical Data: Highlights from ASCO 2006, Dearborn, MI, June 24th, 2006.

186. Grand Rounds, “Pancreas Cancer: Are we making progress?” Karmanos Cancer Institute, Detroit, MI, June 8th, 2006.

187. Lecture, “Multimodality Therapy of Gastro-Esophageal Cancers,” V International Meeting on Esophagus and Stomach Surgery, Porto, Portugal, May 29th, 2006.

188. Tumor Board, “Gastric Cancer,” St. Joseph Hospital, Pontiac, MI, May 24th, 2006. 189. Medical Grad Rounds, “Emerging Trends in the Management of Colorectal Cancer,” St John

Hospital and Medical Center, Detroit, MI, May 23d, 2006. 190. Lecture, “Management of Liver Metastases from Colorectal Cancers,” Cook County Hospital,

Chicago, IL, May12th, 2006. 191. Lecture, Cancer Symposium, Doha, Qatar, April, 2006. 192. Lecture, “Management of Liver Metastases,” 8th Annual Palm Beach Cancer Symposium,

Shifting Paradigms of Treatment, Palm Beach, FL, April 8th, 2006. 193. Lecture, “Liver Metastases from Colorectal Cancer Management,” Kalamazoo, MI, April 5th,

2006. 194. Lecture, “Colorectal Cancer: Recent Advances,” Bixby Hospital, Bixby, March 15th, 2006. 195. Lecture, “Is there a role for neoadjuvant therapy for esophageal cancer," UCLA, GI Cancer

Symposium, Los Angeles, CA, February 18th, 2006. 196. Medicine Grand Rounds, “Colorectal Cancer, Major Steps Forward,” Wayne State University

School of Medicine, Detroit, MI, February 15, 2006. 197. Lecture, “Pancreatic Cancer, How can we make a difference,” Department of Internal

Medicine, Hematology and Oncology, University of Medicine, Ann Arbor, MI, February 2, 2006.

198. Lecture and Case Discussion, “Upper GI Cancers,” 2nd Annual Symposium, Hoag Cancer Center, Huntington Beach, CA, January 26, 2006.

199. Evening of Experts Series, “Advances in the Therapy of Hepatobiliary Cancers,” UT Southwestern, Dallas, TX, January 19, 2006.

200. Internal Medicine Grand Rounds, “Colorectal Cancer: Great Steps Forward,” Henry Ford Hospital, Detroit, MI, January 12, 2006.

201. Debate, “Neoadjuvant Chemotherapy Should be Used in Patients with Resectable Liver Metastases from Colorectal Cancers,” First Annual Roadmap for Colorectal Cancer, American School of Medicine, Salt Lake City, UT, December 17, 2005.

202. Lecture, “Advances in Therapy of Colorectal Cancer,” 1st Annual Symposium on GI Cancer, University of Cincinnati, Cincinnati, OH, November 12, 2005.

203. Lecture, “Pancreatic Cancer,” Mason City, Iowa, October 24, 2005. 204. Lecture, “Pancreatic Cancer,” SWOG CRAs Symposium, Dallas, TX, September 23, 2005. 205. Lecture, “Is Adjuvant Therapy Necessary in Gastric Cancer,” Gastrointestinal Cancer

Symposium, Washington University School of Medicine, St. Louis, MO, September

Page 46: PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C ...igicc.org/wp-content/uploads/2019/05/Philip-Agop-Philip-CV.pdfPage 1 of 53 . PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C

Page 46 of 53

10, 2005. 206. Lecture, “Targeting the Signaling Pathways in Pancreas Cancer,” Ireland Cancer Center,

University Hospitals, Case Western Reserve University, Cleveland, OH, August 23, 2005. 207. Lecture, “Pancreatic Cancer,” INOVA Alexandria Hospital, Alexandria, VA, June 29, 2005. 208. Lecture, “GI Malignancies: An Update,” Annual Oncology Review, Karmanos Cancer

Institute/Wayne State University, Dearborn, MI. June 11, 2005. 209. Lecture, “The Progress in Targeted Therapies for Pancreatic Cancer,” Arizona Cancer Center,

Tucson, AZ, May 27, 2005. 210. Workshop, Lecture and Hospital Rounds, Second Annual Symposium on Colorectal and

Prostate Cancers, Hamad Medical Center, Doha, Qatar, April 23 – 27, 2005. 211. Lecture, “Advances in Colorectal Cancer,” St. Joseph Hospital, Ann Arbor, MI, March 8,

2005. 212. Lecture, “Colorectal Cancer,” King Hussein Cancer Center Multidisciplinary Cancer

Treatment Symposium, Amman, Jordan, December 5, 2004. 213. Lecture, “New Therapies for Gastric Cancer,” GI Congress / 8th TCOG Annual Meeting,

Taipei, Taiwan, December 4, 2004. 214. Tumor Board, “Colorectal Cancer; Novel Therapies,” Providence Hospital, Southfield, MI,

November 18, 2004. 215. Lecture, “Targeted Therapies in GI Cancers,” Van Andel Research Institute, Grand Rapids,

MI, November 12, 2004. 216. Grand Rounds, “Colorectal Cancer,” Elyria Hospital, Elyria, OH, November 10, 2004. 217. Lecture, “Colorectal Cancer,” MSHO Annual Meeting Symposium, Frankenmuth, MI,

October 16, 2004. 218. Lecture, “Gastric Cancer,” Genesis Medical Center, IL, October 14, 2004. 219. Lecture, “Pancreas Cancer,” Texas A & M University, College Station, Texas, October 4, 2004. 220. Lecture, “Pancreatic Cancer,” Sylvester Cancer Center, University of Miami, Miami, FL,

September 29, 2004. 221. Lecture, “Colorectal cancer,” Sparrow Hospital Grand Rounds, Lansing, MI, September 24,

2004. 222. Lecture, “Pancreas Cancer,” Karmanos Cancer Center, Population Program’s Annual

Retreat, September 10, 2004. 223. Lecture, “Colorectal Cancer,” Miami Valley Hospital, Dayton, OH, September 3, 2004. 224. Lecture, “Targeted Therapies in GI Cancers,” Karmanos Cancer Institute Annual Retreat,

August 27, 2004. 225. Lecture, “Recent Advances in the Therapy of Gastric Cancer,” GI Malignancies Management

Symposium, Colorado Springs, CO, July 10, 2004. 226. Lecture, “Therapy: Molecular and Cellular Targets,” Annual Meeting of the Lustgarten

Foundation for Pancreatic Cancer Research and the American Association for Cancer Research, San Francisco, CA, June 26, 2004.

227. Lecture, “Colorectal Cancer,” Parma Hospital, Parma, OH, June 21, 2004. 228. Lecture, “ASDCO 2004 Update on Gastrointestinal Cancers,” Dearborn, MI, June 19, 2004. 229. Lecture, “Adjuvant Therapy of Colorectal Cancer,” St. Mary’s Hospital, Livonia, MI, May 26,

2004. 230. Grand Rounds, “Colorectal Cancers,” South Bend, IN, May 19, 2004. 231. Lecture, “Recent Developments in Treating Colorectal Cancer,” the Mayo Clinic, Jacksonville,

FL, May 12, 2004. 232. Lecture, “Use of EGFR blockade in Pancreas cancer, SWOG, Huntington Beach, CA, April 29,

2004. 233. Lecture, “Colorectal cancer,” Metrohealth Hospital, Cleveland, OH, April 22, 2004. 234. Lecture, “Pancreatic cancer,” Case Western University, Ireland Cancer Center, Cleveland, OH, April

14, 2004. 235. Lecture, “Angiogenesis as a Target in Colorectal Cancer,” University of Kentucky, Lexington, KY,

April, 7, 2004. 236. Lecture, “Update of GI Cancer ASCO Symposium,” St. Joseph Mercy CME activity, Dearborn, MI,

March 6, 2004.

Page 47: PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C ...igicc.org/wp-content/uploads/2019/05/Philip-Agop-Philip-CV.pdfPage 1 of 53 . PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C

Page 47 of 53

237. Lecture, “Colorectal cancer,” University of Tennessee at Memphis, Memphis, TN, March 2, 2004. 238. Lecture, “Colorectal Cancer,” Beaumont Hospital Fellowship Training Program, Royal Oak, MI,

February 16, 2004. 239. Grand Rounds, “Angiogenesis Therapies,” Pittsburgh, PA, January 30, 2004. 240. Poster presentation, Philip PA, Mahoney MR, Thomas JP, Pitot HC, Donehower R, Kim GP, Picus

J, Fitch TR, Geyer SM, Erlichman C. Phase II Trial of OSI-774 in Patients with Hepatocellular and Biliary Cancer. 2004 Gastrointestinal Cancers Symposium, San Francisco, CA, January 23, 2004.

241. Poster presentation, El-Rayes, FB, Ali S, Sarkar F, Philip PA. Targeting the Epidermal Growth Factor Receptor (EGFR) and Cyclooxygenase 2 (COX-2) Pathways in Pancreatic Cancer, Gastrointestinal Cancers Symposium, San Francisco, CA, January 23, 2004.

242. Tumor Board, “Advances in Colorectal Cancers,” St. Joseph Hospital, Pontiac, MI, January 7, 2004. 243. Session Chair, “Pancreatic Cancer,” First Annual GI Cancer Symposium, ASCO, January 2004, San

Francisco. 244. Lecture, “What is New in the Systemic Therapy of Colorectal Cancer,” St. Vincent Hospital,

Indianapolis, IN, December 10, 2003. 245. Lecture, “Colorectal Cancer,” Huron Valley Hospital, Commerce Township, MI, November 19,

2003. 246. Oral presentation, P.A. Philip, M. R. Mahoney, J. P. Thomas, H.C. Pitot, R. Donehower, G. P. Kim,

J. Picus, T. R. Fitch, S. M. Geyer, C. Erlichman. OSI-774 (Tarceva) in Patients (pts) with Unresectable or Metastatic Hepatocellular Carcinoma (HCC): A multi-center Phase 2 Consortium (P2C) study. NCI/EORTC/AACR Annual Targeted Therapies Meeting, Boston, MA, November 18-21, 2003.

247. Lecture, “Drug therapy of Colorectal Cancer,” Ingham Regional Medical Center, Michigan State University, East Lansing, MI, November 7, 2003.

248. B.F. El-Rayes, S. Ali, F. Sarkar, P. Philip. Cyclooxygenase 2 (COX-2) as a Target in Pancreatic Cancer. American Pancreatic Association Annual Meeting, Chicago, IL, November 2003.

249. Tumor Board, “Optimization of Chemotherapy for Early Stage Breast Cancer,” St. Joseph Hospital, Atlanta, GA, October 14, 2003.

250. Lecture, “Improving the Outcome of Colorectal Cancer: New Drugs,” Jaffar Oncology Conference, Strategies for Prevention and a Cure: Colorectal Cancer, Providence Cancer Institute, Dearborn, MI, September 19, 2003.

251. Lecture, “New Advancements in the Management of Breast Cancer,” The Arab-American Medical Association, Michigan Chapter, Troy, MI, September 18, 2003.

252. Oral presentation, “Phase II study of OSI-774 in Hepato-Biliary Cancers,” CTEP/NCI Meeting, Bethesda, MD, September 9, 2003.

253. Lecture, “Gastric Cancer,” Dayton VA Hospital, Dayton, OH, July 16, 2003. 254. Lecture, “Recent Advances in Gastric Cancer,” University of Columbia, Columbia, MO, July 13,

2003. 255. Lecture, “Gastrointestinal Tumors,” Annual Review in Oncology and ASCO Update, Wayne State

University/University of Michigan, The Michigan Society of Hematology and Oncology, Dearborn, MI, June 21st, 2003.

256. Poster Presentation, B. F. El-Rayes, S. Ali, F. Sarkar, P. A. Philip. Protein Kinase C (PKC): A target for therapy in pancreatic cancer. Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago, IL, June 1, 2003.

257. Lecture, “New Developments in the Treatment of Colorectal Cancer,” the Meeting of the Indiana Oncology and Hematology Consultants, Indianapolis, IN, May 29, 2003.

258. Visiting Professor, Tumor Board, St Luke’s Hospital and Health Science Center, Milwaukee, WI, May 21, 2003.

259. Lecture, “Pancreas Cancer, An Update,” Gastrointestinal Cancer Symposium, Wayne State University, Dearborn, MI, May 17, 2003.

260. Lecture, “Neoadjuvant Chemotherapy of Breast Cancer,” Fellows Meeting, Cancer Center, Oklahoma University, Oklahoma City, OK, May 16, 2003.

261. Lecture, “Update on Pancreas Cancer,” Promedica Health System CME Department, Toledo, OH, May 14, 2003.

262. Lecture, “Neoadjuvant Chemotherapy of Breast Cancer,” Cooper Clinic, UAB,

Page 48: PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C ...igicc.org/wp-content/uploads/2019/05/Philip-Agop-Philip-CV.pdfPage 1 of 53 . PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C

Page 48 of 53

Birmingham, AL, May 8, 2003. 263. Lecture, “New Trends in the Treatment of Advanced Colorectal Cancer,” GI Symposium, Ohio State

University, Columbus, OH, April 26, 2003. 264. Grand Rounds, “Treatment of Colorectal Cancers,” The Cleveland Clinic, Cleveland, OH, March 28,

2003. 265. Chairperson, GI cancer session, Fox Chase Cancer Center Annual Meeting, Lanai, HI, March 25,

2003. 266. Lecture, “Current Trends in the Treatment of Advanced Colorectal Cancer,” Fox Chase Cancer

Center annual meeting, Lanai, HI, March 25, 2003. 267. Tumor Board, “Developments in the Therapy of Early Breast Cancer,” Jupiter Medical Center, West

Palm Beach, Fl, March 12, 2003. 268. Lecture, “Development of Systemic Therapies of Pancreas Cancer”, Tokyo University of Women,

Department of Surgery, Tokyo, Japan, January 27, 2003. 269. Lecture, “Treatment of Metastatic and Recurrent Pancreas Cancer,” 16th International Symposium on

Recent Advances in Pancreatic Cancer, National Cancer Hospital of Japan, Tokyo, Japan, January 24, 2003.

270. Session Chair, “Surgical Therapy of Pancreas Cancer,” 16th International Symposium on Recent Advances in Pancreatic Cancer, National Cancer Hospital of Japan, Tokyo, Japan, January 23, 2003.

271. Lecture, “Advances in the Chemotherapy of Pancreas Cancer,” Ohio State University, Columbus, OH, November 4, 2002.

272. Lecture, “Chemotherapy of Metastatic Breast Cancer,” Midwestern Medical Center, Zion, IL, October 18, 2002.

273. Lecture, “Adjuvant and Neoadjuvant Chemotherapy of Breast Cancer,” Society of Hematology and Oncology of Ohio, Columbus, OH, October 17, 2002.

274. Grand Rounds, “Management of Early Breast Cancer,” Northwestern University, Chicago, IL, October 11, 2002.

275. Lecture, “Utilization of Oral Agents in GI Carcinoma: Current and Future Strategies,” Third Annual Cancer Symposium, Mercy Cancer Care and St Joseph Mercy Oakland, Troy, MI, Sept 12, 2002.

276. Grand Rounds, “COX-2 as an emerging target for the prevention and treatment of colorectal cancer,” Henry Ford Hospital, Detroit, MI, August 2, 2002.

277. Lecture, “Pancreas Cancer,” Tumor Board, Petoskey, MI, May 30, 2002. 278. Lecture, “Gemcitabine-based Combination Chemotherapies,” Global Eli Lilly Meeting, Indianapolis,

IN, May 17, 2002. 279. L.A. Newman, N.L. Pernick, P. Philip, K. Carolin, D. Bouwman, M. Kosir, M. White and D.W.

Visscher. Histopathologic Evidence of Tumor Regression in the Axillary Lymph Nodes of Patients Treated with Preoperative Chemotherapy Predicts Breast Cancer Outcome. Society of Surgical Oncology, Annual Meeting, May 2002.

280. Lecture, “Advances in Breast Cancer Therapy,” Semi-annual meeting of the South Carolina Hematology and Oncology Society, Charleston, SC, April 26, 2002.

281. Lecture, “Neoadjuvant therapy of esophagus cancer,” III Reuniao Internacional De Actualizacao Em Cirurgia Do Esofago E Do Estomago,” Granja, Portugal, 16th April, 2002.

282. Lecture, “Primary and adjuvant therapy of stomach cancer,” III Reuniao Internacional De Actualizacao Em Cirurgia Do Esofago E Do Estomago,” Granja, Portugal, 15th April, 2002.

283. Lecture, “Recent Advances in Pancreas Cancer,” Division of Gastroenterology, Department of Internal Medicine, Wayne State University, Detroit, MI, March 20, 2002.

284. Spring Phase I Investigators’ Meeting, “Phase I Study of Bryostatin 1 and Gemcitabine (Gemzar),” National Cancer Institute, Bethesda, Maryland, March 18, 2002.

285. Tumor Board, “Advances in the Neoadjuvant Chemotherapy of Breast Cancer,” St. Joseph Mercy Hospital, Ypsilanti, MI, March 6, 2002.

286. Breast Tumor Board, “Molecular Monitoring of the Effects of Chemotherapy,” Karmanos Cancer Institute, Detroit, MI, February 4, 2002.

287. Grand Rounds, “Update from San Antonio Breast Cancer Symposium,” St. Vincent’s Hospital, Toledo, OH, January 24, 2002.

288. Al-Sukhun SA, Ali S, Heilbrun L, Lababidi S, Philip PA. Protein kinases C Isozymes are

Page 49: PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C ...igicc.org/wp-content/uploads/2019/05/Philip-Agop-Philip-CV.pdfPage 1 of 53 . PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C

Page 49 of 53

289. Differentially Expressed in Human Breast Carcinoma. Annual Meeting of the American Association of Cancer Research, 2002.

290. Lecture, “San Antonio Breast Cancer Symposium,” Breast Tumor Board, Karmanos Cancer Institute, Detroit, MI, December 17, 2001.

291. Fellows Core Lecture, “Pancreas Cancer,” Oncology Fellowship Training Program at WSU, Detroit, MI, December 7, 2001.

292. Lecture, “Neoadjuvant Chemotherapy for Breast Cancer,” Tumor Board, St. Joseph Mercy Hospital, Pontiac, MI, October 22, 2001.

293. Lecture, “Gastro-Intestinal Malignancies,” Oncology Board Review Course, Michigan Hematology and Oncology Society, Novi, MI, October 17, 2001.

294. Grand Round, “Colorectal Cancer,” Bixby Cancer Center, Adrian, MI, October 17, 2001. 295. Invited Speaker,” Colorectal Cancer,” Duke Comprehensive Cancer Center Symposium, Pinehurst,

NC, October 13, 2001. 296. Lecture, “New Drug Development in Pancreas Cancer,” Grand Rounds, University of Michigan,

Ann Arbor, MI, October 12, 2001. 297. Discussant, Tumor Board, St. Joseph Mercy Hospital, Macomb, MI, October 10, 2001. 298. Lecture, “Developments in the Systemic Therapy of Early Breast Cancer,” Tumor Board, St. Joseph

Mercy Hospital, Ypsilanti, MI, October 3, 2001. 299. Lecture, “Monitoring the Effects of Therapy in Early Breast Cancer”, 1st Annual Breast Cancer

Symposium, Wayne State University, Dearborn, MI, September 29, 2001. 300. Lecture, “Monitoring Effects of Chemotherapy,” First Annual Breast Cancer Symposium of

Karmanos Cancer Institute, Detroit, MI, September 28, 2001. 301. Lecture, “Neoadjuvant Chemotherapy in Operable Breast Cancer”, Grand Rounds, Michigan State

University, East Lansing, MI, September 27, 2001. 302. Lecture, “Developments of Therapy of Early Breast Cancer,” Tumor Board, St. John’s Hospital in

Macomb, MI, September 21, 2001. 303. Lecture, “Neoadjuvant Chemotherapy for Breast Cancer,” Grand Rounds, Elkhart Hospital, Elkhart,

IN, August 8, 2001. 304. Lecture, “Gastrointestinal Cancers, ASCO 2001,” McLaren Regional Cancer Center, Flint, MI, June

6, 2001. 305. Lecture, “Annual Review in GI Oncology and ASCO Update,” Karmanos Cancer Institute and

Wayne State University, Dearborn, MI, June 2, 2001. 306. Lecture, “ASCO 2001, Breast Cancer,” Good Samaritan Hospital CME activity, Dayton, OH, May

30, 2001. 307. Grand Round, “Pancreatic Cancer,” North Michigan Hospital, Petoskey, MI, April 23, 2001. 308. Philip PA, Shadan Ali, Michael J. Kraut, Fazlul Sarkar. Flavopiridol sensitizes human breast cancer

cells to gemcitabine. Annual meeting of the American Association for Cancer Research, April, 2001. 309. Grand Round, “New Therapies in Breast Cancer,” Providence Hospital, Southfield, MI, March 29,

2001. 310. Grand Round, “Advances in the Therapy of Colorectal Cancer,” Oakwood Hospital, Dearborn, MI,

March 20, 2001. 311. Grand Round, “Developments in the Treatment of Colorectal Cancer,” St. Joseph Hospital,

Ypsilanti, MI, March 7, 2001. 312. Symposium on New Strategies and Future Directions for the Treatment of Metastatic Colorectal and

Breast Cancer, “Advances in the Therapy of Breast Cancer,” Houston, TX, January 13, 2001. 313. Fellow’s Core Lecture Series, “Herceptin,” Oncology Fellowship Program, WSU, January, 2001. 314. Grand Round, “New Drug Development in Pancreas Cancer,” Southwestern University Medical

School, Dallas, TX, December 1, 2000. 315. Lecture, “Therapy of Pancreas Cancer,” Fellows Journal Club, William Beaumont Hospital, Royal

Oak, MI, November 21, 2000. 316. Lecture, “Colo-Rectal Cancer,” 2nd Annual Update in Cancer and Hematology for the Primary Care

Physician, Wayne State University and Karmanos Cancer Institute Symposium, November 18, 2000. 317. Lecture, “Multimodality Therapy of Pancreatic Cancer,” Pasco-Hernando ONS Chapter, Tampa, FL,

November 9, 2000. 318. Tumor Board and presentation, “Advances in the Diagnosis and Therapy of Pancreatic

Page 50: PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C ...igicc.org/wp-content/uploads/2019/05/Philip-Agop-Philip-CV.pdfPage 1 of 53 . PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C

Page 50 of 53

Cancer,” Tampa, FL, November 9, 2000. 319. Philip, P.A., Shields, A.F., Zalupski, M.M., Foster, B., Arlauskas, P., Adsay, V., Vaitkevicius, V.K.

Phase II study of gemcitabine, 5-fluorouracil and cisplatin in patients with advanced pancreatic cancer. Joint Annual Meeting of the American Pancreatic Association and the International Association of Pancreatology, Nov 1-5, 2000, Chicago, IL.

320. Lecture, “New Therapies for Pancreas Cancer” Drug Discovery Program, Karmanos Cancer Institute, November, 2000.

321. Lecture Series, “Chemotherapy of Pancreatic Cancer,” Metro Health Center, Cleveland OH, October 11, 2000.

322. Lecture, “Advances in the Therapy of Colorectal Cancer,” Bixby Cancer Center, Adrian. MI, October 2000.

323. Annual Breast Lecture, “Advances in the Therapy of Breast Cancer,” Baptist Health System, Montgomery, AL, September 25, 2000.

324. Lecture, “DNA repair genes in breast cancer,” Annual Breast Retreat, Karmanos Cancer Institute, September 2000.

325. Lecture, “Pancreatic Cancer,” Memphis Cancer Center, Memphis, TN, August 28, 2000. 326. Lecture, “Taxanes in Breast Cancer”, Annual Meeting of the Association for Kerala Medical

Graduates, Chicago, IL, July 15, 2000. 327. Seminar, “Advances in the Treatment of Breast Cancer”, Beth Israel Hospital, Boston, MA, June

2000. 328. Lecture, Advances in the Chemotherapy of Stomach Cancer,” 2nd International Congress on Surgery

of Stomach and Esophagus Cancers” Porto, Portugal, May 9, 2000. 329. P.A. Philip, M. Zalupski, B. El-Rayes, V. Adsay, L. Heilbrun, V.K. Vaitkevicius, A. Shields. Phase

II study of gemcitabine, cisplatin and infusional 5-fluorouracil in patients with metastatic pancreatic cancer. Annual Meeting of the American Society for Clinical Oncology (ASCO), Orlando, May 2002.

330. Philip, PA, Ensley J, Heilbrun L, Ali S. Expression of cytochrome P-450 enzymes and glutathione S-transferase P1 in peritumoral tissue from patients with head and neck cancers and its relationship to the tumoral expression of p16. Annual Meeting of the AACR, San Francisco, April, 2000.

331. Lecture, “Colo-Rectal Cancer”, St Joseph Hospital, Pontiac, MI, March 22, 2000. 332. Tumor Board, "Pancreatic Cancer", North Oakland Medical Center, Pontiac, MI, March 9, 2000. 333. Symposium, US Gemzar Investigators Meeting, "Gemcitabine, 5-Fluorouracil, and Cisplatin in

Patients with Advanced Pancreatic Cancer,” San Antonio, TX, March 2, 2000. 334. Symposium, US Gemzar Investigators Meeting, "Phase I Study of Gemzar and UFT/Leucovorin,"

San Antonio, TX, March 2, 2000. 335. Grand Round, "Pancreatic Cancer", Department of Internal Medicine, Wayne State University,

March 1, 2000. 336. Lecture, "Advances in the Chemotherapy of Pancreas Cancer", Premiere Pancreas Support Group

Meeting, Karmanos Cancer Institute, February 12, 2000. 337. Lecture, "Advances in the Treatment of Metastatic Breast Cancer", Pharmacy, Akron General

Hospital, Akron, Ohio, November 1999. 338. Grand Rounds, "Advances in the Treatment of Pancreatic Cancer", Division of Hematology and

Oncology, Cancer Center, University of Alabama at Birmingham, September 16, 1999. 339. Invited Speaker, Detroit Gilda's Club, "Colo-Rectal Cancer", August 9, 1999. 340. Grand Rounds, "Advances in the Therapy of Metastatic Breast Cancer", St Mary's Hospital, Livonia,

July 28, 1999. 341. Annual Oncology and ASCO Review Course, "Update in Gastrointestinal Malignancies", Karmanos

Cancer Institute, Ritz Carlton Hotel, Dearborn, MI, June 12, 1999. 342. Grand Rounds, "Reducing the Incidence of Breast Cancer in Women with High Risk", St Mary's

Hospital, Livonia, May 26, 1999. 343. P.A. Philip, M. Zalupski, V.K. Vaitkevicius, P. Arlauskas, A. Shields. Phase II study of gemcitabine

and cisplatin in advanced or metastatic pancreatic cancer. Annual Meeting of ASCO, Atlanta, Georgia, May 1999.

344. Philip, P.A., Heilbrun, L., Lababidi, S., Vischer, D., Ali, S. Expression of Cytochrome P450 (CYP) Enzymes in Malignant and Morphologically Normal Human Breast Tissues.

Page 51: PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C ...igicc.org/wp-content/uploads/2019/05/Philip-Agop-Philip-CV.pdfPage 1 of 53 . PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C

Page 51 of 53

Proceedings of Annual Meeting of AACR, Philadelphia, Penn., April 1999. 345. Philip, P.A., Li, Y., Alonso, M., Manji, H., Sarkar, F., Ensley, J., Ali, S. Sensitization of Human

Breast Cancer Cells to Gemcitabine by Bryostatin 1. Proceedings of Annual Meeting of AACR, Philadelphia, Penn., April 1999.

346. Breast Program, Karmanos Cancer Institute, "Role of Carcinogen Metabolizing Enzymes in Susceptibility and Response to Therapy", Karmanos Cancer Institute, April 7, 1999.

347. Internal Residency Program, "Colo-Rectal Cancer", St. Joseph Hospital, Pontiac, April 2, 1999. 348. Gemzar Investigators' Meeting, "Phase II Study of Gemcitabine and Cisplatin in Advanced

Pancreatic Cancer", New Orleans, March 1999. 349. Gemzar Investigators' Meeting, "Phase I Study of Gemzar and Orzel", New Orleans, March 1999. 350. Fox Chase Cancer Center meeting, "Update on Carboplatin and Taxol in Upper GI and Unknown

Primary Cancers", Lanai/Hawaii, March 1999. 351. Tumor Board, Bixby Medical Center, Adrian, Ohio, “Updates on the Treatment of Advanced Breast

Cancer”, February 17, 1999. 352. Talk, Drug Discovery Program, Karmanos Cancer Institute, “Updates on the Treatment of Pancreas

Cancer”, January 27, 1999. 353. Seminar, Pancreas Group at Karmanos Cancer institute, “Phase II Study of Gemcitabine and

Cisplatin”, January 22, 1999. 354. Lecture, Dr Cobau’s Group in Toledo, “Advances in the Treatment of Pancreas Cancer”, January 14,

1999. 355. Philip, P.A., Ali-Sadat, S., Alonso, M., Manji, H., Sarkar, F., Ensley, J. Bryostatin 1 sensitizes

human breast cancer cells to gemcitabine (Gemzar). 21st Annual San Antonio Breast Cancer Symposium, TX, December 1998.

356. Invited Speaker, Western Massachusetts Chapter of Oncology Nursing Society, “Colo-Rectal Cancer”, December12, 1998.

357. Invited Speaker, 2nd International Symptom on Molecular Diagnosis in Medicine, “Molecular Biology in the Diagnosis and Treatment of Colo-Rectal Cancer”, Madrid, Spain, November 26, 1998.

358. Invited Speaker, MD Anderson Cancer Center ORZEL Investigators Meeting and Consensus Conference, Boca Raton, FL, October 19, 1998.

359. Invited Speaker, “Protein Kinase C Modulators in Cancer Therapy: Bryostatin 1” Iowa Oncology Society Annual Meeting, Des Moines Oct 2, 1998.

360. Seminar, “Bryostatin and Gemcitabine”, Mechanisms of Drug Resistance Group, Sept 23, 1998. 361. Grand Rounds, Department of Medicine, “Advances in the Therapy of Pancreatic Cancer”, Hutzel

Hospital, Sept 11, 1998. 362. Seminar, “AACR”, Mechanisms of Drug Resistance Group, Karmanos Cancer Institute, June 1998. 363. Seminar, “Pancreatic Cancer”, Detroit Mercy Hospital, Department of Internal Medicine, Detroit,

MI, April 15, 1998. 364. Grand Rounds, “Colo-Rectal Cancer”, Department of Internal Medicine, St. Joseph’s Hospital,

Pontiac, MI., March, 1998. 365. Seminar, “Role of Cytochrome P450 3A4 Enzyme in the Pharmacogenetics of Cyclophosphamide”.

Kresge Eye Institute, Detroit, MI., March 1998. 366. Seminar, U.S. Gemzar Investigator’s Meeting, “Phase II Study of Gemzar and Cisplatin in Advanced

or Metastatic Pancreatic Cancer”, Memphis, TN, March 1998. 367. Seminar, Fox Chase and Free University Symposium, “Phase II Study of Carboplatin and Paclitaxel

in Gastric and Esophageal Cancer”. St. Thomas, Virgin Islands, March 25-28, 1998. 368. Grand Rounds, “Pancreatic Cancer”, Detroit Mercy Hospital, Internal Medicine Rounds, Detroit,

MI., January 1998. 369. Philip, P.A., et al. Expression of cytochrome P450 enzymes in the oral mucosa of African-

Americans (AA) and Caucasians (CC). AACR, New Orleans, LA. 1998. 370. Philip, P.A., et al. Interactions of bryostatin 1 with tamoxifen, paclitaxel, and doxorubicin in human

breast cancer cells. AACR, New Orleans, LA. 1998. 371. Philip, P.A., Gadgeel, S., Shields, A., Zalupski, M., Hussain, M. Phase II study of paclitaxel and

carboplatin in patients with advanced gastric and esophageal cancers. Proceedings of ASCO, 1998. 372. Seminar, “Drug-Metabolizing Enzymes”, Mechanisms of Drug Resistance Group,

Page 52: PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C ...igicc.org/wp-content/uploads/2019/05/Philip-Agop-Philip-CV.pdfPage 1 of 53 . PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C

Page 52 of 53

Barbara Ann Karmanos Cancer Institute, Detroit, MI., December 1997. 373. Grand Rounds, Department of Medicine, “Advances in Colo-Rectal Cancer”, Harper Hospital,

Detroit, MI., July 1997. 374. Seminar, Breast Multidisciplinary Conference. “Mechanisms of Drug Resistance in Human Breast

Cancer, Detroit, MI, May 15, 1997. 375. Philip P.A., Ali-Sadat, S., Chan, K.K., Kocarek, T., Doehmer, J. Influence of differential

metabolism of cyclophosphamide (CPA) on cytotoxicity in MCF-7 and V-79 cells. AACR, San Diego, CA. April 1997.

376. Grand Rounds, “Colo-Rectal Cancer”, Department of Internal Medicine, St. Joseph’s Hospital, Pontiac, MI., March 1997.

377. Philip P.A., Zalupski, M.M., Gadgeel, S., Hussain, M., Shields, A. A phase II study of carboplatin and paclitaxel in patients with gastric and esophageal cancer. Fox Chase and Free University Symposium, Puerto Rico, March 12-14, 1997.

378. Seminar, “Expression of Xenobiotic-Metabolizing Enzymes in Tonsilar Tissues”, Institute of Chemical Toxicology, Detroit, MI., December 1996.

379. Grand Rounds, “Clinical Dilemmas”, Division of Hematology and Oncology, Detroit, MI., October 1996.

380. Seminar, Pancreas Cancer Group, Barbara Ann Karmanos Cancer Institute, Detroit, MI., June, 1996. 381. Seminar, Gene Therapy Journal Club, Barbara Ann Karmanos Cancer Institute, Detroit, MI., May,

1996. 382. Philip P.A., Ali-Sadat, S., Kocarek T., Doehmer J. The use of the V9 cells stably transfected with

cytochrome P-450 cDNAs in studying the metabolism of cyclophosphamide and ifosfamide. ASCO meeting in Philadelphia, PA May 1996.

383. Department of Internal Medicine, St. Joseph Hospital, (Pontiac, MI.). “Colo-rectal and Primary Hepatic Cancers”, March 1996.

384. Philip P.A., Ali-Sadat, S., Kocarek T., Doehmer J. In vitro metabolism of cytotoxic drugs using V79 cells stably transfected with human cytochrome P-450 cDNAs. AACR meeting in Washington, D.C., April 1996.

385. Philip P.A., and Hsieh J.T. Correlation between an apoptosis-associated gene (TRPM-2) and apoptotic cell death induced by Adriamycin in a rat prostatic epithelial cell line (NbE). AACR special conference in cancer research: Basic and clinical aspects of prostate cancer, Special AACR meeting, Palms Springs, CA, December 8-12, 1994.

386. Philip P.A., Talbot D., Rea, D., et al. Phase I study of protein kinase C partial agonist, bryostatin-1. EORTC Early Drug Development Meeting, Rotterdam, The Netherlands, June 23- 26, 1993.

387. Philip P.A., et al. Expression of xenobiotic-metabolizing enzymes (XMEs) by primary and secondary hepatic tumors in man. Eighth International Congress on Chemical Modifiers, Kyoto, Japan, June 1993.

388. Philip P.A., et al. High-dose hydroxyurea increases the formation of O6-methylguanine but not N7-methylguanine DNA adducts in lymphocytes from melanoma patients treated with dacarbazine without induction of HPRT mutations or micronuclei formation. EORTC/PAMM winter meeting in Brest, France, January 14-16, 1993.

389. Philip P.A., et al. Phase I trial of bryostatin-1. Influence on the plasma concentrations of interleukin-6 and tumor necrosis factor-a. AACR, Orlando, FL, 1993.

390. Philip P.A., et al. Modulation of drug resistance with antimetabolites: The influence of high- dose hydroxyurea (HU) on the repair of cisplatin induced DNA damage. British Association of Cancer Research (BACR) spring meeting at University of Southampton, Southampton, England, March 1992.

391. Philip P.A., et al. Hormonal therapy in pancreatic carcinoma: A phase II study of LHRH agonist goserelin plus hydrocortisone. British Association of Cancer Research (BACR) spring meeting at University of Southampton, Southampton, England, March 1992.

392. Philip P.A., et al. Expression of drug metabolizing enzymes (DME) in primary hepatic tumors in man. British Association of Cancer Research (BACR) spring meeting at University of Southampton, Southampton, England, March 1992.

393. Philip P.A., Kaklamanis L., Morrison H., Gatter K.C., Carmichael J., Harris A.L. The influence of a continuous infusion of hydroxyurea (HU) on the uptake of 5-iod0-2-deoxyuridine

Page 53: PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C ...igicc.org/wp-content/uploads/2019/05/Philip-Agop-Philip-CV.pdfPage 1 of 53 . PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C

Page 53 of 53

(IUdR) by bone marrow and tumor cells in man. British Association of Cancer Research meeting in Manchester, England, April 1991.

394. Lecture, Oxford Pain Course, Somerville College, University of Oxford, United Kingdom, “Role of Bisphosphonates in Management of Cancer Pain”, November 1990.